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Abstract	
According	to	WHO	(August	2011),	346	million	people	worldwide	have	diabetes	and,	of	
those,	90%	have	type	2	diabetes	(T2DM).	This	equates	to	approximately	$465	billion	
(USD)	in	healthcare	costs.	Current	treatments,	which	include	various	different	drug	
types,	both	oral	and	injectable,	are	somewhat	effective	(i.e.	do	not	prevent	associated	
complications)	but	also	still	heavily	rely	on	patient	and/or	care-giver	regimen	adherence	
for	the	therapies	to	be	effective.		
One	of	the	most	recent	classes	of	drugs	is	known	as	Glucagon-like	peptide	1	receptor	
(GLP-1-R)	agonists.	Current	treatment	interval	extends	to	only	once	weekly	injections	
and,	whilst	this	is	far	superior	to	daily	or	even	twice	daily	injections,	any	possible	
extension	would	potentially	provide	an	increased	safety	profile	(by	removing	non-
physiological	peaks	in	hormone	pharmacokinetics)	and	would	generally	be	better	
received	by	the	patient.	
Gene	therapy	is	one	area	of	investigation	for	T2DM,	which	aims	to	provide	longer-term	
therapeutic	peptide	delivery	and	therefore	reduce	the	number	injections	required	for	
satisfactory	glucose	homeostasis.	
GLP-1	is	a	hormone	within	the	group	known	as	incretins.	This	group	comprises	
hormones	which	enhance	glucose-dependent	insulin	synthesis	and	secretion	(from	
pancreatic	β-cells)	in	response	to	glucose	(and	other	nutrients)	and	subsequently	
suppresses	post-prandial	hyperglycaemia.	One	of	the	major	pitfalls	of	GLP-1	is	its	
incredibly	short	half-life	(2-3	minutes)	due	to	degradation	by	a	ubiquitous	dipeptidyl	
peptidase	(DPP4).	Current	therapeutics	are	small	compounds	activating	incretin	
functions,	for	example	the	GLP-1	analogue	mimetics	exenatide	or	liraglutide,	or	are	
DPP4	inhibitors,	for	example	stigaliptin.	However,	due	to	the	progressive	nature	of	the	
disease	and	pathophysiological	differences	between	individuals,	these	treatments	may	
not	be	suitable	for	everyone	and	may	not	provide	a	long-term	sustainable	solution.		
This	thesis	aimed	to	compare	the	efficacy	and	efficiency	of	utilising	both	plasmid	and	
viral	based	(AAV)	vectors	for	transgene	delivery	via	skeletal	muscle.	Skeletal	muscle	is	
used	mainly	for	its	ease	of	access	and	its	highly	vascularised	system,	which	is	extremely	
capable	of	uptake	and	expression	of	foreign	DNA.	
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The	transgenes	chosen	for	this	study	encoded	unaltered	human	GLP-1	and	the	longer-
acting	GLP-1-R	agonist,	Exendin-4.	Exendin-4	shares	53%	homology	with	GLP-1	and	
exerts	insulinotropic	activity	while	lacking	the	amino	acid	cleavage	site	via	which	DPP4	
degrades	GLP-1.	Enhanced	green	fluorescent	protein	(eGFP)	was	also	used,	as	a	control	
vector	and	an	easy	to	visualise	reporter	that	would	aid	in	the	determination	of	
expression	both	during	the	study	(for	use	in	live	animals)	and	in	post-mortem	analysis.		
In	vitro	studies	for	proof	of	concept	were	performed	in	the	C2C12	murine	muscle	cell	
line,	and	in	a	minor	part,	HEK293	fibroblasts,	before	being	progressed	into	both	normal	
(CD1)	and	diabetic	(db/db)	mouse	models.			
Transgene	expression	was	attained	in	C2C12	cells,	as	determined	via	
immunofluorescence	staining	and	ELISA/EIA	analysis	of	both	the	cells	and	the	cell	media.	
Standard	transfection/infection	protocols	were	utilised.	The	longest	study	concluded	at	
5	days	post	transfection/infection.	
In	vivo	studies	also	attained	expression	of	the	three	transgenes,	eGFP,	GLP-1	and	
Exendin-4	via	direct	hind	limb	skeletal	muscle	injection.	In	situ	plasmid	uptake	was	
augmented	by	pre-injection	of	the	muscle	with	hyaluronidase	and	external	calliper	
electroporation.	Circulating	peptide	levels	were	confirmed	via	blood	serum	analysis	
using	ELISA/EIA.	Muscle	peptide	concentration	was	determined	from	muscle	
homogenates	and	by	immunofluorescence	staining	together	with	circulating	hormone	
concentration	by	ELISA/EIA.	Pancreas	samples	were	evaluated	for	β-cell	mass.	IPGTT	
data	were	obtained	throughout	the	study.	In	addition,	each	mouse	was	subject	to	non-
invasive	imaging	(IVIS),	which	allowed	visualisation	of	the	eGFP	reporter	gene.	Gene	
expression	was	followed	to	a	suitable	end	point,	which	was	determined	on	a	study-by-
study	basis.			
Results	showed	the	delivery	system	to	be	effective	yielding	promising	circulating	peptide	
concentrations	in	all	animal	models.	The	data	obtained	from	IPGTT	analyses	in	the	
diseased	model	showed	the	improved	capability	of	glucose	clearance	when	transfected	
with	Exendin-4	transgenes.	Expectedly,	no	differences	were	noted	in	the	healthy	model.	
The	plasmid	vectors	appeared	to	give	a	greater	efficacy	profile	than	the	AAV	vectors,	
based	on	both	eGFP	expression	analysed	via	IVIS	and	circulating	peptide	concentrations.	
In	light	of	this,	only	the	plasmid	vector	studies	were	performed	in	the	diseased	animal	
model.		
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In	conclusion,	a	skeletal	muscle	based	gene	delivery	system	for	GLP-1	and	longer	acting	
GLP-1-R	agonists	has	proven	to	be	tolerated	by	both	normal	and	diseased	animal	
models,	Furthermore,	the	administration	of	the	Exendin-4	to	diseased	animals	suggests	
positive	glucose	lowering	effects.	The	current	work	suggests	that	further	studies	are	
worthwhile,	including	those	conducted	in	a	range	of	animals	with	overt	and	perhaps	
spontaneous	diabetes	mellitus.	
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1.1 Diabetes	Mellitus	
	
There	are	many	conflicting	reports	of	who	first	described	the	disease	and	when.	Some	
say	that	the	observation	of	‘sweetened’	urine	dates	back	as	far	as	ancient	Greece.	
However,	it	is	arguably	not	until	the	late	1800’s	that	recognised	medical	records	show	
the	gradual	observations	and	discoveries	that	have	led	to	the	current	classifications	of	
Type	1	and	Type	2	Diabetes	Mellitus.	
The	two	main	types	of	diabetes	mellitus,	now	known	as	Type	1	(T1DM)	and	Type	2	
(T2DM),	were	first	fully	characterised	in	1951	by	Lister,	Nash	and	Ledingham,	who	
differentiated	between	the	two	based	on	their	different	aetiologies	(Lister	et	al.,	1951).	
Broadly,	diabetes	mellitus	is	defined	as	a	group	of	metabolic	disorders	culminating	in	
chronic	hyperglycemia	as	a	result	of	insulin	deficiency	or	defectiveness.	
In	addition	to	the	two	major	forms,	intermediary	stages	have	been	determined,	at	which	
time	the	individuals	suffering	from	impairment	in	glucose	tolerance	are	at	a	higher	risk	
of	developing	frank	T2DM	but	this	is	not	a	certainty	and	in	some	cases	the	condition	can	
be	reversed.	States	such	as	Metabolic	syndrome	and	Gestational	Diabetes	can	be	
reversed	with	diet	and	lifestyle	changes	and	in	the	case	of	gestational	diabetes,	resolve	
at	least	in	the	short	term	post-pregnancy	(UK,	2012).	
According	to	WHO,	346	million	people	worldwide	have	diabetes	mellitus	and	of	those,	
90%	have	T2DM	((WHO),	2011a).	The	focus	of	the	research	within	this	thesis	is	T2DM.	
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Figure	1-1-	Estimated	prevalence	of	T2DM	worldwide	in	2025.	(Downloaded	18.06.12	
http://ocpstore.com/store/wp-content/uploads/2012/05/prevalence_diabetes_map_2025.jpg)	
	
1.1.1 Economic	impact	
	
As	mentioned	previously,	T2DM	is	one	of	the	most	common	non-communicable	diseases	
and	is	the	fifth	most	common	cause	of	death	worldwide.	Diabetes	UK	reports	that	1	in	
10	people	admitted	to	hospital	(in	the	UK	alone)	have	some	form	of	diabetes	and	15%	of	
all	deaths	per	year	can	be	attributed	to	diabetes	or	a	diabetes	related	complication	
(DiabetesUK,	2011).		
Figure	1-1	refers	to	the	estimated	global	distribution	of	T2DM	in	the	year	2025.	As	can	
be	seen,	the	distribution	really	is	global	and	the	health	and	economic	consequences	of	
this	could	be	catastrophic	to	some	health	care	providers	and	their	recipients,	especially	
in	poorer	areas	of	the	world.		
According	to	Hex	et	al	(2012)	(Hex	et	al.,	2012),	diabetes	cost	the	NHS	approximately	
£23.7billion	in	the	fiscal	2010/2011,	which	equates	to	roughly	10%	of	the	entire	NHS	
budget.	Of	this,	£8.8billion	is	a	directly	attributable	to	T2DM.	Projections	for	costs	in	the	
year	2035/2036,	assuming	current	procedures	are	still	adhered	to	and	population	
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demographic	assumptions	are	correct,	are	that	a	total	of	£39.8billion	(17%	of	total	NHS	
budget)	will	be	spent	on	diabetes,	with	a	£15.1billion	spend	on	T2DM.	
Furthermore,	Kanavos	et	al	(Kanavos	et	al.,	2012)	estimate	the	EU	cost	(across	the	5	
major	EU	countries	of	Spain,	Italy,	Germany,	France	and	UK)	to	be	€90billion.	
	
1.1.2 Type	1	Diabetes	Mellitus	(T1DM)	
	
T1DM	is	thought	to	be	caused	by	an	auto-immune	attack	on	the	body’s	own	pancreatic	
islets,	resulting	in	loss	of	β-cell	function.	It	can	occur	at	any	age,	but	due	to	the	strong	
link	with	genetic	predisposition,	it	is	most	commonly	detected	in	children	and	young	
adults	(Lernmark,	1999)	.		Patients	suffering	from	this	produce	little	or	no	insulin	of	their	
own	and	are	therefore	completely	reliant	on	exogenous	insulin,	normally	via	
injection(Gale,	2002).			
 
1.1.2.1 T1DM	Associated	Complications		
	
There	are	some	major	and	potentially	devastating	microvascular	complications,	which	
are	common	to	both	T1DM	and	T2DM,	which	occur	when	an	increased	concentration	of	
glucose	is	present	in	the	blood	and	causes	some	of	the	smaller	blood	vessels/capillaries	
to	become	chronically	damaged.	These	include	retinopathy	(damage	to	retinal	cells,	
which	can	ultimately	lead	to	blindness),	nephropathy	(kidney	damage)	and	neuropathy	
(nerve	damage)(Fowler,	2008)	.		
	
1.1.2.2 T1DM	Treatment	
	
There	is	no	‘cure’	for	T1DM	and	insulin	replacement	is	needed	daily	for	life.	This	is	why	
T1DM	is	also	often	known	as	insulin-dependent	diabetes.	The	amount	of	insulin	needed	
is	calculated	depending	on	what	food	has	been	ingested.	As	insulin	therapy	is	a	non-
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disease	modifying	agent,	progressive	β-cell	failure	is	a	certainty.	Current	research	is	
focusing	on	approaches	beyond	insulin	injection	or	insulin	pump	therapy.	
A	relatively	new	method	of	treatment	for	T1DM	is	islet	transplantation.	There	are	two	
main	types	of	transplant;	auto-	and	allo-transplantation.	Auto-transplantation	is	not	
suitable	for	T1DM	patients	but	can	be	used	for	those	who	are	undergoing	a	complete	
pancreatectomy	for	reasons	such	as	chronic	pancreatitis,	and	involves	removing	islets	
from	the	patient’s	own	pancreas	and	re-implanting	them	into	their	liver.	In	allo-
transplantation,	islets	are	removed	from	a	deceased	donor,	purified	and	then	implanted	
into	T1DM	patients.	The	Edmonton	protocol,	developed	by	J.	Shapiro	(2000),	is	
considered	the	standard	and	most	successful	method	and	has	resulted	in	several	
patients	becoming	insulin	free	for	at	least	1	year	(Shapiro	et	al.,	2000)	
 
1.1.3 Type	2	Diabetes	Mellitus	(T2DM)	
	
T2DM	tends	to	have	a	later	age	of	onset	in	comparison	to	T1DM	and	is	characterised	by	
a	decreased	sensitivity	to	insulin	(also	known	as	insulin	resistance)	together	with	
decreased	insulin	secretion	rather	than	the	complete	loss	of	β-cell	function	seen	in	
T1DM.		
Impaired	glucose	tolerance	often	progresses	to	T2DM.	This	and	T2DM	are	associated	
with	progressively	increased	risk	of	cardiovascular	disease.	Once	glucose	levels	are	
diagnostically	high	enough	for	T2DM,	there	is	an	increased	risk	of	diabetic	microvascular	
complications.			
Other	symptoms	can	include,	but	are	not	limited	to,	an	increase	in	the	volume	of	
urination,	known	as	polyuria	which,	in	turn,	increases	thirst,	known	as	polydipsia,	and	
leads	to	weight	loss	through	loss	of	glucose	in	the	urine.	Although	blood	plasma	glucose	
level	is	still	the	formal	method	of	diagnosis	for	T2DM,	a	new	method	utilising	
glycosylated	haemoglobin	(known	as	HbA1c)	has	been	acknowledged	as	a	diagnostic	
tool.	WHO	guidelines	suggest	a	cut-off	point	of	48mmol/l	(6.5%)	glycosylated	
haemoglobin	in	the	sample,	but	concentrations	lower	than	this	do	not	necessarily	rule	
out	diabetes	mellitus	in	that	individual,	and	there	are	several	situations	where	this	test	
may	not	be	appropriate(International	Diabetes	Federation;	(WHO),	2011b).		
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1.1.3.1 T2DM	Risk	Factors	
	
There	are	several	risk	factors	that	have	been	identified	as	a	diabetes-risk	precursor,	
including	ageing	and	genetics.	However	the	major	risk	factor	linked	to	the	onset	of	
T2DM	is	obesity((WHO),	2011a).	A	sedentary	lifestyle	coupled	with	the	easy	availability	
of	cheap,	poor	quality	processed	food	items,	which	have	a	high	fat	and	high	carb	
content,	and	a	lack	of	understanding	of	the	nutritional	value	of	different	food	choices	
can	be	implicated	in	increases	in	obesity,	which	as	described	before,	is	a	major	
contributor	to	the	onset	of	T2DM,	which	is	occurring	at	an	ever	increasing	younger	age.	
Furthermore,	genetic	factors	which	have	been	shown	to	run	in	families	and	a	
predisposition	to	‘weak’	β-cells	which	cannot	overcome	the	stress	of	glucolipotoxicity	
are	also	to	blame	(Campbell,	2011).	Campbell	(2011)	demonstrates	this	in	an	extremely	
easy	to	read	diagram,	shown	in	Figure	1-2.		
	
	
Figure	1-2	–	Pictorial	representation	of	T2DM	risk	factors.	This	diagram,	taken	directly	from	
Campbell	(2011),	shows	the	multifactorial	risk	factors	associated	with	T2DM	(Campbell,	2011).	
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1.1.3.2 T2DM	Associated	Complications	
	
Elevated	blood	glucose,	as	seen	in	T2DM,	has	strong	links	to	both	microvascular	and	
macrovascular	complications,	with	cardiovascular	disease	(CVD)	being	the	major	
macrovascular	risk	and	microvascular	conditions	including	retinopathy,	nephropathy	and	
neuropathy		
Diabetic	retinopathy	can	be	classified	as	background	or	proliferative	and	involves	
disturbances	in	the	blood	flow	to	the	retina,	with	background	involving	reducing	the	
blood	flow	and	proliferative	expanding	the	blood	flow,	often	resulting	in	micro-
haemorrhages.	Both	ultimately	result	in	deterioration	and	even	loss	of	vision.	
Nephropathy	is	an	increase	in	protein	in	the	urine,	which	can	ultimately	lead	to	kidney	
failure.	Neuropathy	is	any	evidence	of	nerve	alteration,	after	any	other	causes	have	
been	ruled	out.	A	classic	symptom	of	neuropathy	is	‘diabetic	foot’,	in	which	an	ulcer	
forms	after	a	small	injury	which	is	persistent	and	hard	to	heal.	In	severe	cases,	injuries	
such	as	these	result	in	amputation.	
Macrovascular	CVD	is	essentially	increased	atherosclerosis,	although	the	precise	
mechanism	by	which	diabetes	(both	T1	and	T2)	increase	this	risk	is	unknown,	many	
studies	have	shown	the	link	is	true	(Fowler,	2008;	Peterson,	2012).	
In	addition	to	the	common	micro/macrovascular	conditions,	there	is	currently	a	strong	
belief	that	increased	blood	glucose	is	also	linked	to	some	forms	of	cancer,	although	
published	literature	describes	conflicting	results.	Shih	et	al	conducted	a	literature	review	
investigating	the	link	between	thyroid	cancer	and	diabetes,	and	concluded	there	was	no	
statistical	evidence	to	support	the	theory	of	a	link	(Shih	et	al.,	2012)	whereas	a	paper	
published	the	previous	year	by	Aschebrook-Kilfoy	et	al	concluded	there	was	a	link	
between	diabetes	and	thyroid	cancer	(Aschebrook-Kilfoy	et	al.,	2011).	However,	on	close	
inspection	of	the	paper,	they	do	state	the	adjuvant	health	states	that	are	often	found	in	
people	with	diabetes,	such	as	increased	BMI	(with	associated	poor	lifestyle	choices),	
may	in	itself	be	a	risk	factor	for	thyroid	cancer,	and	additionally,	thyroid	cancer	is	the	
sixth	most	common	cancer	in	American	women.		
An	alternative	area	of	study	on	the	link	between	cancer	and	diabetes	is	thought	to	be	
the	diabetic	treatments	rather	than	the	conditions	itself.		Gallagher	and	LeRoith	have	
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published	findings	that	Metformin,	commonly	used	as	the	first	treatment	methodology	
for	T2DM,	has	been	shown	to	supress	breast	cancer	stem	cells		(Gallagher	and	LeRoith,	
2011).	
	
1.1.3.3 T2DM	Treatment	
	
As	discussed	previously,	90%,	or	346	million	people,	equates	to	healthcare	costs	of	
approximately	$465	billion	(USD)(International	Diabetes	Federation;	(WHO),	2011a).	
Current	treatments	are	somewhat	effective	but	still	rely	heavily	on	patient	and/or	carer	
regimen	adherence	for	the	therapies	to	be	effective	and	none	of	these	medications	
address	the	underlying	problem	of	decreasing	β-cell	function	(S.Niessen,	2011).		
Current	treatment	options	for	T2DM	vary	from	patient	to	patient.	There	is	not	one	‘treat	
all’	medication	available.	If	caught	early,	exercise	and	modified	(calorie	controlled)	diet	
has	been	proven	to	lower	blood	glucose,	however,	as	T2DM	is	a	progressive	disease,	
treatment	options	may	have	to	be	altered	without	any	specific	time	frame,	to	address	
current	glycaemic	control	in	the	individual.	
There	are	several	medications	which	can	be	considered	singly	or	in	combination,	with	
various	actions.	
	
1.1.3.4 Conventional	Therapy	
	
The	current	normal	primary	treatment	for	T2DM	involves	diet	and	lifestyle	modification,	
which	is	essentially	used	to	lower	BMI,	which	has	been	shown	to	aid	in	improving	
glucose	homeostasis	(Group,	2002).	If	this	is	not	effective,	treatment	moves	on	to	
Metformin,	which	is	the	first	line	of	medication	for	early	T2DM	(Peterson,	2012).	
Metformin	is	a	biguanide	which	allows	enhanced	glucose	uptake	by	various	tissue	types,	
including	skeletal	muscle,	therefore	reducing	the	concentration	of	circulating	glucose.	It	
does	not	stimulate	insulin	secretion	so	there	is	no	risk	of	hypoglycaemia	(Viollet	et	al.,	
2012).		If	metformin	fails	to	control	glucose	homeostasis,	a	Sulphonylurea	may	be	
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considered.	These	work	in	a	complementary	fashion	to	metformin	and	stimulate	insulin	
release	by	triggering	cascade	pathways	within	the	β-cells.		
These	are	both	non-disease	modifying	treatments	and,	due	to	the	progressive	nature	of	
the	disease,	will	ultimately	fail	to	provide	adequate	glucose	control	and	the	patient	may	
still	end	up	on	insulin	therapy.	
 
1.1.3.5 Newer	and/or	novel	therapies	
	
Various	other	agents	are	available	which	are	less	commonly	prescribed.	These	include,	
Meglitinides	which	act	in	a	similar	fashion	to	sulphonylureas	but	on	different	receptors	
within	the	β-cell	but	still	triggering	cascade	pathways.	These	also	result	in	an	increase	in	
insulin	secretion.	Glucosidase	inhibitors	don’t	have	a	direct	influence	on	control	of	
insulin	but	inhibit	disaccharide	digestion	in	the	gut,	which	in	turn	slows	entry	of	glucose	
into	the	bloodstream	therefore	reducing	the	release	of	insulin.		
However,	some	effective	treatments	are	proving	to	be	cause	for	concern	due	to	
generating	unwanted	side	effects	which	may	outweigh	the	benefits	of	glucose	
homeostasis.	One	such	drug	was	the	Thiazolidinedione	(or	glitazone)	group,	containing,	
amongst	others,	Rosiglitazone	(associated	with	increased	CVD),	Troglitazone	(withdrawn	
after	reports	of	severe	liver	damage)	and	Pioglitazone.	Pioglitazone	is	the	only	drug	that	
is	available	in	the	UK.	This	group	of	drugs	act	directly	on	gene	transcription	factors	
involved	in	glucose	and	lipid	metabolism,	by	activating	the	nuclear	receptor	peroxisome	
proliferator-activated	receptor	gamma	(PPAR ).	The	resulting	effect	is	the	reduction	in	
insulin	resistance	in	fatty	tissue,	muscle	and	liver	(Hauner,	2002).	This	would	be	an	ideal	
treatment	for	long	term	glucose	homeostasis	if	it	were	not	for	the	adverse	side	effects	
associated	with	this	drug,	such	as	weight	gain	(somewhat	of	an	oxymoron	in	diabetes	
care),	oedema,	decreased	bone	density	and	again,	CVD	(Shah	and	Mudaliar,	2010).	
A	relatively	new	class	of	drugs	known	as	Gliflozins	have	been	developed	which	act	by	
inhibiting	sodium-glucose	transport	protein	2	(SGLT2)	(and	are	therefore	also	known	as	
SGLT2	inhibitors).	These	drugs	work	by	preventing	the	reabsorpbtion	of	glucose	in	the	
kidney,	resulting	in	any	excess	glucose	being	expelled	via	urine.		
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However,	arguably	the	most	promising	forms	of	treatment	lie	in	being	able	to	harness	
what	is	referred	to	as	the	‘incretin	effect’	(see	section	1.2.1).	Again,	this	is	an	example	of	
how	this	‘effect’	can	control	glucose	homeostasis.	This	will	be	discussed	in	more	detail	in	
section	1.4,	but	briefly,	comprises	agents	such	as	DPP4	inhibitors	(sitagliptin,	
vildagliptin,	saxagliptin,	linagliptin)	which	increase	endogenous	GLP-1	concentrations	by	
preventing	the	enzyme	dipeptidyl	peptidase	4	(DPP4)	degrading	GLP-1	and	GLP-1	
receptor	agonists	(GLP-1-R)	(exenatide,	liraglutide)	which	bind	to	receptors	on	β-cells	
and	elsewhere,	in	place	of	endogenous	GLP-1,	triggering	insulin	release.	An	example	of	a	
GLP-1	receptor	agonist	is	Exenatide.	Exenatide	is	a	synthetic	version	of	Exendin-4.	There	
are	currently	two	versions	of	exenatide,	a	twice	daily	10µg	injection	or	a	once	weekly	
2mg	injection	(NHS;	UK;	DeFronzo	et	al.,	2010;	Riedel	and	Kieffer,	2010;	Derosa	et	al.,	
2012;	Peterson,	2012)	
Exendin-4			is	one	of	the	compounds	of	interest	for	this	study	and	will	be	discussed	in	
more	detail	later	(see	1.2.3).			
	
	
	
1.2 The	pancreas	and	the	β-cell	
	
The	endocrine	pancreas	is	mainly	comprised	of	islets	(of	Langerhans),	which	inturn,	are	
comprised	of	three	main	cell	types.	Briefly,	Alpha	(α)	cells	secrete	glucagon	to	increase	
blood	glucose,	Beta	(β)	cells	secrete	insulin	to	decrease	blood	glucose	and	Delta	(Δ)	cells	
secret	somatostatin	to	aid	regulation	of	the	α	and	β	cells.	All	of	which	are	polypeptide	
hormones	which	play	a	role	in	glucose	homeostasis.		
The	trigger	of	the	pathways	that	instigate	the	stimulation	of	these	cells	and	the	
subsequent	secretion	of	peptide	are	a	group	of	hormones	known	commonly	as	incretins.	
These	are	gastrointestinal	hormones	comprising	mainly	of	GLP-1	and	GIP,	which	play	a	
key	role	in	what	is	known	as	the	‘gastroenteropancreatic-brain	axis’,	maintaining	glucose	
homeostasis	(Brubaker	and	Drucker,	2004).	The	effect	that	these	hormones	exert	is	
known	as	the	incretin	effect.	
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1.2.1 The	incretin	effect	
	
The	incretin	effect	is	a	term	used	to	describe	the	increased	insulin	response	that	occurs	
post	oral	glucose	ingestion,	when	compared	to	the	response	seen	after	intravenous	
glucose	loading	(Bagger	et	al.,	2011b).	The	incretin	effect	is	controlled	by	incretin	
hormones,	these	are	a	group	of	circulating,	gut	derived	hormones	which,	amongst	other	
functions,	enhance	glucose-dependent	insulin	production	and	secretion,	from	pancreatic	
β-cells,	in	response	to	glucose	(and	other	nutrients	in	food)	and	subsequently	suppress	
postprandial	hyperglycaemia	by	playing	a	key	role	in	what	is	known	as	the	‘gastro-
enteropancreatic-brain	axis’	(Brubaker	and	Drucker,	2004).	It	is	estimated	that	60-70%	
of	insulin	secretion	after	the	intake	of	food	is	brought	about	by	the	incretin	effect	
(Drucker,	2006;	Ahren,	2012;	Kinalska	et	al.,	2012).		
The	major	hormones	involved	in	the	incretin	effect	are	glucagon-like	peptide-1	(GLP-1),	
glucagon-like	peptide-2	(GLP-2)	and	gastric	inhibitory	peptide	(GIP).	The	discovery	of	GIP	
first	occurred	in	the	1970’s	and	was	the	first	incretin	to	be	identified.	GIP	is	a	42	amino	
acid	peptide	and	is	secreted	from	K	cells	located	in	the	intestinal	wall.	GLP-1	was	not	
identified	until	the	late	1980’s	(Drucker,	2006)	and,	along	with	GLP-2	and	glicentin,	is	
secreted	from	L	cells	located	in	the	ileum,	colon	and	rectum.	GLP-1	and	GLP-2	have	
previously	been	studied	in	conjunction	with	diabetes	control	due	to	the	fact	that	both	
hormones	are	encoded	by	the	preproglucagon	gene,	and	additionally	share	a	significant	
homology	with	glucagon,	however,	only	GLP-1	was	determined	to	have	any	
insulinotropic	activity	(Mojsov	et	al.,	1987).	
	
1.2.2 Incretin	structure,	function	and	action	
	
As	previously	mentioned,	GLP-1	and	GLP-2	are	synthesised	and	secreted	from	intestinal	
L	cells.	The	process	by	which	this	happens	involves	translation	of	the	proglucagon	gene	
by	the	prohormone	convertase	PC	1/3,	in	response	to	oral	nutrient	intake.	Both	
glucagon-like	peptides	have	approximately	50%	homology	with	glucagon,	but	only	GLP-1	
exhibits	insulinotropic	properties.	The	secretion	of	GLP-1	is	in	response	to	nutrient	
intake,	with	some	studies	showing	the	macronutrient	content	of	the	meal	and	the	time	
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of	day	the	meal	is	consumed	affects	the	levels	of	GLP-1	released.	Circulating	levels	of	
GLP-1	drop	shortly	after	secretion	(within	2	minutes)	due	to	the	endogenous	enzyme	
dipeptidyl	peptidase	4	(DPP4),	which	cleaves	the	alanine	at	position	2,	resulting	in	GLP-1	
(7-36)	turning	into	the	inactive	forms	GLP-1	(9-36),	GLP-1	(9-37)	and	GLP-2	(3-33).		
Circulating	GLP-1	(7-36)	forms	at	least	80%	of	the	biologically	active	GLP-1	in	humans.	
(Drucker,	2006;	Drucker	and	Nauck,	2006)	
The	action	of	GLP-1,	which	includes	increased	insulin	secretion,	reduced	β-cell	apoptosis,	
stimulated	β-cell	proliferation,	slowing	gastric	emptying,	regulating	appetite	and	
increasing	insulin	sensitivity	in	several	tissue	types,	starts	when	it	binds	to	cell	surface	G-
coupled	receptors	(GLP-1-R)	located	on	pancreatic	islet	cell	membrane	(beta,	alpha	and	
delta	cells),	along	with	other	locations	in	the	GI	tract,	heart,	lung	and	CNS	and	adipose	
tissue,	which	goes	to	somewhat	explain	the	action	of	GLP-1	on	other	tissue	types	
(Davidson,	2011).	It	has	also	been	to	exhibit	some	form	of	protective	effect	on	the	β	-
cells	themselves,	shielding	from	apoptosis	and	stimulating	β-cell	proliferation	via	up	
regulation	of	PDX-1	(a	β-cell	transcription	factor;	pancreatic	duodenal	homeobox-1)	
which	has	been	shown	to	augment	insulin	gene	transcription	and	up-regulate	
glucokinase	and	glucose	transporter-2.	However,	the	main	action	of	GLP-1	is	on	the	β-
cell	to	promote	postprandial	insulin	secretion,	dependent	on	glucose	levels.	This	has	
been	confirmed	via	many	studies	not	only	in	rodent	and	cell	line	models,	but	also	in	
human	studies.	Willms	et	al	(1996)	showed	exogenous	GLP-1	administration	inhibited	
gastric	emptying	and	stimulated	insulin	secretion	whilst	simultaneously	inhibiting	
glucagon	secretion,	thus	contributing	to	blood	glucose	homeostasis,	in	8	T2DM	patients	
(Willms	et	al.,	1996).	In	a	high	glucose	environment,	GLP-1-R	stimulation	leads	to	the	
activation	of	adenylate	cyclase,	which	increases	intracellular	cyclic	AMP	(cAMP)	levels	
and	calcium	activation.	An	increase	in	cAMP	activates	protein	kinase	A	(PKA)	and	cAMP-
regulated	guanine	nucleotide	exchange	factor	II	(cAMP-GEFII).	These	two	proteins	are	
linked	to	various	routes	of	GLP-1	based	insulin	secretion,	including	the	closing	of	ATP-
sensitive	potassium	(KATP)	channels	which	influence	membrane	depolarization	and	other	
electrical	activity	and	increased	calcium	activity	resulting	in	increased	mass/volume	of	
insulin	containing	granules	available	for	release	(insulin	exocytosis)	(Holst	and	Gromada,	
2004).	This	is	shown	concisely	in	Figure	1-3,	taken	from	Drucker,	2006	(Drucker,	2006).	
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cAMP,	via	GLP-1	activation,	has	also	been	proposed	to	play	a	role	in	β	cell	proliferation	
and	reduced	apoptosis	(Farilla	2002,	Drucker	2006).		
Studies	conducted	in	both	human	islets	and	Zucker	diabetic	rats	have	shown	that	
administration	of	GLP-1	resulted	in	a	decreased	level	of	pre-apoptosis	factors	and	
reduced	levels	of	cell	death	in	freshly	prepared	human	islets	and	decreased	apoptotic	β-
cells	and	increased	β-cell	mass	in	Zucker	diabetic	rats	(Farilla	et	al.,	2002;	Farilla	et	al.,	
2003;	Li	et	al.,	2003)	
	
 
	
Figure	 1-3	 -	 GLP-1	 receptor	 signalling	 pathways	 in	 the	 pancreatic	 β-cell.	 GLP-1	 receptor	
activation	 leads	 to	 insulin	 release	 via	 the	 stimulation	 of	 exocytotic	 pathways.	 	 Some	 of	 these	
pathways	also	lead	to	cell	proliferation	and	survival	(Drucker,	2006).	
	
In	T2DM,	the	ability	of	GLP-1	to	stimulate	insulin	secretion	is	reduced.	GLP-1	sensitivity	
remains	and	external	administration	of	GLP-1	shows	insulinotropic	activity	(Kinalska	et	
al.,	2012).		
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However,	even	exogenous	GLP-1	is	still	subject	to	DPP4	degradation.	Due	to	this	greatly	
reduced	half-life,	GLP-1-R	agonists	have	been	developed	which	are	resistant	to	DPP4	
degradation.		
	
1.2.3 GLP-1-R	Agonists	
	
GLP-1-R	agonists	have	been	developed	that	are	structurally	resistant	to	DPP4	
degradation,	which	increases	the	circulating	half-life	of	the	protein.		
Several	iterations	of	this	approach	are	currently	available,	and	in	use,	as	therapeutic	
agents.	Commonly	known	as	incretin	mimetics,	Exenatide	is	one	such	agent	(trademark	
Byetta	for	twice	daily	administration	or	Bydureon	for	once	weekly).	
Exenatide	is	a	synthetic	version	of	a	hormone	called	Exendin-4.	Exendin-4	was	originally	
isolated	from	the	saliva	of	the	lizard	Heloderma	suspectum.	It	is	a	39	amino	acid	peptide	
which	has	53%	homology	with	human	GLP-1	and	binds	to	GLP-1-R	on	β-cells	with	equal	
efficacy	and	efficiency.	It	also	shows	the	same	therapeutic	effects	as	GLP-1	on	reducing	
blood	glucose	levels,	increasing	insulin	sensitivity	and	secretion	and	slowing	gastric	
emptying	and	regulating	appetite.	However,	Exendin-4			contains	the	amino	acid	glycine	
at	position	2	rather	than	the	alanine	which	is	seen	in	GLP-1,	and	is	therefore	not	subject	
to	DPP4	degradation		(Baggio	et	al.,	2006;	Drucker,	2006).	Figure	1-4	shows	the	amino	
acid	sequence	of	both	endogenous	GLP-1	and	Exendin-4,	and	indicates	the	position	of	
the	alanine	substitution	with	glycine,	which	removes	the	cleavage	site	and	increases	the	
half-life.	
Several	studies	have	been	conducted	to	examine	the	effects	of	Exendin-4	and	the	
potential	of	Exendin-4	as	a	therapeutic	agent.	As	with	GLP-1,	Exendin-4	has	been	shown	
to	improve	β-cell	function	by	reducing	apoptosis	and	promoting	proliferation.	Derosa	et	
al	used	Homeostatic	Model	Assessment	(HOMA)	to	assess	β-cell	function	(HOMA-β)	in	a	
trial	which	assessed	how	much	exenatide	added	to	metformin	improved	β-cell	function	
when	compared	to	metformin	alone.	Their	results	showed	that	the	combination	of	
exenatide	and	metformin	decreased	body	weight,	increased	glycaemic	control	and	
increased	HOMA-β	(Derosa	et	al.,	2012).	
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There	are	additional	therapeutics	which	have	been	developed	that	whilst	being	DPP4	
resistant,	do	still	contain	the	DPP4	degradation	site.	For	example,	Liraglutide	is	a	daily	
injectable	GLP-1-R	agonist	that	has	been	formulated	by	replacing	a	lysine	amino	acid	
with	an	arginine	and	adding	a	fatty	acid	chain,	which	provides	protection	to	the	cleavage	
site	and	consequently	provides	DPP4	resistance	and	an	increased	half-life	up	to	13	hours	
(hence	once	daily	injection)(Campbell,	2011).		
	
The	only	current	method	of	GLP-1	R	agonist	treatment	still	currently	involves	regular	
injections	by	the	patient	or	carer.	This	can	cause	distress	and	other	psychological	
influences	to	the	patient	and/or	caretaker.	Other	physical	issues	associated	with	
multiple	injections	at	the	same	site	(such	as	bruising	and	scar	tissue)	can	also	occur	with	
prolonged	insulin	use.	Any	method	of	providing	prolonged	exposure	to	a	therapeutic	
agent	would	be	beneficial	to	the	patient,	and	also	help	reduce	costs.	One	such	
treatment	modality	under	extensive	investigation	for	many	disease	types	is	gene	
therapy.	
 
Figure	1-4	–	Diagrammatic	representation	of	the	homology	between	GLP-1	and	Exendin-4			
sequences	and	the	absence	of	the	DPP4	cleavage	site	in	Exendin-4	.	One	of	the	most	important	
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reasons	Exendin-4			is	used	as	a	GLP-1	R	agonist	is	the	absence	of	the	DPP4	cleavage	site.	This	
allows	the	Exendin-4			to	have	a	much	longer	half-life	than	the	endogenous	GLP-1. 
 
1.3 Gene	Therapy		
	
There	are	many	sources	which	provide	a	definition	for	gene	therapy,	the	American	
Society	of	Gene	and	Cell	Therapy	(ASGCT)	describe	gene	therapy	as	being	‘the	approach	
to	treating	disease	by	either	modifying	the	expressions	of	an	individual’s	genes	or	
correction	of	abnormal	genes,	by	administration	of	DNA	rather	than	a	drug’	(ASGCT,	
2015).	The	concept	of	gene	therapy	as	a	whole	has	a	20+	year	history,	with	the	first	
clinical	trials	conducted	in	the	late	1980’s.	Since	then,	there	have	been	many	
documented	success	stories.	A	move	to	a	gene	therapy	treatment,	with	the	genes	of	
interest	introduced	into	appropriate	target	cells	for	sustained	therapeutic	expression,	
provides	a	potential	logical	next	step	in	treatment	advance	for	T2DM.	
Successful	gene	transfer	has	several	considerations,	not	least	the	delivery	methods.	
Considerations	must	include	vector	uptake	and	persistence,	sustained	gene	expression	
and	favourable	host	immune	response	or	ideally,	no	immune	response	at	all,	and	all	with	
limited	side	effects.		
For	any	successful	translation	to	a	commercial	setting,	practical	considerations	must	also	
include	the	ease	of	large	scale	manufacturing	and	the	cost	of	the	resulting	treatment,	
again,	taking	into	consideration	delivery	material	and	any	adjuvant	treatment	that	may	
be	necessary.	There	is	also	many	discussions	taking	place	around	the	ethical	and	social	
impact	of	gene	therapy,	including	questions	such	as	those	posed	in	a	review	by	Misra	
(2013)	–	which	described	issues	such	‘what	is	the	difference	between	a	disease	and	
disability?’,	‘should	disabilities	be	cured?’,	‘is	somatic	gene	therapy	more	or	less	ethical	
than	germ	line	gene	therapy?’	(Misra,	2013).	
Gene	therapy	has	been	used	successfully	in	a	number	of	trials	for	several	other	
disorders;		
• Gene	therapy	trials	for	haemophilia	B	are	arguably	one	of	the	most	publicised	
and	well	known	disorders	for	which	gene	therapy	is	a	success.	Trials	have	been	
performed	using	both	plasmid	and	viral	vectors;	however	viral	vectors	(mainly	
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Adeno-associated	vectors	(AAV))	have	definitely	conferred	most	successful	
results	(Buchlis	et	al.,	2012;	Cancio	et	al.,	2013).	
	
• Severe	combined	immunodeficiency	(SCID)	has	been	the	subject	of	gene	therapy	
trials	for	many	years.	This	is	a	disorder	whereby	a	defect	in	the	adenosine	
deaminase	(ADA)	enzyme	encoding	gene	results	in	the	failure	of	the	deamination	
of	deoxydenosine	which	then	triggers	failures	of	other	cascade	pathways	and	
results	in	a	build-up	of	many	intra-cellular	bio-molecules.	This	ultimately	inhibits	
lymphocyte	activation.	This	results	not	only	in	a	severe	lack	of	immunity	but	also	
a	‘failure	to	thrive’,	as	ADA	is	expressed,	at	some	level,	in	all	cells.	Trials	using	
autologous	transplantation	of	hematopoietic	stem	cells	transduced	with	a	
recombinant	viral	vector	(Gammaretrovirus)	encoding	a	functional	ADA	gene	has	
been	successfully	used	to	treat	patients	suffering	from	SCID-ADA.	Trials	
conducted	in	both	the	US	and	in	Europe	have	results	in	more	than	30	patients	
having	100%	survival	post	treatment	(at	time	of	publication-	2012)	(Montiel-
Equihua	et	al.,	2012).			
	
• Clinical	trials	using	AAV	vectors	have	been	undertaken	for	Age	Related	Macular	
Degeneration	(AMD),	a	disease	in	which	vision	loss	is	caused	by	leaking	blood	
vessels	in	the	retinal	layer.	This	is	most	commonly	seen	in	patients	over	the	age	
of	70	and	current	treatment	involves	regular	injections	directly	into	the	eye,	
which	is	clearly	invasive	and	potentially	distressing.	Gene	therapy	treatments	
also	need	injections	into	the	eye,	but	at	reduced	frequency	with	sustained	
expression	of	therapeutic	agents	(Scholl	and	Sahel,	2014)	
	
To	date	(July	2015),	The	Journal	of	Gene	Medicine	reported	that	2255	gene	therapy	
clinical	trials	have	been	approved	worldwide.	Of	these,	only	6.2%	employed	AAV	vectors	
whereas	plasmid	vectors	and/or	naked	DNA	made	up	17.5%	(the	split	between	plasmid	
mediated	and	naked	DNA	was	unavailable).	The	remaining	76.3%	were	from	46	different	
vector	or	gene	delivery	systems.	The	top	4	most	popular	systems	were	adenovirus	
(21.7%),	retrovirus	(18.9%)	with	naked/plasmid	DNA	3rd	and	AAV	4th	most	frequent.	18%	
of	all	trials	have	used	skeletal	muscle	injection	as	the	delivery	method.	
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1.3.1 Gene	delivery	methods	
	
There	are	many	methods	which	can	be	utilised	to	achieve	clinically	successful	gene	
delivery	and	expression.	They	can	be,	broadly,	broken	down	into	two	main	categories,	
viral	and	non-viral.	Potential	limitations	exist	with	both	approaches,	with	concerns	
mainly	surrounding	safety	and	efficacy.	Traditionally,	viruses	were	seen	as	the	less	safe	
option	but	conferred	good	expression,	whereas	non-viral	methods	had	fewer	concerns	
around	safety	but	the	transgene	expression	was	not	as	good	as	that	seen	in	the	viral	
vectors	(Wells,	2010;	Zhou	et	al.,	2010).	
	
1.3.1.1 Non-Viral	Vectors	
	
Non-viral	vector	methods	can	include	a	variety	of	vector	backbones,	different	types	of	
vector	modification	and	vector	delivery	system,	all	mechanisms	which	are	designed	to	
achieve	the	best	levels	of	transgene	expression	without	instigating	any	negative	
reactions,	particularly	related	to	immune	response.	These	methods	can	include,	but	are	
not	limited	to,	direct	‘naked’	DNA	delivery,	DNA	plasmid-mediated	gene	transfection,	
with	gene	delivery	potentially	augmented	by	electroporation,	chemical	agents	or	
transposons.	
Apart	from	the	reduced	safety	concerns,	non-viral	methods	also	have	the	additional	
appeal	of	being	less	restrictive	regarding	size	of	insert,	which	can	be	quite	limiting	in	a	
viral	system.	
 
1.3.1.1.1 Plasmids	for	non-viral	delivery	
There	are	many	plasmids	currently	available	for	gene	transfer.	The	initial	plasmid	
proposed	for	the	current	studies	is	the	Vical	(CA,	USA)	plasmid	pVR1012,	with	human	
cytomegalovirus	(CMV)	promoter	and	kanamycin	resistance.		
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Plasmids	are	circular	molecules	of	DNA	which	can	replicate	independently	of	the	host	
chromosomes.	They	are	non-essential	for	normal	cell	function.	An	area	of	selectivity,	
which	is	often	based	on	antibiotic	resistance,	is	an	advantage	in	cloning	and	bacterial	
growth,	as	only	the	cells	that	show	this	antibiotic	resistance	can	grow.	For	example,	the	
plasmid	chosen	for	study	in	this	thesis,	pVR1012,	contains	a	region	of	kanamycin	
resistance,	so	when	grown	in	media	containing	the	antibiotic	kanamycin,	as	part	of	the	
transformation	process,	only	the	bacteria	containing	the	vector,	and	therefore	resistant	
to	this	antibiotic,	will	survive,	therefore	producing	a	batch	of	bacteria	all	of	which	should	
contain	the	plasmid.	
The	pVR1012	constructs,	including	those	able	to	express	Exendin-4	GLP-1	and	eGFP,	
were	already	available	within	the	group.	The	Exendin-4	and	GLP-1	sequences,	which	
both	include	an	upstream	human	preproinsulin	signal	peptide	sequence,	were	sub-
cloned	between	BamH1	and	EcoRV	restriction	sites	whereas	the	eGFP	sequence	was	
sub-cloned	between	two	Xba1	restriction	sites	(Mahmoud,	2010).	Inserting	the	
transgenes	downstream	of	the	human	signal	sequence	enables	continuous	secretion	via	
the	constitutive	secretory	pathway.	Using	known	restriction	sites	enables	the	bacterially	
grown	and	selected	subsequent	batches	of	plasmid	preparations	to	be	checked	easily	via	
restriction	digests	and	standard	gel	electrophoresis.		
Another	region	of	interest	in	pVR1012	vector	is	the	promoter	region.	In	this	case	it	is	a	
constitutively	active	CMV	promoter.	Figure	1-4	is	a	diagrammatic	representation	of	the	
pVR1012	plasmid	map,	and	the	site	of	insertion	for	each	of	the	transgenes.		
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Figure	1-5	–	Plasmid	map	of	pVR1012	showing	the	points	of	insertion	of	the	GLP-1,	Ex4	and	
eGFP	sequences	(Audonnet	et	al.,	2003;	Mahmoud,	2010)	
	
 
1.3.1.1.1.1 Plasmid	promoter	sequences	
Promoters	are	an	integral	part	of	a	plasmid	system.	They	regulate	the	transcription	
process	and	determine	the	expression	type	of	the	transgene	within	the	transfected	cells.	
Transgene	expression	can	be	what	is	known	as	‘constitutive’,	which	is	constant	
expression,	or	inducible,	which	is	regulated	by	transcription	factors.	Inducible	promotors	
can	also	be	used	to	‘dial’	up	or	down	the	amount	of	expression	generated.	
	
Constitutive	systems	aim	to	provide	continuous	expression	of	the	gene	of	interest	by	
allowing	continuous	transcription.	Most	constitutive	promoters	are	viral	based,	due	to	
providing	stable	expression	in	many	tissue	type.	The	most	common	viral	based	
promoters	include	human	cytomegalovirus	(CMV),	Rous	sarcoma	virus	(RSV)	and	simian	
virus	40	(SV40).	Wells	(1998)	showed	CMV	gave	greater	transgene	expression	efficiency	
when	used	via	skeletal	muscle	injection	over	RSV	or	SV40	promoters	(Wells	et	al.,	1998).			
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In	pVR1012	the	CMV	promoter	DNA	sequence	initiates	transcription	of	not	only	the	
transgene	sequence	but	also	the	antibiotic	resistance	gene.	Other	vectors	may	also	have	
other	regions	that	need	to	be	expressed	along	with	the	transgene	of	interest,	such	as	a	
reporter	gene	like	GFP.	This	allows,	once	validated,	a	direct	correlation	to	be	made	
between	expression	of	the	reporter	gene	and	expression	of	the	transgene,	meaning	non-
invasive	monitoring	of	expression	can	be	made	throughout	the	study.	This	is	particularly	
advantageous	when	completing	long	term	in	vivo	investigations.		
	
In	addition	to	basic	function	of	promoters,	there	have	been	many	studies	conducted	on	
the	effect	of	different	promoter	types	when	used	as	a	target	for	specific	tissues.	For	
example,	Wang	et	al	(2008)	showed	that	modified	variants	of	the	muscle-specific	
promoter	muscle	creatine	kinase	(MCK),	gave	high	efficiency	expression	in	muscle	cells	
(in	vitro	in	C2C12	and	in	vivo),	equal	to	or	greater	than	CMV,	but	showed	no	activity	in	
other	cell	types	(Wang	et	al.,	2008)	
	
Inducible	or	regulatable	systems	have	been	developed	to	control	the	level	of	transgene	
expression	to	a	clinically	beneficial	level.	Too	little	or	too	much	and	the	protein	levels	
would	remain	ineffective	or	could	generate	potentially	unsafe	levels.	Systems	that	
control	expression	include,	but	are	not	limited	to;	
• Rapamycin	induced	
• GAL4	
• Tetracycline	transcriptional	systems	
	
An	example	of	one	of	the	first	inducible	systems	is	tetracycline	(Tet).	This	chemical	
based	induction	allows	the	expression	to	be	tightly	controlled.	Expression	is	controlled	
by	managing	the	transcription	of	the	transgene	via	Tet	regulation.	This	can	be	an	on	or	
off	system,	and	the	amount	of	Tet	can	be	used	to	control	the	amount	of	expression	
(Scougall	et	al.,	2003;	Wilson	et	al.,	2005).		
	
1.3.1.2 Viral	Vectors	
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In	viral	vectors,	the	DNA	of	the	gene	of	interest	(therapeutic	or	otherwise)	is	introduced	
into	the	virus	and	packaged	in	such	a	way	in	which	the	gene	of	interest	is	expressed.	
Expression	can	be	constitutive	or	regulated.		Viral	vectors	can	be	further	subdivided	into	
those	vectors	which	integrate	into	the	host	chromosome	(chromosomal)	and	those	
which	do	not	(episomal)(Kootstra	and	Verma,	2003).		Table	1-1	outlines	the	pros	and	
cons	of	each	vector	type	described.	
	
Virus	 Advantages	 Disadvantages	
Adeno-associated	viruses	
(AAV)	
Non-pathogenic,	Long	term	
expression	
Low	level	‘production’	
capabilities	
Retroviruses	 Long	term	expression	 Infects	dividing	cells	only,	
potential	oncogenesis	
Adenoviruses	 Good	safety	profile	 Innate	immunity	
Table	1-1	–	Pro/Con	list	of	most	popular	viral	vectors		
	
1.3.1.2.1 Adeno-associated	viral	(AAV)	vectors	
AAV’s	belong	to	a	class	of	virus	called	Parvoviridae	dependovirus,	which	means	they	are	
a	single	stranded	parvovirus	and	require	‘helper’	viruses	to	allow	them	infect	and	
replicate.	The	most	common	helper	viruses	are	adenovirus	(AD)	or	herpes	simplex	virus	
(HSV)	(Choi	et	al.,	2005;	Wu	et	al.,	2006).	There	are	currently	11	classified	serotypes	of	
naturally	occurring	AAV	(Choi	et	al.,	2005),	all	of	which	share	similar	advantageous	
characteristics	for	use	as	a	vector,	depending	on	the	nature	of	the	therapy	and	the	
target	cell	or	tissue.	Parvoviruses	are	non-pathogenic	to	humans	and	therefore	do	not	
generate	an	innate	immune	response	(Choi	et	al.,	2005;	Wu	et	al.,	2006;	Hirsch	et	al.,	
2010),	they	are	capable	of	transducing	both	dividing	and	non-dividing	cells	(Hirsch	et	al.,	
2010;	Tang	et	al.,	2010)	and	their	DNA	exists	as	epsiomes	therefore	not	requiring	
integration	into	the	host	chromosome	for	expression(Hirsch	et	al.,	2010).		
Although	parvoviruses	do	not	generate	an	innate	immune	response,	some	recent	
studies	have	shown	that	most	people	have	been	exposed	to	wild	type	AAV2	and	have	
therefore	generated	neutralising	antibodies	(NAbs)	which	may	impede	the	viral	vector	
transduction	and	prevent	any	expression	(Zaiss	and	Muruve,	2008;	Li	et	al.,	2012).	As	the	
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name	suggests,	NAbs	neutralize	the	biological	effect	by	binding	with	the	target	antigen	
located	on	the	surface	viral	particle.		
Of	the	11	serotypes,	AAV	2	was	the	most	commonly	used	for	several	reasons,	the	
primary	one	being	that	it	was	the	first	AAV	to	be	cloned	into	a	bacterial	plasmid	in	1982	
by	Samulski	and	is	therefore	the	serotype	that	has	been	most	studied	(Wu	et	al.,	2006).	
A	basic	map	and	schematic	of	AAV	2	(encoding	eGFP)	can	be	seen	in	Figure	1-6.	
However,	as	AAV	use	has	been	increasingly	used	in	research,	each	of	the	serotypes	has	
gained	prominence	in	several	specific	fields.		
Several	AAV	serotypes	have	been	used	as	the	gene	therapy	vector	for	clinical	trials	for	
various	diseases	and	disorders,	including	haemophilia,	muscular	dystrophy	and	cystic	
fibrosis,	which	was	the	first	AAV	human	gene	therapy	trial	which	began	in	1995	(Grieger	
and	Samulski,	2005;	Wu	et	al.,	2006).	Studies	of	particular	interest	relevant	to	this	
project	are	those	using	skeletal	muscle	as	a	target	tissue,	such	as	Murakami	et	al	(2011)	
using	a	recombinant	AAV2	vector	demonstrating	continued	expression	of	luciferase	in	
mice,	using	the	MCK	promoter,	post	intramuscular	(IM)	injection	(Murakami	et	al.,	2011)	
and	Bosch	et	al	(2013)	who	have	demonstrated	long-term	(4+	years)	glucose	
homeostasis	in	diabetic	beagle	dogs	using	AAV1	(Callejas	et	al.,	2013).	
Recombinant	AAV	(rAAV)	vectors	are	engineered	by	removing	two	viral	portions	of	the	
genome,	rep	and	cap.	In	their	place,	a	transgene	expression	cassette	is	added(Choi	et	al.,	
2005).	
One	major	limitation	of	AAV’s	is	the	size	of	the	DNA	fragment	inserted	must	be	less	than	
4.8Kb,	this	causes	problems	when	AAV	would	be	the	vector	of	choice	for	diseases	such	
as	muscular	dystrophies,	where	the	entire	dystrophin	gene	is	2.3Mb	(Bushby	et	al.,	
1992;	Wang	et	al.,	2012).	
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Figure	1-6	–	Example	of	an	AAV	construct	which	could	be	used	for	viral	gene	therapy.	This	
particular	example	shows	the	map	of	a	basic	AAV	serotype	2	from		VectorBiolabs	(Philadelphia,	
PA)	(Vector	Biolabs)	(Vector	Biolabs)		
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1.3.1.2.2 Retrovirus	vectors	
Retroviruses	are	enveloped,	single	stranded	RNA	viruses	which	contain	four	main	gene	
regions;	gag	encodes	for	the	structural	capsid	proteins,	pro	the	viral	protease	enzymes,	
pol	encodes	for	integrase	and	viral	reverse	transcriptase	and	env	refers	to	the	envelope	
glycoproteins.	Retrovirus	vectors	are	only	able	to	infect	dividing	cells.		
The	most	commonly	used	retrovirus	for	vector	usage	is	the	Moloney	leukaemia	virus	
(Mo-MLV)	although	other	viruses	have	been	used	such	as	HIV.	As	with	AAVs,	
retroviruses	do	not	induce	any	immune	response	from	the	host	and	have	been	shown	to	
provide	sustained	expression	for	over	2	years	in	humans,	due	to	the	virus	integrating	
into	the	host	genome.	However,	said	integration	is	random	and	depending	on	where	the	
insertion	occurs,	this	could	alter	the	host	gene	which	may	induce	cancer	(Stone	et	al.,	
2000).	
Clinical	success	with	a	retroviral	vector	has	been	seen	in	SCID	patients,	however,	four	
out	of	nine	patients	went	on	to	develop	a	leukaemia-like	state	(Hacein-Bey-Abina,	2008).		
	
1.3.1.2.3 Adenoviral	vectors	
Adenoviral	Vectors	(AV)	are	suitable	for	gene	transfer	into	both	dividing	and	non-
dividing	cells.	The	AV	genome	remains	extrachromosomal	within	the	nucleus	therefore	
sustained	long-term	expression	would	require	repeated	exposure	and	is	therefore	one	
of	the	major	drawbacks	of	using	this	particular	vector.	The	extrachromosomal	nature	
does	however	remove	the	safety	concerns	around	random	insertion	into	the	host	
genome,	and	the	resulting	cancer	fear,	as	seen	with	the	retroviral	vectors.	AV	does	still	
induce	an	immune	inflammatory	response,	however,	it	has	been	suggested	that	this	may	
be	favourable	when	using	gene	therapy	for	cancer,	as	this	may	aid	in	tumour	destruction	
(Choi	et	al.,	2012).	
	
1.3.1.3 Other	methods	
Several	other	methods	have	been	developed	in	an	attempt	to	increase	the	efficiency	
and	efficacy	of	transgene	expression.	Most	of	these	methods	are	based	on	the	physical	
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process	of	permeabilising	the	membrane	wall	to	allow	the	transgene	DNA	directly	into	
the	cell.	Some	of	these	are	outlined	as	follows.		
  
Electroporation is	 a	 technique	 which	 is	 often	 also	 used	 in	 conjunction	 with	 skeletal	
muscle	injection.	This	method	uses	an	external	electrical	field	across	the	site	of	injection	
in	order	to	generate	small	(nano)	sized	pores	in	the	cell	membrane	which	allow	water-
soluble	 molecules	 to	 cross	 through	 the	 hydrophobic	 lipid	 layer(Lee	 and	 Deng,	 2012).	
Electroporation	aided	delivery	has	shown	very	good	transfection	efficiencies	 in	both	 in	
vitro	 and	 in	 vivo	 studies.	 Although	 some	 areas	 of	 damage	 can	 sometimes	 be	 seen	 in	
muscle	 fibres	 post	 electroporation,	 this	 is	 often	 minimal	 and	 does	 not	 have	 enough	
effect	to	deter	the	high	efficiencies	seen	with	this	technique.		
The	electrical	 field	 can	be	 induced	using	 several	 types	of	electrode,	depending	on	 the	
transfection	system.	Small	calliper	electrodes	are	commonly	used	in	vivo,	these	are	non-
invasive	plates	which	can	be	placed	either	side	of	a	limb	to	generate	the	electrical	field	
required	across	the	target	site.	Other	electrodes	include,	needle	electrodes,	which	is	an	
invasive	 in	 vivo	 technique	 in	 which	 the	 needles	 are	 inserted	 directly	 into	 the	muscle	
tissue,	and	various	in	vitro	electrodes.		
The	 electrical	 field	 is	 generated	 using	 a	 range	 of	 pulsed	 voltage	 ‘waves’,	 which	 have	
been	 studied	 to	 obtain	 the	most	 optimum	 settings	 for	 a	 range	 of	 systems.	Mir	 et	 al	
(1999)	 determined	 that	 the	 optimal	 electrotansfer	 efficiency	 into	 skeletal	muscle	was	
found	with	8	pulses	 (20ms	 in	 length)	with	a	 low	 intensity	setting	of	200V/cm	and	at	a	
frequency	of	1Hz,	when	determined	experimentally	in	vivo	(Mir	et	al.,	1999).	
In	 addition	 to	 the	 enhancement	 provided	 by	 electroporation,	 Mennuni	 et	 al	 (2002)	
showed	 that	 pre-treatment	 with	 hyaluronidase	 further	 increased	 gene	 expression	
approximately	 5	 fold	 with	 no	 permanent	 damage	 or	 injury	 seen	 to	 the	 tissue	 post	
procedure	 (Mennuni	 et	 al.,	 2002).	 Hyaluronidase	 hydrolyses	 hyaluronic	 acid,	 a	 major	
component	 of	 the	 extra	 cellular	 matrix	 found	 in	 connective	 tissue.	 Connective	 tissue	
protects	 skeletal	muscle	 fibres	 against	 potentially	 harmful	 organisms	 such	 as	 bacteria	
and	 viruses,	 and	 therefore	 would	 also	 hamper	 any	 other	 exogenously	 introduced	
compounds,	 such	 as	 DNA/DNA	 carrying	 vectors.	 The	 hydrolysis	 of	 this	 component	 of	
connective	tissue	provides	further	permeability	to	allow	DNA	access	to	the	target	tissue.		
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Ultrasound or	 sonoporation	 utilises	 the	 ‘microbubble	 collapse	 during	 acoustic	
cavitation’	 (Yoon	 and	 Park,	 2010).	 There	 have	 been	 a	 number	 of	 different	 studies	
investigating	 the	 use	 of	 sonoporation	 on	 various	 different	 tissues	 types.	 The	 overall	
results	 suggest	 that	 whilst	 sonoporation	 yields	 a	 lower	 transfection	 rate	 than	
electroporation,	 the	 damage	 caused	 in	 doing	 so	 is	much	 less.	 This	 gives	 sonoporation	
some	grounds	for	continued	investigation	(Wells,	2010).		
 
Nano-particle	 encapsulation, as	 described	 by	 Zhou	 et	 al,	 the	 Nano-particles	 are	
contained	 in	a	calcium-phosphate	and	 lipid	shell	which	encases	 the	transgene	DNA,	 to	
protect	 it	during	delivery.	Once	inside	the	target	cell,	the	case	‘self-destructs’	but	does	
not	generate	a	strong	immune	response	due	to	it	being	formed	of	components	found	in	
the	body	already.	This	vector	has	been	reported	to	be	2.5-10	times	more	effective	than	
other	methods	(Zhou	et	al.,	2010)  
 
Carbon	 nano-tube	 spearing is	where	nickel-embedded	nanotubes	 are	driven	 into	 cell	
membranes	by	a	magnetic	field.	It	has	been	shown	that	plasmids	containing	eGFP	were	
immobilised	onto	the	tubes	and	‘speared’	into	target	cells.	The	transfection	rates	were	
reported	to	be	‘high’(Cai	et	al.,	2005).	
 
Chitosan	nanoparticles	are	glucosamine-based	polymers.	They	have	been	shown	to	
have	high	in	vitro	transfection	rates	when	delivering	both	GLP-1	receptor	agonists	and	
siRNA	aimed	at	silencing	DPP4	activity(Jean	et	al.,	2012)	
 
pFAR	plasmids, which	have	been	developed	at	INSERM,	France,	are	novel	plasmid	
vectors	that	are	free	from	antibiotic	resistance	(Marie	et	al.,	2010).	This	group	have	
shown	these	plasmids	remain	excellent	at	providing	sustained	expression	and	secretion,	
as	seen	with	non-viral	vectors,	without	the	dangers	surrounding	any	antibiotic	resistance	
that	may	occur	using	traditional	plasmid	vectors	whose	selectively	is	based	solely	on	
antibiotic	resistance.	
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1.3.2 Muscle	targeted	gene	therapy	
	
Muscle	targeted	gene	therapy	is	currently	under	investigation	for	several	diseases	and	
disorders,	including,	but	not	limited	to;	several	muscular	dystrophies	(Mendell	et	al.,	
2012;	Wang	et	al.,	2012),	factor	IX	expression	for	haemophilia	B	(Buchlis	et	al.,	2012)	and	
for	the	systemic	secretion	of	various	therapeutic	proteins,	including	inflammatory	
cytokines	and	erythropoietin(Mir	et	al.,	1999)	as	well	as	insulin	therapy	for	diabetes	
(Niessen	et	al.,	2012).	
This	is	mainly	due	to	the	ease	at	which	transgene	expression	is	obtained.	Skeletal	muscle	
has	the	ability	to	uptake	naked	DNA	by	a	simple	injection,	the	muscle	fibres	are	stable,	
end-differentiated,	multi-nucleated	fibres	and	are	thought	to	persist	for	the	lifetime	of	
the	individual.	Even	if	the	muscle	fibre	is	damaged,	only	part	of	the	fibre	is	affected,	the	
remaining	fibre	structure,	and	nuclei	contained	within,	survive.	This	provides	an	
exceptionally	stable	substrate	for	prolonged	gene	expression	(Lu	et	al.,	2003).	
Furthermore,	it	is	easily	accessible	and	with	it	being	a	very	well	vascularised	system,	any	
protein	secretions	are	circulated	in	a	short	period	of	time.		(Aihara	and	Miyazaki,	1998;	
McMahon	et	al.,	1998).		
The	safety	profile	of	skeletal	muscle	targeted	gene	therapy	has	been	proven	in	humans	
previously,	through	several	clinical	trials.	Bowles	et	al	(2012)	showed,	during	a	phase	1	
trial,	that	the	novel	AAV2.5	viral	vector	was	effective	in	delivering	a	mini-dystrophin	
gene	into	the	bicep	muscle	in	Duchenne	muscular	dystrophy	suffers	(Bowles	et	al.,	
2012).						
Prior	to	in	vivo	studies	taking	place,	in	vitro	investigations	can	be	undertaken	using	
primary	muscle	cell	culture	or	immortalised	cell	lines.	C2	cells	are	an	immortal	mouse	
myoblast	cell	line	originally	obtained	by	serial	passage	of	myoblasts	of	the	thigh	of	C3H	
mice	after	crush	injury	in	1977	(Yaffe	and	Saxel,	1977)	and	then	sub-selected	to	C2C12	
cells	by	Blau	et	al	in	1985	(Blau	et	al.,	1985)	.	C2C12	cells	were	employed	in	this	thesis	
due	to	their	ease	of	use	with	regards	to	growth	and	differentiation.		There	are	little	to	no	
sources	which	detail	any	age	(passage)	limitations.	
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Other	skeletal	muscle	lines	are	available,	such	as	L6	–	Rat	skeletal	muscle,	and	of	course	
human	primary	lines,	however,	as	the	next	stage	was	murine	in	vivo,	it	was	thought	
logical	to	utilise	the	murine	cell	line.		
 
1.3.3 Current	diabetic	gene	therapy	
	
Several	studies	have	been	conducted	which	demonstrate	the	feasibility	of	using	gene	
therapy	methods	as	a	promising	new	route	for	diabetes	treatment.	
Shaw	et	al	have	previously	demonstrated	that	long	term	secretion	of	human	insulin	has	
resulted	in	a	reduction	of	blood	glucose	levels	in	both	disease	and	non-disease	models,	
when	administered	via	skeletal	muscle	injection	in	plasmid	format	(Shaw	et	al.,	2002)	
Other	groups	have	had	more	success	utilising	viral	based	methods	in	conjunction	with	
GLP-1,	such	as	Riedel	et	al	(Riedel	et	al.,	2010)	who	have	demonstrated	successful	
expression	and	secretion	of	GLP-1	from	pancreatic	β-cells	in	vivo	via	a	double	stranded	
AAV	vector	of	serotype	8	(DsAAV8)	or	Choi	and	Lee	(Choi	and	Lee,	2011)	who	also	
demonstrated	long	term	expression	of	GLP-1	with	dsAAV,	amongst	others	(Voutetakis	et	
al.,	2010;	Gaddy	et	al.,	2011;	Gaddy	et	al.,	2012),which	suggests	that	GLP-1	expression	
may	be	more	compatible	with	viral	based	vectors.	Samson		et	al	(2008)	demonstrated	
Exendin-4	levels	were	found	15	weeks	post	injection	with	an	AD	vector,	and	that	this	
administration	successfully	improved	glucose	homeostasis,	however,	the	in	vivo	model	
chosen	was	diet-induced	obesity	in	standard	black	6	mice	rather	than	a	model	of	
spontaneous	diabetes,	which	confers	a	greater	affinity	to	the	phenotypes	seen	in	human	
T2DM.	
	
These	studies	suggest	that	whilst	great	inroads	are	being	made	in	developing	a	realistic	
therapy	for	T2DM,	work	is	still	needed	to	produce	a	vector	which	is	consistent	in	its	
expression	of	the	transgene	of	choice	and	has	little	chance	of	inducing	any	sort	of	
toxicity	or	immune	response.		
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1.4 Models	for	studying	muscle-targeted	gene	therapy	for	diabetes	mellitus	
	
Disease	models	can	be	studied	both	in	vitro	and	in	vivo.	In	this	thesis,	I	used	an	in	vitro	
model	of	C2C12	cells	to	assess	the	capabilities	of	the	vectors	used,	and	two	in	vivo	models:	
CD1	and	db/db	mice	to	assess	the	efficiency	of	expression	and	efficacy.	
	
The	C2C12	cell	line	is	a	common	in	vitro	muscle	cell	line	which	is	well	established	and	
studied	and	provides	a	very	stable	phenotype	for	repeat	studies.	Myoblasts	can	be	induced	
to	form	multinucleated	myotubes	(often	characterised	by	having	3	or	more	nuclei)	and	are	
used	for	various	circumstances	which	require	mature	skeletal	muscle	fibre	as	a	model.	
It	was	first	established	in	the	Blau	lab	from	primary	murine	skeletal	muscle.		
This	study	aims	to	confirm	the	efficacy	of	muscle	targeted	gene	therapy,	with	skeletal	
muscle	being	the	route	of	ingress	for	the	treatment.	As	the	in	vivo	disease	model	is	murine,	
it	is	the	most	sensible	option	to	use	a	murine	in	vitro	model	also	(Yaffe	and	Saxel,	1977;	
Burattini	et	al.,	2004).	
	
Type	2	diabetes	in	rodents	can	be	split	into	three	groups;	spontaneous,	chemically	induced	
and	transgenic	(Rees	and	Alcolado,	2005).		
The	‘db/db’	model	is	a	spontaneous	homozygous	point	mutation	on	the	leptin	receptor	
gene	(Lepr	db)	which	leads	to	polyphagia,	polydipsia	and	polyuria.	Mice	become	obese	at	
approximately	3	weeks	old	and	plasma	insulin	levels	being	to	rise	at	10-14	days	old.	At	
anywhere	between	4	and	8	weeks	old	blood	glucose	levels	being	to	rise.	Exogenous	insulin	
does	not	control	the	blood	glucose	levels.	These	elevated	levels	are	uncontrollable	and	lead	
to	severe	β-cell	death,	which	ultimately	causes	death	of	the	animal	at	approximately	10	
months	old.		
The	back	strain	is	C57BLKS/J,	which	confers	84%	homology	with	the	standard	black	6	
(C57BL/6)	and	16%	homology	with	DBA/2J	and	was	initially	maintained	by	Dr	N	Kaliss	(hence	
‘KS’).	The	updated	strain	name	(The	Jackson	Laboratory)	is	BKS.Cg-Dock7m+/+Leprdb/J,	
homozygous	Leprdb.	The	abbreviated	form	of	this	is	‘db/db’.	The	homozygous	strains	are	
maintained	with	Dock7m	and	Leprdb	in	repulsion.	This	is	commonly	accepted	to	be	a	severe	
model	for	type	2	diabetes.	
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1.5 Overall	Objectives	
	
The	principal	aim	of	this	thesis	was	to	investigate	the	hypothesis	that	over-expression	of	
an	externally	introduced	gene,	whether	in	an	unmodified	form	such	as	GLP-1	or	a	GLP-1	
homologue,	such	as	Exendin-4,	will	alleviate	the	symptoms	associated	with	T2DM	
without	the	need	for	daily	or	even	weekly	medical	intervention.		Efficacy,	longevity	and	
the	most	appropriate	vector	were	to	be	determined	experimentally.	
	
	
To	explore	this	hypothesis,	this	thesis	had	the	following	specific	objectives:	
	
• To	establish	in	vitro	and	in	vivo	models	for	muscle	targeted	gene	therapy.	
	
• Compare	expression	obtained	from	plasmid	constructs	and	AAV	viral	vectors	for	
reporter	gene	studies.	
	
• Compare	GLP-1	and	Exendin-4	plasmids	and	AAV	vectors	in	vitro.	
	
• Evaluate	GLP-1	and	Exendin-4	plasmids	and	AAV	vectors	in	long	term	in	vivo	
studies,	in	addition	to	the	potential	impact	in	diabetic	models.	
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2 Chapter	2	-	Material	and	Methods	
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2.1 Materials	
	
Materials	were	purchased	from	several	different	sources	however:	
• All	general	reagents	and	chemicals	were	purchased	from	Sigma-Aldrich,	Dorset,	
UK,	unless	otherwise	stated;	
• Tissue	culture	plastic	ware	was	purchased	from	Greiner	Bio-One	Ltd,	
Gloucestershire,	UK;		
• Tissue	culture	media	were	purchased	from	Life	Technologies,	Paisley,	UK;	
• Primary	antibodies	were	purchased	from	Abcam,	Cambridge,	UK	and	Phoenix	
Pharmaceuticals	Inc.,	CA,	USA;	
• Secondary	antibodies	were	purchased	from	Life	Technologies,	Paisley,	UK;	
• Restriction	digest	reagents	were	purchased	from	Promega,	WI,	USA.	
	
Some	assays	and	reagents	needed	for	certain	protocols	were	readily	available	as	pre-
made	‘kits’.	Table	1	indicates	the	kits	used	and	the	suppliers.	
 
Analytical Kit Supplier 
GLP1 (active) ELISA Millipore, MA, USA 
Exendin 4 EIA 
Phoenix Pharmaceuticals, 
Karlsruhe, Germany 
Mouse Insulin ELISA Mercodia, Uppsala, Sweden 
Plasmid Purification and 
extraction kit 
Qiagen Ltd, West Sussex, UK 
Table	2-1	-	List	indicating	pre-designed	kit-based	assays	and	suppliers	
 
The	vectors	used	are	outlined	in	Chapter	1.	(1.3.1.1	and	1.3.1.2).	
The	plasmid	vector	was	a	pVR1012	with	a	CMV	promoter	and	Kanamycin	resistance,	and	
were	already	available	within	the	group.		
The	AAV	vectors	were	purchased	from	the	Viral	Vector	Production	Unit	(UPV),	University	
of	Barcelona.	Standard	serotype	1	was	used	for	all	studies	involving	GLP-1	and	Exendin-
4.	A	series	of	serotypes	were	used	for	reporter	analysis,	with	standard	eGFP.	
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2.2 Methods	
	
2.2.1 Cell	culture	and	characterisation	
	
C2C12	mouse	muscle	cell	line	(originally	established	in	the	Helen	Blau	laboratory	(Blau	et	
al.,	1985)),	which	was	previously	obtained	and	already	available	within	the	group,	was	
seeded	into	a	T75	flask	from	liquid	nitrogen	frozen	stock,	in	Dulbecco’s	Modified	Eagle	
Medium		(DMEM)		media	containing	10%	foetal	bovine	serum	(FBS)	and	1%	pen/strep	
(100	U/ml	each	for	penicillin	and	streptomycin)	.	This	combination	will	be	referred	to	as	
‘growth	medium’.	The	growth	medium	was	changed	at	least	every	other	day,	whilst	cells	
were	incubated	at	37oC	in	a	humidified	environment	containing	5%	carbon	dioxide.	
Cells	were	‘passaged’	when	they	reached	70-80%	confluence,	which	constituted	of	the	
following	procedures:	medium	was	aspirated,	PBS	was	used	to	wash	off	any	remaining	
serum	and	approximately	2-3	ml	of	a	0.05%	solution	of	Trypsin/EDTA	(containing	0.21	
mmol	Trypsin	and	4.81	mmol	EDTA)	was	added.	The	flask	was	then	re-incubated	for	up	
to	15	minutes	to	achieve	single	cell	suspension.	Cells	were	regularly	monitored	during	
this	re-suspension	process	to	ensure	no	adverse	effects	occurred.	After	suspension,	an	
equal	amount	of	serum-containing	DMEM	was	added	to	the	flask	to	neutralise	the	
action	of	Trypsin.	The	total	volume	of	solution	was	transferred	to	a	Falcon	tube	and	
centrifuged	at	150	relative	centrifugal	force	(RCF)	for	3minutes.	The	supernatant	was	
aspirated	and	the	pellet	re-suspended	in	an	appropriate	volume	of	growth	medium.	The	
cells	were	then	prepared	for	counting	and	re-seeding	as	necessary.	
If	subsequent	use	of	the	cells	included	any	staining,	seeding	would	occur	in	standard	size	
6	well	plates	containing	22x22	mm	coverslips	layered	with	a	fibronectin	(Sigma-Aldrich,	
Dorset,	UK	)	coating	(10	µl/ml).		
Fibronectin	coating	was	achieved	by	steeping	coverslips	in	70%	ethanol	for	5	minutes	
and	allowing	to	air	dry.	Coverslips	were	dropped	into	each	well	of	a	6	well	plate	and	400	
µl	of	fibronectin	(10	µl/ml)	was	used	to	cover	the	surface	of	the	coverslip.	This	was	
allowed	to	‘set’	for	1	hour	at	room	temperature	(RT)	or	overnight	at	4	0C.		
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2.2.1.1 Cell	Counting	
	
To	calculate	number	of	cells	in	suspension,	10	µl	of	the	cell	suspension	was	combined	
with	10	µl	of	0.4%	Trypan	Blue	(1:1	ratio).	10	µl	of	the	total	solution	was	added	to	a	
Neubauer	chamber	and	observed	under	x20	magnification.	The	cells	in	the	four	corner	
squares	of	the	counting	chamber	were	counted	and	averaged.	This	number	was	then	
multiplied	by	2	to	take	into	account	the	1:1	dilution	factor	and	then	multiplied	again	by	1	
x	104	to	obtain	number	of	cells	per	ml.	
	
2.2.1.2 Freezing	and	preservation	of	cells	
	
To	protect	and	store	stocks	of	C2C12	cells,	flasks	at	70-80%	confluence	were	trypsinised,	
separated	and	re-suspended	in	1	ml	cell	freezing	buffer	(90%	FBS,	10%	DMSO)	in	a	1.5ml	
cryotube.	The	cryotubes	were	then	stored	at	-80	0C	overnight	in	a	slow	freeze	‘Mr	
Frosty’	Nalgene	container	(Thermo	Scientific,	Hemel	Hempstead,	UK)	before	being	
transferred	to	liquid	nitrogen	for	long	term	storage.	
	
2.2.1.3 Cell	differentiation	
	
Cells	were	grown	in	6-well	plates	containing	22x22	mm	coverslips	until	approximately	
80-90%	confluent.	Medium	was	then	changed	to	a	reduced-serum	medium	
(Differentiation	medium),	which	consisted	of	DMEM	containing	2%	horse	serum	and	1%	
pen/strep.	Differentiation	medium	was	changed	every	3-5	days	until	myotube	formation	
was	seen.	
	
2.2.2 In	vitro	transfections	using	Lipofectamine2000	
	
The	transfection	protocol	followed	the	recommended	steps	included	in	the	
manufacturer-provided	literature.		
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All	transfections	were	carried	out	in	cells	growing	on	coverslips	coated	with	fibronectin	
in	a	6-well	plate.	The	concentration	of	cells	seeded	per	well	was	~2x105	and	
transfections	were	performed	at	70-80%	confluence.			
The	following	components	and	volumes	are	for	1	well	of	a	6-well	plate:	
10	µl	of	Lipofectamine	2000	was	added	to	150	µl	Opti-MEM	serum	free	medium	and	2	µl	
of	1.0	µg/µl	of	DNA	was	added	to	250	µl	Opti-MEM	(serum-free	media).	Both	were	
incubated	separately	at	room	temperature	(RT)	for	5	minutes.		After	the	incubation,	
both	suspensions	were	mixed	together	gently	by	pipetting.	Once	mixed,	250	µl	of	
combined	suspension	was	added	to	each	well.	The	plate(s)	were	returned	to	incubate	at	
37	0C,	5%	CO2	for	1-3	days,	or	as	the	study	required.	
	
2.2.3 Gene	expression	analysis	of	C2C12	cells	using	either	reporter	gene	GFP	or	genes	
of	interest	Exendin-4	and	GLP-1	by	immunofluorescence	staining	
	
Cells	grown	on	coverslips	in	6-well	plates	were	fixed	using	fresh	4%	paraformaldehyde	
(PFA)	for	15-20	minutes	on	a	shaker.		After	fixing,	the	cells	were	washed	twice	in	
phosphate	buffered	saline	(PBS)	(at	this	point,	cells	could	be	stored	at	2-8	0C	in	PBS	until	
needed).	PBS	was	removed	and	cells	were	permeabilised	in	0.5%	Triton	X-100	in	PBS	by	
shaking	at	RT	for	10	minutes.	The	Triton	X-100	solution	was	removed	and	cells	were	
washed	twice	in	PBS.	PBS	was	removed	and	the	non-specific	binding	blocking	buffer	20%	
FBS	in	PBS	was	added	to	the	wells.	Subsequent	incubation	was	at	RT	for	approximately	1	
hour	on	a	shaker.	The	blocking	buffer	was	removed	and	the	cells	washed	twice	in	PBS.	
PBS	was	removed	and	the	required	primary	antibody	was	added,	at	the	required	
concentration	(see	Table	2-2)	in	0.05%	FBS	in	PBS.	For	all	fluorescent	staining,	primary	
antibodies	were	used	in	conjunction	with	Invitrogen	Alexa	Fluor	488	or	568	secondary	
antibodies.		The	cells	were	incubated	at	RT	for	1	hour	on	a	shaker.	After	incubation,	the	
cells	were	washed	twice	in	PBS.	The	PBS	was	removed	and	the	appropriate	secondary	
antibody	was	added,	at	a	1:500	dilution	in	0.05%	FBS	in	PBS.	The	plate	was	incubated	in	
the	dark	at	room	temperature	for	1	hour	on	a	shaker.	After	incubation,	the	solution	was	
removed	and	the	cells	were	washed	twice	in	PBS.	PBS	was	removed	and	a	10	µg/ml	
working	solution	of	4',6-diamidino-2-phenylindole	(DAPI)	was	added.	This	was	incubated	
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at	RT	in	the	dark	on	a	shaker	for	5	minutes.	The	DAPI	solution	was	removed	and	cells	
were	washed	twice	with	PBS.	The	second	wash	was	left	for	3-5	minutes	to	reduce	the	
intensity	of	the	DAPI	stain.	After	5	minutes,	the	coverslips	were	removed	from	the	wells	
and	mounted	onto	microscope	slides	using	Vectashield	and	sealed	with	clear	nail	
varnish.	The	slides	were	labelled	appropriately	and	stored	in	the	dark	at	2-80C	until	
needed.	
Alternatively,	Vectashield	containing	DAPI	was	used;	in	which	case,	coverslips	were	
washed	with	PBS	and	mounted	directly	onto	slides	without	the	need	for	a	DAPI	staining	
step.					
	
Primary	Antibody	 Supplier	 Dilution	
(In	0.05%	FBS	in	PBS)	
Desmin	 Abcam,	Cambridge,	UK	 1/100	
Exendin-4	 Phoenix 
Pharmaceuticals, 
Karlsruhe, Germany	
1/50	
GLP-1	 Abcam,	Cambridge,	UK	 1/1000	
	Table	2-2	–	primary	antibody	dilutions	used	for	immunohistochemical	analyses	
2.2.4 Visualising	stained	cells	
	
To	analyse	cells	from	in	vitro	samples	(e.g.	C2C12	transfection	studies),	the	cells	were	
seeded	on	fibronectin	coated	coverslips	(10	µl/ml)	which	were	then	used	in	various	
capacities,	depending	on	requirements.		
In	all	cases,	either	a	Nikon	Eclipse	E400	fluorescent	microscope	with	a	DXM1200	camera	
(Nikon,	Sendai,	JP)	or	a	Zeiss	AxioImager		Z1	with	CoolSnap	HQ2	camera	(Zeiss,	
Oberkochen,	DE),	in	conjunction	with	either	Qcapture	Pro	image	capture	program	
(QImaging,	British	Columbia,	CA)	and	Lucia	GF	counting	software	(version	3.81))	or	
Axiovision	(version	4.8.2)	(Zeiss,	Oberkochen,	DE),	respectively,	were	used	for	analysis.	
Images	were	subsequently	further	analysed	using	ImageJ	(version	1.48u)	(Wayne	
Rasband,	NIH,	US.		
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2.2.4.1 Percentage	transfection	efficiency	
	
Using	the	pVR1012-CMV-GFP	plasmid,	transfections	were	performed	(see	2-2-2)	and	
DAPI	stained	(see	2-2-3).	Ten	fields	of	view	per	coverslip	were	counted	in	a	randomised	
yet	consistent	procedure	in	an	attempt	to	eliminate	any	bias,	with	percentage	
transfection	efficicncy	established	by	calculating	the	number	of	cells	showing	positive	
GFP	expression	as	a	proportion	of	the	number	of	nuclei	in	a	particular	field	of	view.	
 
2.2.5 Growth	medium	
	
Luria	Bertani	(LB)	agar	containing	the	antibiotic	kanamycin	(50	mg/ml)	was	made	using	
the	following	recipe:	
Component Amount 
Tryptone 10.0 g 
Sodium chloride 5.0 g 
Yeast extract 5.0 g 
Agar 15.0 g 
Antibiotic 50 µg/ml final concentration (added 
once media cool to touch) 
Table	2-3	Kanamycin	containing	LB	agar	recipe	
	
LB	broth	was	made	to	the	same	ratios	as	in	Table	2-3,	minus	the	agar.	
	
2.2.6 Transformation	of	competent	bacteria		
	
Bacterial	competent	cells	(E.coli	DH5α)	were	used	for	transformations.	
The	transformation	method	was	provided	with	the	competent	DH5α	cells.	
In	short,	sterile,	polypropylene	culture	tubes,	the	frozen	(-80	0C)	competent	cells,	cold	
super	optimal	broth	(SOC)	medium	and	pipette	tips	were	placed	on	ice	to	cool,	or,	in	the	
case	of	the	cells,	thaw.	Once	thawed	(approx.	5	minutes),	the	cells	were	mixed	gently	
and	100	µl	was	transferred	to	a	culture	tube	(100	µl	per	transformation).	Ten	ng	(in	10	
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µl)	of	DNA	was	added	to	the	100	µl	of	competent	cells.	The	suspension	was	mixed	by	
flicking.	The	tubes	were	returned	to	ice	for	10	minutes	before	being	heat-shocked	for	
45-50	seconds	at	42	0C.	After	heat	shock,	the	tubes	were	returned	to	ice	once	more	for	a	
further	2	minutes.	After	the	2	minute	ice	incubation,	900	µl	of	SOC	medium	was	added	
to	each	transformation	reaction.	The	tubes	were	then	incubated	at	37	0C	on	a	shaker	at	
approximately	225	rpm	for	60	minutes.	
After	incubation,	the	transformation	reaction	was	plated	onto	LB/kanamycin	plates	and	
incubated	at	37	0C	for	12-14	hours.	
The	antibiotic	Kanamycin	was	added	once	the	LB	medium	was	cooled	to	touch	(The	
Duran	bottle	containing	the	sterilised	media	should	be	warm	to	the	touch	but	not	so	hot	
that	it	can’t	be	held	with	bare	hands)	after	steam	sterilisation	–	1210C	for	a	minimum	of	
15minutes,	before	being	poured	aseptically	into	a	90	mm	Petri	dish..	The	plates	were	left	
to	solidify	in	an	aseptic	atmosphere	before	being	stored	in	a	cold	room	until	needed.	
Fifty	ng	(in	1	µl)	of	DNA	was	added	to	50	µl	of	competent	DH5α	cells	and	were	mixed	
gently	(not	pipetting).	The	tubes	were	incubated	on	ice	for	30	minutes,	then	transferred	
to	a	heat	block	for	heatshock	treatment	at	45	0C	for	30-45	seconds,	then	transferred	to	
ice	again	for	2	minutes.	Subsequently,	950	µl	of	SOC	media	was	aseptically	transferred	
to	each	tube	and	incubated	for	a	further	60	minutes	at	37	oC	in	a	shaking	incubator	at	
225	rpm.	After	incubation,	250	µl	of	the	mixture	was	spread	onto	an	LB	plate,	containing	
the	antibiotic.	The	plates	were	re-incubated	at	37	0C	for	24-48	hours,	or	until	bacterial	
growth	was	observed.	Once	growth	was	observed,	the	plates	were	stored	at	4-8	0C	until	
needed.	
	
2.2.7 Obtaining	plasmid	
	
One	colony-forming	unit	(cfu)	of	transformed	E.coli	was	inoculated	into	5	ml	sterile	LB	
broth	containing	kanamycin	(see	Table	3	–	without	agar)	in	a	50ml	falcon	tube	and	
incubated	at	37	0C	and	300	rpm	for	8	hours.	This	5	ml	so-called	‘starter	culture’	was	then	
inoculated	into	500	ml	sterile	LB	in	a	2	L	flask	and	again	incubated	under	the	same	
conditions	for	12-16	hours.	Post-incubation,	the	Qiagen	Mega	Prep	protocol	was	
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followed,	with	no	deviations,	as	per	literature	provided	within	the	kit.	This	resulted	in	a	1	
ml	stock	solution	of	required	plasmid	DNA.		
2.2.8 Spectrophotometry	
	
The	NanoDrop	2000	(Thermo	Scientific,	Hemel	Hempstead,	UK)	Spectrophotometer	was	
used	to	determine	the	concentration	of	DNA	obtained	from	the	Qiagen	Mega	prep	kit	
(2.2.4.3).		One	μl	of	DNA	was	placed	onto	the	loading	pad.		The	two	pads	were	then	
made	to	touch	creating	a	column	of	fluid	through	which	the	light	beam	could	be	passed	
through.		An	absorbance	curve	was	generated,	measuring	DNA	peak	at	260	nm	and	
contaminating	protein	peak	at	280	nm.		The	amount	of	DNA,	calculated	in	ng/μl,	was	
then	used	to	standardise	all	DNA	samples	to	1	μg/μl.	
	
2.2.9 Restriction	Enzyme	Digest	
	
Restriction	enzyme	digests	(double	digests)	were	performed	on	GLP-1	and	Exendin-4	
plasmids,	as	per	the	Promega	protocol	(which	was	included	as	part	of	the	literature	
provided	with	the	enzymes),	using	enzymes	BamHI	and	EcoRV.		
	
The	digest	mix	consisted	of:	
Component Volume 
Sterile, deionised water 16.3 µl 
Restriction enzyme 10x Buffer 2.0 µl 
Acetylated BSA (10µg/µl) 0.2 µl 
DNA (1.0 µg/µl) 1.0 µl 
Mix the above by pipetting, then add: 
Restriction Enzyme (10 u/µl) 0.5 µl 
FINAL VOLUME 20.0 µl 
Table	2-4-		Restriction	digest	master	mix	
	
Tubes	were	then	centrifuged	briefly	and	gently	mixed	by	pipetting	before	being	
incubated	at	~37	0C	for	1-4	hours.	
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2.2.10 Agarose	gel	electrophoresis	
	
Plasmid	fragments	were	separated	and	visualised	on	a	1%	agarose	gel,	which	was	
prepared	by	dissolving	1	g	agarose	powder	(Melford,	Suffolk,	UK)	in	100	ml	of	1x	TBE	
buffer	(89	mM	Tris-base,	89	mM	Boric	acid,	2	mM	EDTA).	Then,	4	μl	of	10	mg/ml	
ethidium	bromide	(Sigma,	Dorset,	UK)	was	added	to	the	molten	gel.		The	gel	was	run	
with	a	potential	difference	of	70-90V	across	the	gel	using	1X	Tris/Borate/EDTA	(TBE)	
buffer.	
	
2.2.11 In	Vivo	Studies	
2.2.11.1 Ethics	Statement	and	Animal	details	
	
All	experiments	were	conducted	under	the	Animals	(Scientific	Procedures)	Act	1986		in	
accordance	with	the	British	Home	Office	animal	licence	guidelines	and	under	a	Project	
Licence	(Project	Licence	holder:	Professor	James	Shaw,	Personal	Licence	holder:	Gillian	
Patterson).	
All	animals	were	housed	within	the	Comparative	Biology	Centre	located	within	the	
University	of	Newcastle	and	kept	on	12	hour	light	/	dark	cycles.	All	animals	were	allowed	
free	access	to	stock	chow	and	water,	unless	they	were	subject	to	fasting	for	glucose	
tolerance	tests	(see	individual	in	vivo	protocols	in	Appendix),	at	which	stage	they	were	
allowed	free	access	to	water	only.		
	
All	mice	were	sourced	from	Charles	River,	via	the	CBC	facility	within	the	university.		
All	‘normal’	model	mice	used	were	CD1	females,	with	the	exception	of	the	initial	eGFP	
reporter	expression	in	vivo	study,	which	used	males	(see	5.4.3).		
All	‘diseased’	model	mice	were	dbdb	females.	
The	CD1	mouse	is	general-purpose	model	often	used	for	wide	range	of	studies	with	
reliable,	consistent	baseline	parameters.	
Dbdb	mice,	originally	developed	from	The	Jackson	Laboratory	(JAX),	form	from	a	
homozygous	point	mutation	on	the	leptin	receptor	gene	(Lepr	db)	which	leads	to	
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polyphagia,	polydipsia	and	polyuria.	Mice	become	obese	at	approximately	3-4	weeks	old	
and	plasma	insulin	levels	being	to	rise	at	10-14	days	old.	At	anywhere	between	4	and	8	
weeks	old	blood	glucose	levels	being	to	rise.	Exogenous	insulin	does	not	control	the	
blood	glucose	levels.	These	elevated	levels	are	uncontrollable	and	lead	to	severe	β-cell	
death,	which	ultimately	causes	death	of	the	animal	at	approximately	10	months	old.		
The	back	strain	is	C57BLKS/J,	which	confers	84%	homology	with	the	standard	black	6	
(C57BL/6)	and	16%	homology	with	DBA/2J	and	was	initially	maintained	by	Dr	N	Kaliss	
(hence	‘KS’).	The	updated	strain	name	(The	Jackson	Laboratory)	is	BKS.Cg-
Dock7m+/+Leprdb/J,	homozygous	Leprdb.	The	abbreviated	form	of	this	is	‘db/db’.	The	
homozygous	strains	are	maintained	with	Dock7m	and	Leprdb	in	repulsion.	This	is	
commonly	accepted	to	be	a	severe	model	for	type	2	diabetes.		
	
All	mice	were	brought	into	the	university	facility	at	approx.	3-4	weeks	old,	which	is	the	
earliest	possible	age	mice	can	be	sourced.	After	adhering	to	the	1	week	acclimatisation	
period	in	place	at	the	CBC,	mice	were	approx.	4-5	weeks	old	at	the	onset	of	any	study.		
	
2.2.11.2 Non-invasive	imaging	using	the	In	Vivo	Imaging	System	(IVIS)	
	
A	non-invasive	imaging	technique	was	employed	to	monitor	eGFP	gene	expression	in	the	
mice	during	the	study.	The	mice	were	lightly	anaesthetised	using	the	inhalant	isoflurane	
so	as	to	render	them	immobile	during	the	imaging	process.		
Mice	were	imaged	under	epi-illumination	conditions	from	both	dorsal	and	ventral	views.	
The	spectral	un-mixing	function	in	the	software	was	utilised	to	subtract	any	possible	
auto	fluorescence	from	the	fluorescence	seen	from	GFP	expression.	Regions	of	interest	
(ROI)	were	established	and	GFP	intensity	measured	under	the	same	conditions	for	each	
subject.	
Living	Image	In	Vivo	Imaging	software	(Version	4.1)	was	used	(PerkinElmer,	MA,	US).	
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2.2.11.3 Vector	Administration	
Plasmid	administration	was	coupled	with	hyaluronidase	and	electroporation	as	a	
method	to	increase	the	efficiency	of	vector	uptake	and	subsequent	gene	expression.		
	
For	plasmid	administration,	the	mouse	was	anaesthetised	lightly	to	prevent	movement	
and	reduce	pain	and	stress	via	inhalant	anaesthetic	isoflurane.	The	analgesic	carprofen	
was	administered	subcutaneously	into	the	scruff	of	the	mouse	(dose	50	mg/kg,	total	
volume	0.1	ml).	Hyaluronidase	was	administered	into	the	muscle	in	the	location	of	the	
subsequent	plasmid	administration,	at	a	concentration	of	0.4	U/µl	in	a	total	volume	of	
25µl	prior	to	plasmid	injection,	which	was	at	a	concentration	of	1	µg/µl	in	a	total	volume	
of	50	µl.	Post	plasmid	injection,	the	leg	was	subjected	to	electroporation	(settings	used:	
200	V/cm,	eight	20	ms	pulses).	The	calliper	electrodes	were	stainless	steel	plates	and	
ECG	gel	was	applied	to	the	plates	prior	to	electroporation	taking	place.	All	injections	
were	made	percutaneously	to	both	tibialis	anterior	and	gastrocnemius	muscles,	
perpendicular	to	the	central	portion	of	the	muscle.	
	
AAV	vectors	were	administered	under	the	same	conditions,	without	the	use	of	the	
hyaluronidase	or	electroporation.	The	AAV	vectors	were	administered	in	a	total	volume	
of	50	µl	in	the	following	titre	of	vector	genome	(vg)	(as	determined	appropriate	from	
published	literature	(Zincarelli	et	al.,	2008):	
	
• Exendin	4	-		 1.776x1011	vg/mouse		
• GLP1	-			 1.784x1011	vg/mouse	
• eGFP	-			 1.745x1011	vg/mouse	 	
	
	
Whole	blood	samples	were	obtained	using	standard	tail	venepuncture,	as	larger	
volumes	(approximately	100	µl,	depending	on	the	weight	of	the	animal)	were	required.	
The	exact	volume	obtained	was	kept	within	the	NC3R	guidelines	for	blood	sampling	
(which	was	also	reflected	within	the	PPL	-	https://www.nc3rs.org.uk/blood-sample-
volumes	
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2.2.12 Tissue	harvesting	
2.2.12.1 Muscle	samples	
	
When	indicated	and	after	humane	Schedule	1	euthanasia,	muscle	samples	were	
harvested	from	mice	and	subjected	to	further	processing	(snap	freezing	or	buffer	
immersion).	
Samples	for	freezing	were	snap-frozen	by	placing	them	directly	into	isopentane,	pre-
cooled	in	a	70%	ethanol/dry	ice	bath,	until	uniformly	frozen.	Samples	were	then	placed	
into	a	pre-labelled	cryotube	and	maintained	on	dry	ice	until	longer	term	storage	at	-80	
0C	was	possible.	 
Other	samples	were	placed	directly	into	1	ml	of	Buffer	A	(10	mM	HEPES	pH	7.9,	10	mM	
KCl,	0.1	mM	EDTA	pH	8.0,	0.1	mM	EGTA	pH	8.0,	1.0	mM	dithiothreitol	and	10	µl/ml	
protease	inhibitor	(Roche,	UK).	
Frozen	samples	were	sectioned	using	a	Leica	cryostat	(Leica,	Nussloch,	DE),	creating	
sections	of	4-5	µm	thickness	after	which	they	were	mounted	onto	superfrost	glass	slides	
for	subsequent	staining.	
Samples	in	buffer	A	were	then	homogenised	by	depositing	them	into	Lysing	Matrix	D	
green-cap	tubes	containing	1.4mm	ceramic	beads	(mpBio,	CA,	USA),	and	shaking	them	in	
a	FastPrep	instrument	(mpBio,	CA,	US).	The	instrument	was	run	for	20	seconds	at	a	
speed	setting	of	6.5	m/s	to	fully	homogenise	the	tissue.	If	any	further	homogenisation	
was	required,	the	sample	was	held	on	ice	for	~5minutes	before	another	run	was	
performed.	The	resulting	homogenate	was	centrifuged	for	5	minutes	at	12,000	RCF.	The	
supernatant	was	collected	in	fresh	eppendorfs	and	frozen	at	-80	0C	until	needed.	
	
2.2.12.2 Pancreas	samples	
	
The	pancreas	was	removed	from	each	animal,	weighed	and	placed	directly	into	small	
universals	containing	5	ml	10%	formalin.	
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Samples	were	sent	for	processing	into	paraffin	blocks	and	sectioned,	using	a	Microm	
HM330	microtome	(Microm,	Heileberg,	DE),	at	4-5µm	and	mounted	onto	superfrost	
glass	slides	for	staining.	
	
2.2.13 Blood	sampling	
	
Blood	samples	were	taken	as	directed	by	the	protocol	and	in	accordance	with	the	Home	
Office	Project	Licence	(PPL).	Peripheral	blood	samples	were	taken	using	tail	
venepuncture	method	and	collected	in	a	blood	capillary	microvette	(Sarstedt,	
Nümbrecht,	DE).	
Terminal	samples	were	taken	under	terminal	anaesthesia	through	cardiac	puncture.	
	
2.2.14 Analytical	Methods	
	
The	following	methods	were	employed	for	analysing	the	blood	samples	and	the	
homogenised	tissue	samples.	
	
2.2.14.1 Exendin-4	EIA	
	
Exendin-4	concentrations	in	serum	derived	from	blood	samples	from	mice	and	the	
supernatant	derived	from	homogenised	muscle	samples	were	analysed	using	a	
commercial	exendin-4	EIA	kit	(Phoenix	Pharmaceuticals,	Karlsruhe,	DE).	The	
manufacturer-recommended	protocol	was	followed	without	deviation.		
	
2.2.14.2 GLP-1	ELISA	
	
Equally,	serum	and	muscle	GLP-1	concentrations	were	evaluated	using	an	active	GLP-1	
ELISA kit	(Millipore,	MA,	US).	Prior	to	serum	separation,	10	µl/ml	of	DPP4	inhibitor	
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(Millipore)	was	added	to	the	blood	sample.	The	manufacturer’s	protocol	was	followed	
without	deviation.	
2.2.14.3 Mouse	Insulin	ELISA	
	
Serum	separated	from	blood	sampled	through	cardiac	puncture	(under	terminal	
anaesthesia)	was	analysed	for	insulin	content	using	a	mouse	insulin	ELISA	kit	(Mercodia,	
Uppsala,	SWE).	The	blood	was	allowed	to	clot	at	room	temperature	before	being	quick	
spun	to	separate	the	serum	from	the	clot.	The	manufacturer’s	protocol	was	followed	
without	deviation.	
	
2.2.15 Analytical	method	validation	 	
	
Where	appropriate,	each	assay	was	further	validated	to	demonstrate	accuracy	and	
precision	within	the	laboratory	and	across	the	length	of	the	studies.	Repeatability	and	
intermediate	precision	was	considered	when	performing	these	tests	and	additional	
samples	were	included	where	needed.		
 
2.2.15.1 Inter	assay	Coefficients	of	Variability	(CV)	determination	
	
Each	ELISA/EIA	type	used	was	subject	to	both	inter	and	intra	assay	validation.	As	this	
study	relies	on	comparison	of	studies	conducted	at	different	times,	it	is	important	to	
have	confidence	in	the	robustness	of	the	assays	generating	the	data.		
The	generally	accepted	rule	(as	described	by	the	Statistics	department,	Newcastle	
University)	is	inter	assay	%	CV	values	should	be	less	than	15	and	intra	assay	%	CV	values	
should	be	less	than	10.	Inter	assay	%	CV	was	determined	by	assessing	the	high,	medium	
and	low	values,	which	are	used	to	form	the	standard	curve.	The	%	CV	for	each	assay	type	
is	determined	by	averaging	each	%	CV	gained.	
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Table	2-5	outlines	the	data	obtained	the	data	obtained	from	each	Exendin-4	EIA	used	
throughout	the	study.	The	instructions	included	in	the	kit	protocol	described	manually	
obtained	figures	in	ng/ml	from	the	graph	obtained	from	the	standard	curve.	The	results	
obtained	in	nm	from	the	absorbance	readings	were	more	accurate	and	this	raw	data	
was	used	in	inter	assay	precision	determination.	
	
	 100ng/ml 1ng/ml 0.01ng/ml 
Mean	 1.892	 0.574	 0.111	
SD	 0.271	 0.067	 0.017	
CV	 14.339	 11.642	 15.703	
Total	%	CV	 13.9	
Table	2-5	–	Inter	assay	%	CV	for	Exendin-4	EIA.	Precision	data	from	3	different	EIA	plates,	
performed	on	3	separate	occasions	using	a	high	(100	ng/ml),	medium	(1	ng/ml)	and	low	(0.01	
ng/ml)	concentration	of	protein	standard	as	the	sample.	
	
	
Table	1-6	outlines	the	data	obtained	from	each	GLP-1	ELISA	used	in	the	study.	As	with	
the	Exendin-EIA,	the	determination	of	concentration	was	obtained	manually	from	the	
subsequent	standard	curve.	The	raw	data	spectrophotometry	absorbance	was	again	
used	as	this	was	more	precise.	
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	 2pM 10pM 100pM 
Mean 432.458	 1223.501	 19551.776	
SD 20.344	 201.785	 1678.065	
CV 4.704	 16.492	 8.583	
Total % CV 9.9 
Table	2-6–	Inter	assay	%	CV	for	GLP-1	ELISA.	Precision	data	from	3	different	ELISA	plates,	
performed	on	3	separate	occasions	using	a	high	(100	pM),	medium	(10	pM)	and	low	(2	pM)	
concentration	of	protein	standard	as	the	sample.	
	
2.2.16 Solid	tissue	analysis	
2.2.16.1 Haematoxylin	and	eosin	staining	
	
If	stored	at	-80	0C,	the	frozen	sections	were	left	to	warm	up	to	RT	prior	to	the	staining	
procedure.	The	paraffin-embedded	pancreas	sections	were	de-paraffinised	by	
submerging	the	slides	in	histoclear	for	10	minutes	and	then	re-hydrated	by	submerging	
in	100%	ethanol	for	3	minutes,	95%	ethanol	for	1	minutes	and	then	rinsed	in	distilled	
water	(dH2O).	The	slides	were	then	submerged	in	haematoxylin	solution	for	5	minutes	
before	being	rinsed	with	dH2O.	The	next	step	consisted	of	washing	the	sections	with	
Scott’s	tap	water	for	30-60	seconds	followed	by	washing	with	dH2O.	After	the	wash,	the	
slides	were	submerged	in	eosin	solution	for	1	minute	before	being	washed	again	with	
dH2O.	After	this	final	wash,	slides	were	dehydrated	by	serial	submersions	in	50%,	70%,	
95%	and	twice	in	100%	ethanol	solutions,	all	for	1	minute	each.	The	slides	were	then	
placed	in	2	x	histoclear	solutions	before	being	mounted	with	DPX	using	a	coverslip.	The	
sections	were	visualised	using	a	Zeiss	AxioImager	Z1	with	CoolSnap	HQ2	camera	in	
conjunction	with	Axiovision	4.8.2	software.		
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2.2.16.2 Immunoperoxidase	staining	–	double	labelling	
	
Slides	were	de-paraffinised	and	re-hydrated	as	per	standard	protocol	(10	minute	de-wax	
in	histoclear,	3	minute	re-hydrate	in	100%	ethanol,	1	minute	rehydrate	in	95%	ethanol,	
and	rinse	in	PBS).	The	de-paraffinised	slides	were	then	submerged	in	methanol	and	
hydrogen	peroxide	(200	ml	and	3	ml	respectively)	for	10	minutes	to	block	peroxidise	
activity.	To	retrieve	the	antigen	(epitope	exposure)	the	slides	were	placed	in	a	pressure	
pan	containing	10	mM	sodium	citrate	(pH	6.0)	and	boiled	at	full	pressure	for	1	minute.	
The	slides	were	immediately	rinsed	with	cold	running	tap	water	and	held	in	PBS	until	
needed.	To	perform	non-specific	blocking,	the	sections	were	incubated	in	20%	FBS	for	1	
hour	at	RT,	after	the	sections	had	been	demarcated	with	DAKO	marker	(DAKO,	
Cambridgeshire,	UK).	Following	blocking,	the	slides	were	washed	twice	with	PBS	before	
being	incubated	overnight	(refrigerated)	with	primary	antibody	in	0.05%	FBS	in	PBS.	
After	this	overnight	incubation,	the	slides	were	washed	twice	with	PBS	before	being	
incubated	at	RT	for	1	hour	with	the	secondary	antibody.	After	incubation,	the	slides	
were	again	washed	twice	with	PBS	before	being	incubated	for	approximately	10	minutes	
with	primary	substrate,	which	varied	depending	on	what	was	being	examined	(see	Table	
2-2).	The	slides	were	then	washed	twice	with	PBS	and	peroxidase	action	was	again	
blocked	by	incubating	in	a	solution	of	1	ml	hydrogen	peroxide	and	9	ml	PBS	for	10	
minutes.	The	slides	were	washed	twice	with	PBS	and	incubated	in	the	blocking	solutions	
avidin	and	biotin	for	15	minutes	each	at	RT.	The	slides	were	washed	twice	with	PBS	
before	being	incubated	in	a	non-specific	block,	20%	FBS	in	PBS,	for	1	hour	at	RT.	The	
slides	were	rinsed	with	PBS	and	cold	incubated	at	4	oC	with	the	second	primary	antibody	
overnight.	After	the	overnight	incubation,	the	slides	were	washed	twice	with	PBS	and	
the	second	secondary	antibody	was	added,	slides	were	incubated	for	1	hour	at	RT.	The	
‘ABC’	solution	(Vectastain	ABC	kit,	Vector	Labs,	CA,	US)	was	made	(30	minutes	before	
use).	The	slides	were	washed	twice	with	PBS	before	being	incubated	in	the	ABC	solution	
for	30	minutes.	The	slides	were	given	a	final	wash	with	PBS	before	being	incubated	for	5	
minutes	with	the	secondary	substrate,	rinsed	in	PBS,	counterstained	in	haematoxylin	for	
5	minutes,	washed	with	tap	water	and	mounted	using	DPX	(Sigma-Aldrich,	Dorset,	UK)	
and	a	coverslip.	
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2.2.16.3 Whole	section	imaging	for	transfection	evaluation	
	
Whole	sections	of	frozen	muscle	were	visualised	using	the	Zeiss	AxioImager	software	
mosaic	function.	This	allows	each	field	of	view	to	be	stitched	together	to	form	an	image	
the	entire	section	at	the	desired	magnification.	Standard	exposure	limits	were	
determined	to	ensure	no	variability	from	the	software	interfered	with	the	intensity	of	
the	staining	observed.		
The	image	of	the	whole	section	was	then	imported	into	Image	J	software	programme	
(http://imagej.nih.gov/ij/)	to	analyse	the	entire	area	in	question.	Image	J	is	a	free	
downloadable	open	access	tool	used	globally	by	many	researchers,	and	as	such	is	
classed	as	an	approved	peer	reviewed	system	for	analysing	images.		
For	cell	based	analysis	(myoblasts/myotubes),	the	field	of	view	was	uploaded	to	the	
software	and	a	RGB	colour	deconvolution	was	performed.	This	separated	the	red,	green	
and	blue	stained	images	from	one	another,	ensuring	no	cross-over	in	expression	was	
observed.	The	‘green’	(eGFP)	was	converted	to	a	binary	image	and	the	resulting	area	
calculated	as	a	percentage.	
The	same	principle	was	applied	to	section	images,	however,	as	the	image	was	the	entire	
tiled	area	of	the	section,	the	section	was	drawn	around	to	obtain	a	total	area.	The	image	
was	then	RGB	deconvoluted,	turned	to	binary	and	the	area	obtained.	The	percentage	
area	transfected	was	then	manually	calculated	using	the	two	figures.		
 
2.2.17 Statistical	analysis	
	
Intra-peritoneal	glucose	tolerance	test	(IPGTT)	analyses	were	performed	using	repeated	
measures	analysis	of	variance	(rANOVA)	with	the	Bonferroni	correction	applied.	The	
rANOVA	is	used	in	longitudinal	studies	when	the	same	subjects	are	repeatedly	measured	
under	different	conditions	but	the	results	are	linked	(a	standard	ANOVA	assumes	
independence).	The	Bonferroni	correction	is	applied	as	this	controls	the	‘family	wise	
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error	rate’	(the	probability	of	making	false	discoveries)	and	is	a	standard	correction	filter	
when	analysing	multiple	comparisons.		
All	other	statistical	measurements	were	performed	using	either	t-test	(paired	or	un-
paired)	or	two-way	ANOVA,	depending	on	the	nature	of	the	data.	
All	data	are	reported	as	mean	±	SD,	unless	otherwise	stated.	
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3 Chapter	3	–	Establishment	of	in	vitro	and	in	
vivo	muscle	targeted	gene	transfer	protocols	
and	evaluation	of	the	resulting	expression,	
driven	by	viral	and	muscle	specific	
promoters	in	plasmid	constructs	and	AAV	
vectors	in	eGFP	reporter	gene	studies	
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3.1 Introduction	
	
For	the	purposes	of	this	thesis,	all	‘reporter	gene’	studies	refer	to	the	expression	and	
visualisation	of	the	fluorescence	gene	GFP.	
	
Initially,	the	wtGFP	compound	was	isolated	in	the	1960’s	from	the	jellyfish	Aequorea	
Victoria	(Shimomura	et	al.,	1962).	However,	several	engineered	mutations	have	since	
allowed	more	widespread	use	of	GFP	derivatives	and	have	provided	several	other	colour	
formats	to	be	used	in	multiple	applications.	The	most	commonly	associated	green	colour	
was	first	reported	by	Tsien,	1995	which	allowed	the	fluorescence	to	be	observed	under	
the	FITC	filter,	remaining	the		most	frequently	used	reporter	gene	format	used	today	
(Heim	et	al.,	1995).	
	
In	order	to	predict	the	outcome	for	skeletal	muscle	expression	studies	in	vivo,	in	vitro	
models	can	be	used	to	establish	proof	of	concept.	As	discussed	earlier,	skeletal	muscle	is	
an	attractive	target	for	gene	therapy	as	it	provides	a	stable	end-differentiated	tissue	
platform	for	long	term	expression	with	good	vascularisation	for	easy	delivery	into	the	
circulating	bloodstream.		
	
C2C12	cells	are	a	murine	muscle	cell	line,	initially	derived	from	the	C2	cell	line,	which	in	
turn	was	obtained	from	the	skeletal	muscle	of	normal	C3H	mice	in	the	Blau	lab	in	the	
1980’s	(Blau	et	al.,	1985).	The	C2C12	line	is	a	very	good	model	for	in	vitro	muscular	
based	studies	as	the	cells	readily	proliferate	but	myogenic	phenotype	remains	stable,	
generally	up	to	approximately	Passage	50	when	cells	are	maintained	appropriately.	The	
cells	can	also	be	differentiated	from	myoblasts	into	myotubes	which	mimic	somewhat	
the	events	seen	in	vivo	with	reference	to	skeletal	muscle	myogenesis	from	proliferative	
satellite	precursor	cells.	Several	studies	have	shown	that	C2C12	is	a	good	cell	line	for	
evaluation	of	muscle-targeted	gene	therapy	(Shaw	et	al.,	2002;	Ratanamart	et	al.,	2007).		
	
Three	types	of	vector	were	used	in	GFP	reporter	gene	studies	to	undertake	initial	
evaluation	of	constitutive	viral	promoter	driven	plasmids	(pVR1012.CMV.GFP);	
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eukaryotic	muscle-specific	promoter	driven	plasmids	(	pRRL.sin.PPT.DES.eGFP)	and	
adeno-associated	viral	vectors:	
• pVR1012.CMV.GFP	is	a	plasmid	construct	which	was	originally	obtained	from	
Vical	(CA,	USA)	with	the	genes	of	interest	previously	cloned	between	the	EcoRV	
and	BamHI	regions	within	the	group	and	therefore	ready	to	use.	
• pRRL.sin.PPT.DES.eGFP	was	donated	by	Prof.	H.	Lochmuller	of	the	
Musculoskeletal	Research	Group	located	in	the	Institute	of	Genetics	at	Newcastle	
University.	This	vector	was	included	to	evaluate	a	muscle	specific	promoter,	in	
this	case	DES	(desmin),	in	comparison	to	the	promoter	used	in	all	other	vectors	
CMV	(cytomegalovirus).		
• AAV.CMV.GFP	is	an	AAV	vector	obtained	from	the	Viral	Vector	Production	Unit	
(UPV)	of	the	University	of	Barcelona.	Several	serotypes	were	trialled	in	vitro	
methods	to	determine	the	most	appropriate	vector	for	in	vivo	study,	including;		
AAV2/1,	AAV2/5,	AAV2/6,	AAV2/8,	AAV2/9	and	AAV2/10.	
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3.2 Objectives	
	
The	potential	for	various	muscle-based	cell	lines	to	successfully	take	up	both	plasmid	
and	viral	DNA	has	been	shown	previously.	However,	using	the	C2C12	cell	line	specifically	
and	comparing	directly	with	normal	murine	skeletal	muscle	in	vivo,	using	a	variety	of	
methods	was	important	to	establish	prior	to	starting	investigations	using	Exendin	4	and	
GLP1	vectors.	
Therefore,	the	main	aims	of	this	chapter	were;	
	
• To	establish	an	in	vitro	muscle	cell	model	and	standard	conditions	for	plasmid	
mediated	transfection.	
	
• To	determine	conditions	for	achieving	expression	in	multinucleated	myotubes.	
	
• To	establish	an	effective	MOI	for	AAV	expression	in	HEK293	cells	and	determine	
the	most	appropriate	AAV	serotype	in	C2C12	cells.	
	
• To	establish	an	in	vivo		live	imaging	protocol	to	evaluate	reporter	expression	and	
delivery.		
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3.3 In	vitro	studies	using	the	C2C12	cell	line,	employing	Lipofectamine2000	
as	a	transfection	agent	for	plasmid	DNA,	and	standard	infection	protocols	
for	AAV	vectors.	
	
3.3.1 C2C12	Cell	characterisation	
	
C2C12	cells	were	seeded	in	6	well	plates	with	DMEM	media	containing	FBS	and	
pen/strep	(2.2.1)	and	incubated	in	a	humidified	environment	containing	5%	CO2	until	80-
90%	confluent	myoblasts	were	observed.	Once	confluent,	the	media	was	changed	to	a	
reduced	serum	media	(2.2.1.3)	for	differentiation	into	myotubes.	
	
Skeletal	muscle	requires	the	mononucleated	myoblast	precursor	satellite	cells	to	fuse	
together	to	form	multinucleated	myotubes	(confirmed	in	vitro	by	presence	of	3	or	more	
nuclei	within	a	single	cell).			
Once	the	cells	had	been	differentiated	into	myotubes,	staining	with	the	muscle	specific	
marker	Desmin	confirmed	myogenic	origin.	Desmin	is	a	protein	which	is	only	expressed	
in	certain	cytoskeletal	components	found	in	vertebrates.		
	
Figure	3-1	shows	characteristic	bipolar	morphology	of	C2C12	myoblasts	visualised	under	
phase	contrast	microscopy.		
	
Figure	3-2	shows	standard	myotube	morphology,	as	seen	under	fluorescence	
microscopy,	after	the	media	serum	concentration	was	stepped	down	to	induce	the	
myotube	formation.	
Desmin,	a	muscle	specific	marker,	was	used	to	confirm	myogenesis.	100%	of	fused	
multinucleated	myotubes	showed	desmin	expression.		
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Figure	3-1	C2C12	myoblasts	under	bright	field	at	x20	magnification.	All	cells	are	mononucleated	
indicating	that	no	end-differentiation	has	occurred	and	the	cells	are	still	in	the	precursor	format.	
Standard	growth	media	was	used.	Image	was	taken	48	hours	after	seeding. 
  
Figure	3-2	C2C12	myotubes	stained	for	Desmin	and	highlighted	with	DAPI	at	x20	
magnification.	Whilst	not	all	of	the	myoblasts	shown	in	the	image	have	formed	into	tubes,	100%	
of	tubes	are	showing	positive	desmin	staining,	shown	in	red,	with	the	characteristic	multi-
nucleated	structure.	Cells	were	subject	to	stepped	down	media	(reduced	serum	content)	at	70-
80%	confluence.	Image	was	taken	6	days	after	seeding,	2	days	post	reduced	serum	media	
change.	
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3.3.2 Determination	of	optimal	in	vitro	transfection	conditions	for	C2C12	myoblast	
cells	with	pVR1012.CMV.eGFP	plasmid	using	Lipofectamine2000	
	
C2C12	cells	were	transfected	using	the	standard	Lipofectamine2000	protocol	(2.2.2).		
1x106	C2C12	cells	were	seeded	into	each	well	of	a	6	well	plate	(6x106	C2C12	cells	in	total)	
containing	22x22mm	coverslips	coated	with	fibronectin	(10	µl/ml)	and	were	incubated	
at	37	0C	until	70-80%	confluent.		
The	Lipofectamine2000	transfections	were	performed	using	the	pVR1012.CMV.eGFP	
plasmid	at	various	concentrations.	After	48	hours	incubation,	the	coverslips	were	
removed,	the	cells	were	fixed	and	a	DAPI	nuclear	stain	applied	(2.2.3,	2.2.3.1).	
The	total	number	of	cells	adhered	to	the	coverslip	(counted	as	number	of	nuclei	stained	
positive	with	DAPI)	was	compared	to	the	number	of	cells	showing	positive	GFP	
expression,	(2.2.3.2),	enabling	determination	of	percentage	transfection	efficiency	(%)	
for	different	Lipofectamine2000	concentrations	(Figure	3-3).	
This	procedure	was	then	repeated	using	the	amount	of	DNA	as	a	variable	and	the	
Lipofectamine2000	concentration	as	the	constant	(Figure	3.4).		
Both	of	these	studies	conferred	successful	gene	transfer,	as	confirmed	by	eGFP	
fluorescence	(see	Figure	3-3).	
As	there	were	no	significant	differences	between	any	of	the	Lipofectamine2000	and	
DNA	concentrations	evaluated,	the	amounts	of	lipofectamine2000	reagent	and	DNA	
used	in	all	subsequent	protocols	were	10	µl	and	2	µg	respectively.	These	concentrations	
have	previously	been	demonstrated	to	be	very	successful	in	similar	protocols	used	
previously	within	the	group.	
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Figure	3-3	Examples	of	C2C12	myoblasts	transfected	with	Lipofectamine2000	using	the	
standard	protocol.	Using	10µl	Lipofectamine2000	and	2µg	of	1µg/µl	pVR1012.GFP.CMV	as	
observed	at	48	hours	post	transfection	time	using	the	variant	described	in	figures	3-4	and	3-5.	
2µg	DNA/5µl	lipofectamine2000	(A),	2µg	DNA/10µl	lipofectamine2000	(B),	2µg	DNA/15µl	
lipofectamine2000	(C),	4µg	DNA/10µl	lipofectamine2000	(D),	3µg	DNA/10µl	lipofectamine2000	
(E),	2µg	DNA/10µl	lipofectamine2000	(F).	10	fields	of	view	were	counted	per	condition.	Each	
condition	was	assessed	x6.	
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Figure	3-4	-	%	Transfection	rates	for	variable	amounts	of	Lipofectamine2000	reagent	used	in	
the	transfection	procedure.	Cells	were	seeded	onto	coverslips	in	each	well	of	a	6	well	plate.	The	
coverslips	were	removed,	cells	fixed	and	mounted	and	visualised	under	a	fluorescence	
microscope.10	fields	of	view	were	taken	from	each	coverslip,	the	nucleus	(DAPI)	and	transfected	
cell	(GFP)	were	counted	and	the	%	transfection	rate	calculated	(n=6).	
There	was	no	significant	difference	in	the	percentage	of	myoblasts	transfected	when	using	5-15	
µl	of	Lipofectamine2000	and	2	µg	of	plasmid	DNA	(p>0.05).	10	µl	was	deemed	to	be	the	
appropriate	amount	and	was	the	amount	used	in	similar	protocols	previously	used	within	the	
group.		
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Figure	3-5	Transfection	rates	for	variable	amounts	of	plasmid	DNA	used	in	the	transfection	
procedure.	Cells	were	seeded	onto	coverslips	in	each	well	of	a	6	well	plate.	The	coverslips	were	
removed,	cells	fixed	and	mounted	and	visualised	under	a	fluorescence	microscope.10	fields	of	
view	were	taken	from	each	coverslip,	the	nucleus	(DAPI)	and	transfected	cell	(GFP)	were	counted	
and	the	%	transfection	rate	calculated	(n=6).	
There	was	no	significant	difference	in	the	percentage	of	myoblasts	transfected	when	using	2-4	µg	
of	plasmids	DNA	with	10	µl	of	lipofectamine2000	reagent	when	analysed	(p>0.05).	2	µg	was	
deemed	to	be	the	appropriate	amount	of	plasmid	DNA	to	be	used	in	all	future	protocols.	
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3.3.3 Determination	of	optimal	in	vitro	transfection	conditions	for	C2C12	myotubes	
with	pVR1012.CMV.eGFP	plasmid	using	Lipofectamine2000	and	hyaluronidase	
	
As	myotubes	are	more	akin	to	the	differentiated	skeletal	muscle	targeted	in	in	vivo	
transfection,	C2C12	myotubes	were	transfected	using	the	same	protocol	outlined	in	
2.2.2	for	C2C12	myoblasts.	
Myotubes	did	not	uptake	the	pDNA	as	readily	as	the	myoblasts,	in	fact,	there	was	less	
than	2%	percentage	transfection	efficiency	observed	using	the	standard	
Lipofectamine2000	protocol	(Figure	3-6).	In	an	attempt	to	increase	this	efficiency,	
hyaluronidase	was	added	to	the	lipofectamine2000	protocol.		
In	order	to	determine	the	appropriate	amount	of	hyaluronidase,	4	conditions	were	
examined.	Transfection	of	myoblasts	that	were	allowed	to	differentiate	into	myotubes,	
0U	hyaluronidase,	32U	hyaluronidase	and	96U	hyaluronidase.	
In	some	instances,	myoblasts	were	allowed	to	differentiate	into	myotubes	before	
transfection	took	place.	Hyaluronidase	was	added	to	standard	DMEM	growth	media	at	
32U/ml	or	96U/ml,	1	hour	prior	to	transfection.	
In	other	instances,	myoblasts	were	transfected	as	per	normal	lipofectamine2000	
protocol.		
Control	myotubes	were	not	subject	to	hyaluronidase	and	underwent	the	standard	
lipofectamine2000	protocol,	all	under	the	same	conditions.	
Myotubes	were	allowed	to	grow	up	to	5	days	post	transfection.	
	
As	can	be	seen	in	Figure	3-7,	the	addition	of	the	hyaluronidase	substrate	greatly	
increased	the	transfection	efficiency	in	C2C12	myotubes.	The	images	shown	in	Figure	3-
7	are	representative	examples	of	the	transfection	efficiency	shown	for	each	varying	
amount	of	hyaluronidase.	Based	on	the	images	alone,	these	suggest	that	the	as	the	
amount	of	hyaluronidase	is	increased,	the	transfection	efficiency	is	increased.		
	
Figure	3-8	substantiates	the	theory	from	Figure	3-7	that	the	increased	amount	of	
hyaluronidase	increases	transfection	efficiency.	The	myotubes	that	have	not	been	
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exposed	to	hyaluronidase	show	negligible	transfection	efficiency,	whereas	32U	and	96U	
hyaluronidase	double	the	transfection	efficiency	respectively.	
	
	
	
Figure	3-6	–	Examples	of	transfected	myoblasts	and	myotubes.	A,	B	and	C	are	examples	of	
C2C12	myotubes	transfected	with	pVR1012.CMV.GFP,	using	the	standard	lipofectamine2000	
protocol.	D	is	an	example	of	transfected	C2C12	myoblasts	which	have	been	allowed	to	
differentiate	into	myotubes.	Images	were	taken	5	days	post	transfection,	using	Zeiss	AxioImager	
Z1	with	CoolSnap	HQ2	camera	and	Axiovision	software	v4.8.2.	Exposure	times	were	set	at	400ms	
for	each	image.	Due	to	the	difficulty	in	separating	individual	tubes	in	order	to	count	the	%	
transfection,	in	this	case,	each	field	of	view	was	turned	into	a	binary	image	and	actual	
percentage	area	transfection	calculated	using	ImageJ	software.		
	
	
64 
 
	
Figure	3-7	–	Examples	of	myotube	transfection	using	hyaluronidase	as	an	adjuvant	technique.	
A	and	B	show	myotube	transfection	with	the	addition	of	32U	of	hyaluronidase.	C	and	D	show	
myotube	transfection	with	the	addition	of	96U	of	hyaluronidase.		Images	were	taken	5	days	post	
transfection,	using	Zeiss	AxioImager	Z1	with	CoolSnap	HQ2	camera	and	Axiovision	software	
v4.8.2.	Exposure	times	were	set	at	400ms	for	each	image.	Due	to	the	difficulty	in	separating	
individual	tubes	in	order	to	count	the	%	transfection,	in	this	case,	each	field	of	view	was	turned	
into	a	binary	image	and	actual	percentage	area	transfection	calculated	using	ImageJ	software.		
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Figure	3-8	–	Determination	of	the	most	efficient	method	of	transfecting	C2C12	myoblasts	or	
myotubes.	The	standard	Lipofectamine2000	method	was	employed,	with	the	addition	of	32U	or	
96U	hyaluronidase	immediately	prior	to	the	addition	of	the	Lipofectamine2000/DNA	complex.	
Analysis	using	Image	J	software	shows	the	addition	of	96U	hyaluronidase	shows	a	significant	
improvement	of	gene	expression	(over	20	fold	increase)	in	C2C12	myotubes	over	no	
hyaluronidase	added	(n=6;	p<0.0001)		
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3.3.4 In	vitro	infection	of	AAV	vectors	to	determine	most	appropriate	serotype	for	use	
and	the	multiplicity	of	infection	(MOI)	required.	
	
AAV	vectors	are	available	in	several	different	serotypes.	Serotype	2	has	been	the	most	
extensively	studied,	however,	different	serotypes	have	been	shown	to	exhibit	a	greater	
affinity	to	different	tissue	types	(Wu	et	al.,	2006).		
A	literature	search	returned	variable	results	with	regards	to	the	most	appropriate	
serotype	for	use	in	the	remainder	of	this	study.	As	a	results,	a	suite	of	‘off	the	shelf’	
serotypes	were	purchased	from	the	Viral	Vector	Production	Unit	(UPV)	of	the	University	
of	Barcelona	to	use	in	an	in	vitro	assessment	with	C2C12	myoblasts.		
Along	with	the	most	appropriate	serotype,	the	most	appropriate	MOI	also	needs	to	be	
determined.	As	the	amount	of	AAV	vectors	obtained	for	the	initial	serotype	trial	was	
limited,	it	was	decided	to	use	a	well-known	‘easy	to	transfect’	cell	line	as	opposed	to	the	
C2C12	cell	line	in	order	to	reduce	the	risk	associated	with	failed	experiments.	The	cell	
line	chosen	was	HEK293.	Figure	3-9	demonstrates	the	difference	in	transfection	
efficiency	between	the	C2C12	and	HEK293	cell	lines,	with	an	almost	2	fold	increase	in	
percentage	transfection	obtained	in	the	HEK293	cells.		
A	literature	search	indicated	a	suitable	MOI,	with	the	titre	of	vector	that	was	available	to	
us,	was	between	0.5	and	1.		Again,	due	to	the	limited	volume	of	each	vector	serotype	
and	the	number	of	studies	planned,	a	basic	experiment	to	assess	the	difference	in	
infection	efficiency	between	these	two	MOI’s	was	established	(Figure	3-10).	
As	no	significant	difference	was	observed	between	an	MOI	of	0.5	or	1,	an	MOI	of	0.5	was	
used	for	all	future	in	vitro	experiments	involving	AAV	infection	in	order	to	preserve	as	
much	of	the	vector	as	possible	in	the	case	of	any	adverse	event.	
Once	the	MOI	had	been	established,	an	in	vitro	experiment	using	C2C12	myoblasts	to	
determine	most	suitable	AAV	serotype	for	use	in	future	in	vivo	experiments	returned	
AAV1	as	the	most	appropriate.	The	switch	from	HEK293	to	C2C12	cells	was	deemed	
appropriate	in	order	to	verify	the	use	of	a	muscle	cell	line	before	progressing	to	in	vivo	
experiments.	The	Lipofectamine2000	protocol	was	mimicked,	without	the	use	of	
Lipofecatmine2000	itself.	AAV	is	able	to	infect	cells	without	the	use	of	any	adjuvant	
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techniques,	however	the	results	gained	from	this	study	were	disappointing	and	much	
lower	than	expected.	
	
Figure	3-9	Comparison	of	%	transfection	rates	between	C2C12	and	HEK293	cells	using	
pVR1012.GFP.CMV.	An	almost	2	fold	increase	in	transfection	efficiency	in	HEK293	cells	indicates	
the	ease	at	which	HEK293	cells	are	transfected,	which	can	be	extrapolated	for	use	with	AAV	
vectors	(n=6;	p<0.0001).		
	
Figure	3-10	-	Determination	of	appropriate	MOI	for	use	with	AAV	vector	in	HEK293	cells.	No	
significant	difference	was	observed	between	each	MOI	(n=6,	p>0.05).	As	the	volume	of	AAV1	was	
sparse,	the	lower	MOI	was	deemed	acceptable	and	appropriate	for	all	future	studies.	.	
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Figure	3-11–	In	Vitro	assessment	of	AAV	serotype	to	determine	most	appropriate	for	use.	
C2C12	cells	were	used	in	the	serotype	assessment	to	ensure	the	vectors	were	capable	of	infecting	
a	muscle	line	before	moving	the	studies	in	vivo.	C2C12	myoblasts	were	infected	as	per	standard	
Lipofectamine2000	protocol,	without	the	Lipofectamine2000.	The	only	serotype	to	show	any	
confirmed	expression,	however	limited,	was	serotype	1	(AAV1)	(A).	The	other	serotypes	assessed	
were	AAV2	(B),	AAV5	(C),	AAV6	(D),	AAV9	(E)	and	AAV10	(F).	
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3.4 In	vivo	studies	to	determine	the	efficacy	and	efficiency	of	the	conditions	
established	during	in	vitro	trials.	
	
Two	sets	of	in	vivo	transfections	were	performed	on	normal	(CD1)	mice.		
The	first	was	to	determine	length	of	expression	using	the	current	CMV	promoted	
plasmid	(pVR1012-CMV-eGFP),	and	the	second	to	determine	if	CMV	was	the	most	
appropriate	promoter	or	if	a	muscle	specific	promoter	would	achieve	greater	expression	
(pRRL.sin.PPT.DES.eGFP).	
 
3.4.1 In	vivo	transfection	to	assess	predicted	optimal	procedure	for	gene	expression	
efficiency	in	CD1	males	using	plasmid	vector	
	
The	IVIS	spectrum	is	a	non-invasive	method	of	determining	the	location	and	intensity	of	
fluorescent	(or	luminescent)	biomarkers	without	needing	to	sacrifice	the	animal.		
Each	animal	is	lightly	anaesthetised	purely	to	prevent	any	movement	whilst	the	scans	
are	taking	place.	Any	and	all	auto-fluorescence	is	detracted	from	the	expression	
detected	by	the	transgene	by	the	software	associated	with	the	equipment.	The	specific	
intensity	of	each	individual	region	of	interest	is	then	calculated,	and	the	corresponding	
images	can	be	used	to	assess	locale.		
All	mice	were	subjected	to	IVIS	scans	on	a	weekly	basis.	This	evaluates	the	eGFP	
expression	found	in	a	rodent,	independent	of	any	auto-fluorescence	that	may	be	found	
in	all	mammals.		
5	mice	in	total	were	subjected	to	transfections	using	pVR1012-CMV-eGFP.	eGFP	
expression	was	monitored	over	the	course	of	30days	using	the	non-invasive	imaging	
system	IVIS	Spectrum.	
	
Whilst	the	standard	deviations	are	relatively	high,	the	GFP	expression,	as	observed	using	
the	IVIS	spectrum	and	associated	software,	shows	a	significant	trend	to	increasing	
expression	over	time	in	a	normal	rodent	model,	with	no	indication	of	diminishing	
intensity	even	at	day	30.	
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Figure	3-12	-	GFP	expression,	as	identified	using	IVIS	spectrum	software,	during	course	of	the	
study.	The	total	radiant	efficiency	takes	into	account	the	level	of	auto-	fluorescence	that	may	be	
observed	from	standard	tissue	samples.	The	fluorescence	obtained	was	normalised	against	the	
auto-fluorescence	of	each	animal,	and	therefore	the	pre-treatment	level	was	zero	(n=5;	p<0.05).	
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3.4.2 In	vivo	transfections	to	assess	promoter	effectiveness	in	CD1	females	
	
10	mice	in	total	were	transfected	with	both	pVR1012.CMV.eGFP	and	
pRRL.sin.PPT.DES.eGFP,	5	in	each	batch.	GFP	expression	was	monitored	over	the	course	
of	30	days	to	establish	if	a	muscle	specific	promoter	is	necessary.	
	
The	significant	difference	in	expression	observed,	in	favour	towards	the	CMV	promoter,	
indicated	that	not	only	is	a	muscle	specific	promoter	not	necessary,	but	the	expression	
efficiency	gained	from	the	use	of	the	CMV	promoter	is	far	superior.	In	fact,	some	cases	
of	the	CMV	promoted	plasmid	yielded	such	expression	that	it	was	visible	to	the	naked	
eye	on	harvesting	the	muscle	(see	Figure	3-15).	
	
In	addition	to	the	IVIS	scans	to	obtain	visualisation	of	region	of	expression,	a	technique	
which	incorporated	both	IVIS	and	CT	was	trialled.	The	resulting	image	can	be	seen	in	
Figure	3-16.	Unfortunately,	shortly	after	this	initial	trial,	the	CT	equipment	located	in	the	
CBC	facility	was	no	longer	available	for	use.	The	single	mouse	that	was	used	for	this	trial	
unfortunately	died	shortly	after	this	procedure.	On	consultation	with	the	NVS,	the	
procedure	was	not	deemed	to	be	the	cause	of	this	death.	
	
In	order	to	assess	the	validity	of	the	results	obtained	from	IVIS	scanning,	a	selection	of	
muscle	samples	were	harvested,	snap	frozen,	sectioned	and	mounted	and	assessed	
microscopically	for	GFP	expression.		
	
Each	section	was	imaged	using	the	Zeiss	Axioimager	Z1	fluroescence	microscope	and	the	
associated	AxioVision	software.	The	entire	muscle	section	was	imaged	using	the	mosaic	
function,	which	allows	multiple	fields	of	view	to	be	‘stitched’	together	to	form	the	full	
section.	These	full	stitched	images	were	then	analysed	in	ImageJ,	in	which	the	entire	
area	of	the	section	was	calculated.	The	eGFP	expression	was	then	transformed	into	a	
binary	image,	and	the	percentage	area	of	eGFP	positive	was	gained	from	the	original	
area	of	the	entire	section.	The	full	harvested	sample	was	sectioned,	and	every	tenth	
section	analysed	in	this	way.	An	example	of	the	results	is	shown	in	Figure	3-17.	
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Figure	3-13	Using	GFP	expression,	as	identified	using	the	IVIS	spectrum	software.	Data	was	
analysed	using	T-test,	there	was	a	statistical	significance	(p<0.05)	between	the	CMV	and	muscle	
specific	DES	promoters,	in	favour	of	the	CMV	(n=5,	p<0.001).	
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Figure	3-14	–	IVIS	scan	images	showing	the	expression	gained	from	both	DES	and	CMV	
promoted	plasmid	vectors.	A	mix	of	plasmid	was	used	in	each	animal	in	an	attempt	to	remove	
mouse-mouse	variability.	See	Table	3-1	for	a	description	of	plasmids	used.		
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Box	 Mouse	ID	 Leg	 Plasmid	
1	 RN	 Left	 CMV	
Right	 DES	
LN	 Left	 CMV	
Right	 DES	
BN	 Left	 CMV	
Right	 DES	
2RN	 Left	 DES	
Right	 CMV	
NN	 Left	 DES	
Right	 CMV	
2	 RN	 Left	 CMV	
Right	 DES	
LN	 Left	 CMV	
Right	 DES	
BN	 Left	 CMV	
Right	 DES	
2RN	 Left	 DES	
Right	 CMV	
NN	 Left	 DES	
Right	 CMV	
	
Table	3-1–	List	referencing	the	plasmid	used	for	the	expression	as	determined	by	IVIS	spectrum	
scan,	shown	in	Figure	14.	In	an	attempt	to	remove	variability	in	using	different	animals,	each	
promoter	was	injected	into	the	same	mouse,	using	different	hind	limbs,	and	alternating	between	
left	and	right.		
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Figure	3-15	–	Example	of	strong	eGFP	expression	in	rodent	muscle	as	observed	‘by	eye’.	In	
some	cases,	the	GFP	expression	was	strong	enough	to	be	seen	with	the	naked	eye.	This	is	an	
example	of	a	gastrocnemius	(and	surrounding	area)	transfected	muscle	in	a	CD1	mouse	using	
CMV	promoted	plasmid	vector. 
 
 
Figure	3-16	–	Dorsal	and	Ventral	view	images	of	combined	IVIS	and	CT	scans	showing	the	
location	of	expression	combined	with	skeletal	structure.	This	procedure	was	trialled	with	one	
mouse	(BN)	from	the	plasmid	promoter	trials	(3.4.2).	The	mouse	died	shortly	after	the	procedure	
(hence	missing	from	the	image	shown	in	Figure	3-14,	box	2),	however,	the	NVS	did	not	surmise	
the	death	was	procedure	related. 
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Figure	3-17	GFP	expression	was	determined	throughout	the	entire	cross-section	of	a	randomly	
selected	muscle	sample.	GFP	was	visualised	using	mounting	medium	containing	DAPI	only	and	
analysed	using	the	tiling	feature	on	the	Zeiss	AxioImager		Z1	with	CoolSnap	HQ2	camera	and	
Axiovision	software	v4.8.2	and	Image	J	software. 
 
 
Figure	3-18	a	selection	of	low	(<1%),	medium	(27%)	and	high	(58%)	transfected	area	images	
used	to	complete	the	analysis	in	Figure	3-17		
	
	
	
	
	
77 
 
3.5 Discussion	
	
In	these	studies,	the	use	of	the	reporter	gene	GFP	was	used	to	establish	the	extent	at	
which	the	proposed	protocols	would	successfully	express	the	gene	of	interest,	which	
may	be	more	difficult	to	determine	levels.		
	
The	plasmid	vector,	which	was	previously	established	within	the	group,	contained	the	
GFP	gene	sub-cloned	between	the	BamHI	and	EcoRV	sites	of	the	pVR1012	vector,	
obtained	from	Vical	(CA,	USA).		
	
The	AAV	vector	was	a	standard	AAV2/1	vector	containing	GFP,	both	vectors	use	the	
standard	CMV	promoter	for	constitutive	expression.	
	
The	plasmid	transfection	protocol	followed	on	the	standard	Lipofectamine2000	protocol	
provided	with	the	reagent	from	the	manufacturer	(Life	Technologies),	with	the	
variations	in	reagent	and	pDNA	used	to	establish	an	optimum	process.	Each	variable	
assessed	provided	no	significant	difference	in	expression	efficiency,	indicating	the	
reagent,	Lipfectamine2000,	is	very	robust	method	for	incorporating	transgenes.		
Good	transfection	efficiency	was	obtained	in	myoblasts,	however	the	adjuvant	addition	
of	96U	hyaluronidase	greatly	increased	the	expression	achieved	in	myotubes,	an	
increase	from	<2%	to	>40%	positive	transfection	area	was	observed.	
	
Gene	transcription	is	easily	identifiable	using	a	fluorescence	marker	such	as	GFP.	
Standard	protocols	for	observing	fluorescence	in	cells	and	tissues	are	commonly	known	
and	well	established	for	use	In	Vitro	or	post	mortem,	however,	in	order	to	establish	the	
approximate	duration	of	expression,	based	on	vector,	an	alternative	method	was	
required	which	would	allow	the	vectors	to	be	tracked	In	Vivo.	The	system	used	for	this	is	
known	as	the	In	Vivo	Imaging	System	–	IVIS.	The	IVIS	system	used	in	this	instance	is	the	
Perkin-Elmer	pre-clinical	IVIS	spectrum	system.	Whilst	the	system	is	capable	of	a	
multitude	of	various	detection	methods,	those	employed	for	this	purpose,	and	for	any	
other	reported	uses	hereafter,	epi-illuminated	fluorescence	was	detected	whilst	the	
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animals	were	under	light	inhalant	anaesthesia	(isoflurane)	in	a	specialised	chamber.	
Detection	was	determined	using	a	combination	of	grade	1	CCD	and	a	150W	extended	
tungsten	lamp.	The	camera	temperature	was	constant	at	-900C	and	the	images	captured	
have	a	pixel	ratio	of	2048	x	2048.	The	analysis	of	the	images	was	performed	using	the	
proprietary	‘Living	Image’	imaging	software.		
	
GFP	expression	was	confirmed	using	a	combination	of	staining	methods	and	IVIS	
analysis.	The	staining	analysis	showed,	that	by	traditional	methods,	GFP	expression	can	
be	shown	in	cells	and	tissues	that	have	been	manipulated,	fixed	and	stained.	Although	
this	gives	a	clear	indication	that	GFP	expression	has	been	consistent	and	persistent,	to	
be	of	use	for	In	vivo	applications,	the	animal(s)	in	question	must	be	deceased	prior	to	
obtaining	the	information.	Using	the	IVIS	system,	the	transgene	expression	(either	
fluorescent	or	bioluminescent)	can	be	monitored	in	situ	in	real	time,	without	any	harm	
or	distress	to	the	animals.	The	robustness	of	the	IVIS	system	has	been	somewhat	
validated	by	use	of	the	staining	methods	of	tissue	once	the	study	was	completed.	
However,	attempts	to	fully,	quantitatively	establish	a	direct	lineage	between	muscle	
content	and	IVIS	expression	failed.	eGFP	ELISA’s	were	repeated	many	times,	however,	
precision	analysis	performed	on	the	eGFP	ELISA’s	failed.	Due	to	the	nature	of	the	studies	
(not	being	performed	simultaneously),	the	reliability	of	the	data	was	not	sufficient	to	
allow	any	firm	conclusions	to	be	drawn.	On	a	basic	scale,	the	conclusion	could	be	made	
that	if	no	eGFP	expression	was	found	from	IVIS	scanning,	no	eGFP	expression	was	found	
during	ICC.	Unfortunately,	this	was	the	only	conclusion	that	could	be	formed.			
	
The	experiment	to	determine	promoter	efficacy	and	efficiency	showed	a	significant	
affinity	to	CMV	promotion	over	the	muscle	specific	promoter.	However,	in	order	to	
make	the	experiment	more	robust,	the	plasmid	backbone	of	both	vectors	should	be	the	
same,	with	the	only	difference	being	the	promoters.	This	was	not	the	case	in	this	
instance.	Nevertheless,	this	did	demonstrate	the	superior	ability	of	the	CMV	based	
plasmid	and	does	confer	confidence	that	this	is	a	more	than	appropriate	vector	for	use	
in	this	study.		
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4 Chapter	4	–	Assessment	of	constitutive	
expression	and	secretion	of	Exendin-4	and	
GLP-1	through	plasmid	and	AAV	transfection	
in	vitro	
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4.1 Introduction	
	
Given	the	tremendous	potential	of	GLP-1	and	GLP-1-based	therapies,	especially	when	it	
comes	to	the	limited	potential	for	iatrogenic	hypoglycaemia	due	to	its	endogenous	
glucose	responsiveness,	a	wide	range	of	applications	have	been	considered	(Kim	and	
Egan,	2008;	Salehi	et	al.,	2010;	Ahrén,	2011;	Kielgast	et	al.,	2011;	Butler	et	al.,	2013).	
Treatment	potential	of	GLP-1	is	however	limited	by	its	short	half-life,	due	to	DPP4	
degradation.	The	constitutive/	continuous	over-expression	of	GLP-1	by	muscle-targeted	
gene	therapy	is	thought	to	be	a	possible	route	to	overcome	this	(Mahmoud,	2010).	The	
fact	that	by	using	this	means,	the	GLP-1	amino-acid	sequence	and	structure	remains	
unaltered,	it	is	anticipated	that	this	will	also	reduce	the	potential	of	side-effects	which	
can	be	seen	with	modified	versions	of	endogenous	hormones.	Whilst	it	is	generally	
accepted	that	the	benefits	outweigh	any	potential	side	effects,	studies	examining	the	
potential	link	between	overexpression	of	GLP-1	R	agonists	and	serious	illness,	including	
pancreatitis,	pancreatic	cancer	and	thyroid	cancer,	both	for	and	against	the	theory,	have	
been	published.		
A	cohort	study	looking	at	the	link	between	exenatide	use	and	pancreatitis	found	
exenatide	use	was	no	more	influential	in	the	development	of	pancreatitis	than	any	other	
anti-hyperglycaemic	drug	(Dore	et	al.,	2011)	whereas	Gale	et	al	believe	there	is	still	
insufficient	evidence	to	proclaim	GLP-1	therapies	as	safe	and	further	investigation	is	
warranted	(Butler	et	al.,	2013)		
	
Notwithstanding	this	possible	advantage,	uncertainties	remain	around	this	concept;	for	
instance	will	the	increase	in	GLP-1	trigger	a	concurrent	increase	in	DPP4	activity?	Will	a	
chronic	pharmacological	increase	in	GLP-1	cause	another	adverse	physiological	or	
pathophysiological	effect?		Can	inherent	inefficiencies	in	achieving	desired	circulating	
protein	concentrations	associated	with	plasmid-transfection	be	overcome	or	are	more	
effective	adenovirus-mediated	transfections	warranted?	Would	the	use	of	a	longer-
acting	homologue	such	as	Exendin-4	be	more	effective?	These	questions,	combined	with	
the	obvious	potential	of	constitutive	GLP-1	or	Exendin-4	secretion	through	gene	therapy,	
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warranted	the	further	evaluation	of	both	constructs	in	in	vitro	experiments,	mainly	to	
assess	efficiency,	prior	to	application	in	in	vivo	studies.			
	
	
After	the	initial	proof	of	concept	studies	using	reporter	gene	eGFP	(see	chapter	3),	GLP-1	
and	Exendin-4	gene	constructs	were	included	in	future	studies,	with	the	use	of	GFP	as	
both	a	control	vector	and	a	reporter	gene.	
	
GLP-1	(7-36)	amide	or	Exendin-4	sequences	had	previously	been	subcloned	into	the	
pVR1012	plasmid	(refer	to	vector	map).	This	particular	plasmid	has	been	specifically	
designed	for	use	with	gene	therapy	applications	and	is	driven	by	the	constitutive	CMV	
promoter.		
	
The	GLP-1	and	Exendin-4	constructs	of	the	pVR1012	plasmid	were	initially	assessed	in	
vitro,	to	confirm	they	conferred	expression	as	seen	with	the	reporter	gene	vectors,	
before	progressing	to	studies	in	vivo.	
The	C2C12	murine	muscle	cell	line	was	chosen	as	it	is	an	extremely	stable	line	which	can	
be	used	to	form	muscle-like	myotubes	and	has	been	used	extensively	as	a	model	for	in	
vitro	studies	with	a	view	to	progression	in	in	vivo	muscle	related	investigations	(Burattini	
et	al.,	2004;	Veliça	and	Bunce,	2011)	.	
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4.2 Objectives	
	
This	chapter	reports	attempts	to	evaluate	the	constitutive	expression	of	both	genes	of	
interest,	GLP-1	and	Exendin4,	using	the	GFP	reporter	gene	as	a	control,	in	an	in	vitro	
muscle	model,	before	progression	onto	an	in	vivo	model.	Specific	objectives	were:	
	
• To	compare	percentage	transfection	efficiency	of	eGFP	reporter	with	GLP-1	and	
Exendin-4.	
	
• To	compare	percentage	transfection	efficiency	of	plasmid	constructs	with	AAV	
viral	vectors.	
	
• To	evaluate	the	differences	observed	in	the	therapeutic	peptide	secretion	of	
plasmid	and	AAV	delivery	systems.	
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4.3 In	vitro	confirmation	of	the	biosynthesis	and	constitutive	secretion	of	
Exendin-4	and	GLP-1	
	
As	mentioned	previously,	the	pDNA	vectors	had	already	been	established	within	the	
group.	The	GLP1	(7-36)	amide	and	the	Exendin-4	sequences	were	subcloned	between	
the	bamHI	and	EcoRV	restriction	sites	(see	plasmid	map,	Chapter	1,	Figure	1-5).	
The	eGFP	sequence	was	subcloned	into	two	XbaI	sites.	All	that	remained	for	the	
purposes	if	this	study	was	to	transform	the	vectors	using	competent	E.coli	cells	to	
ensure	the	stocks	persisted.		
The	sequences	of	each	of	the	transgenes	are	shown	in	table	4-1.	
	
Gene	 Sequence	
GLP1		 CATGCTGAAGGGACCTTTACCAGTGATGTGAGTTCTTACTTGGAGGGCCAGGCAG
CAAAGGAATTCATTGCTTGGCT	
Exendin-
4		
CATGGCGAAGGCACCTTTACCAGCGATCTGAGCAAACAGATGGAAGAAGAAGCG
GTGCGTCTGTTTATTGAATGGCTGAAAAACGGTGGTCCAAGCAGCCGTGCACCAC
CACCAAGC	
Table	4-1	–	GLP1	and	Exendin-4	gene	sequences	subcloned	into	pVR1012	(Mahmoud,	2010)	
	
The	in	vitro	transfection	procedure	was	repeated	for	pVR1012.Ex4.CMV	and	
pVR1012.GLP.CMV,	as	per	the	optimised	conditions	determined	in	Chapter	3.	
	
C2C12	myoblasts	were	cultured	on	standard	6	well	plates	in	standard	growth	medium	
until	60-70%	confluent.	The	standard	Lipofectamine2000	protocol	was	employed	and	48	
hours	post-transfection,	the	cell	culture	media	was	retained	and	analysed	via	EIA	for	
Exendin-4	and	ELISA	for	GLP-1,	to	assess	secretion	of	transgenically	expressed	peptide.	
In	order	to	prevent	GLP-1	degradation,	DPP4-inhibitor	(Merck	Millipore,	Germany),	at	a	
concentration	of	10	µl/ml,	was	added	to	the	wells	being	used	for	GLP-1	analysis,	
including	the	negative	controls,	immediately	post	transfection.		
Immunofluorescence	staining	confirmation	of	successful	transfection	was	obtained	up	to	
7	days	in	culture.	
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C2C12	myoblasts	were	cultured	in	standard	6	well	plates	in	standard	growth	media,	
except	this	time,	a	fibronectin	coated	coverslip	was	placed	on	the	bottom	of	the	well	to	
allow	a	stable	growth	platform	for	the	cellular	matrix	that	would	form	after	this	time.	
The	standard	Lipofectamine2000	protocol	was	employed	and	the	cells	were	transfected	
at	approximately	50%	confluence.	Post	transfection,	cells	were	fed	as	needed,	coverslips	
were	removed	and	stained	at	day	1,	2,	5	and	7.			
	
Both	Exendin-4	and	GLP-1	plasmid	transfections	attained	high	levels	of	peptide	
secretion(2439	pmol/L	+/-	0	and	51.75	pmol/L	+/-	37.57)	at	a	significantly	different	level	
(n=6;	p<0.0001)	in	comparison	to	reporter	gene	control	(GFP	plasmid)	when	analysed	via	
ELISA	/	EIA	(Figures	4-1	and	4-2).	Both	plasmids	showed	high	levels	of	extracellular	
hormone	was	excreted	into	the	media,	however	the	levels	of	Exendin-4	were	found	to	
be	almost	50	times	higher	than	those	found	in	the	GLP-1	media.	This	is	possibly	due	to	
the	occurrence	of	DPP4-degradation,	even	after	adding	the	DPP4	inhibitors	to	the	wells	
whilst	cells	were	cultured	and	post	collection.	
	
Both	Exendin-4	and	GLP1	vectors	(plasmid	and	AAV)	showed	evidence	of	expression	
when	analysed	via	staining.	However,	the	intensity	of	the	stain	observed	and	the	day	of	
peak	activity	varied.	
Exendin-4	via	plasmid	transfection	and	AAV	infection	both	showed	highest	levels	of	
expression	at	day	1,	however,	the	AAV-based	expression	persisted	with	a	greater	
intensity	into	day	2	than	plasmid	based	expression	(p>0.05;	Figures	4-3,	4-4	and	4-7).		
GLP-1	showed	all	round	less	expression	than	Exendin-4	in	both	systems.	Although	
plasmid	based	expression	peaked	at	day	2,	the	AAV	based	infection	did	not	show	any	
expression	of	note	throughout	the	study	(p>0.05;	Figures	4-5,	4-6	and	4-8).	
	
Whilst	the	staining	evidence	captured	the	intracellular	expression	of	cells	at	a	fixed	point	
in	time,	indicating	the	peak	level	of	activity	is	day	2,	when	the	media	was	analysed	at	the	
same	time	points,	the	peak	level	of	activity	for	the	Exendin-4	plasmid	system	was	day	5.	
The	AAV	system	showed	variable	levels	with	days	2	and	7	showing	similar	
concentrations,	with	a	dip	at	day	5	(Figures	4-9	and	4-10).	
85 
 
 
Figure	4-1	Exendin-4	concentration	in	C2C12	standard	growth	media.	Media	was	removed	
48hours	post	transfection,	using	2µg	plasmid	DNA	and	10µl	Lipofectamine2000.	Media	was	not	
refreshed	within	the	48	hours	(n=6,	****p<0.0001).		
	
 
Figure	4-2	GLP-1	concentration	in	C2C12	standard	growth	media.	Media	was	removed	48	hours	
post	transfection,	using	2µg	plasmid	DNA,	10µl	Lipofectamine2000	and	10µl/ml	DPP4-inhibitor.	
Media	was	not	refreshed	within	the	48	hours	(n=6,	****p<0.0001).	
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Figure	4-3	–	Time	course	of	plasmid	transfection	using	Exendin-4	in	C2C12	myoblasts.	x20	mag,	
100ms	exp.	Cells	were	grown	on	fibronectin	coated	coverslips	(to	support	the	cell	matrix)	and	
removed	at	day	1	(A),	day	2	(B),	day	5	(C)	and	day	7	(D),	post	transfection.		Cells	were	fixed	in	
fresh	10%	formalin	and	stained	with	Exendin-4	primary	antibody.	Red	fluorescence	areas	indicate	
Exenedin-4	positive	cells;	blue	areas	are	DAPI	positive	nuclei.	
	
87 
 
	
Figure	4-4		-	Time	course	of	AAV	infection	using	Exendin-4	in	C2C12	myoblasts.	x20mag,	100ms	
exp.	Cells	were	grown	on	fibronectin	coated	coverslips	(to	support	the	cell	matrix)	and	removed	
at	day	1	(A),	day	2	(B),	day	5	(C)	and	day	7	(D,	post	transfection.	Cells	were	fixed	in	fresh	10%	
formalin	and	stained	with	Exendin-4	primary	antibody.	Although	the	pattern	of	staining	obtained	
using	AAV	is	similar	to	that	of	plasmid,	the	intensity	appears	to	be	less	with	the	AAV	vectors.	Red	
fluorescence	areas	indicate	Exenedin-4	positive	cells;	blue	areas	are	DAPI	positive	nuclei.	
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Figure	4-5	–	Time	course	of	plasmid	transfection	using	GLP-1	in	C2C12	myoblasts,	x20mag,	
100ms.	Cells	were	grown	on	fibronectin	coated	coverslips	(to	support	the	cell	matrix)	and	
removed	at	day	1	(A),	day	2	(B),	day	5	(C)	and	day	7	(D),	post	transfection.	Cells	were	fixed	in	
fresh	10%	formalin	and	stained	with	GLP-1	primary	antibody.	Red	fluorescence	areas	indicate	
GLP-1	positive	cells;	blue	areas	are	DAPI	positive	nuclei.	
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Figure	4-6	–	Time	course	of	AAV	infection	using	GLP-1	in	C2C12	myoblasts,	x20mag,	100ms	exp.	
Cells	were	grown	on	fibronectin	coated	coverslips	(to	support	the	cell	matrix)	and	removed	at	day	
1	(A),	day	2	(B),	day	5	(C)	and	day	7	(D),	post	transfection.	Cells	were	fixed	in	fresh	10%	formalin	
and	stained	with	GLP-1	primary	antibody.	Red	fluorescence	areas	indicate	GLP-1	positive	cells;	
blue	areas	are	DAPI	positive	nuclei.	
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Figure	4-7–	Exendin-4	expression	data	for	plasmid	v	AAV	in	C2C12	myoblasts.		%	area	as	
observed	using	fluorescence	microscopy.	(n=6,	*p<0.05).	Data	shows	a	peak	in	expression	from	
AAV	infection	at	day	2,	and	with	a	6	fold	increase	in	that	observed	from	plasmid	transfection.		
	
	
Figure	4-8	–	GLP-1	expression	data	for	plasmid	v	AAV	in	C2C12	myoblasts.	%	area	as	observed	
using	fluorescence	microscopy	(n=6,	*p<0.05).	Data	shows	a	peak	in	expression	from	plasmid	
transfection	at	day	1	and	2,	and	with	a	3	fold	increase	in	that	observed	from	AAV	infection.	
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Figure	4-9-	Exendin-4	concentration	in	media	from	C2C12	myoblasts	transfected	with	
Plasmid/infected	with	AAV.	(n=6,	**p<0.01,	***p<0.001)	
	
	
	
Figure	4-10-	GLP-1	concentration	in	media	from	C2C12	cells	transfected	with	plasmid/infected	
with	AAV	(n=6,	*p<0.05,	**p<0.01)	
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4.4 Discussion	
	
The	in	vitro	experiments	to	establish	GLP-1	and	Exendin-4	expression	after	C2C12	
myoblast	transfection	confirmed	the	proof	of	concept	that	this	system	warrants	further	
evaluation.	Transfection	resulted	in	detectable	medium	protein	concentrations,	as	well	
visible	cellular	expression.			
Chemical	transfection	was	successful	and	yielded	results,	albeit	variable,	that	confirmed	
expression	of	Exendin-4	and	GLP1	via	histochemical	and	ELISA/EIA	analysis.		
Some	literature	suggests	DPP-4	inhibitors	do	not	prevent	all	GLP-1	degradation,	
therefore	the	concentrations	observed	throughout	this	study	may	not	be	truly	
representative	of	the	actual	secretory	levels	that	may	be	achievable	(Mahmoud,	2010).	
Inhibitor	concentration	optimisation	studies	should	also	be	considered.	
The	current	studies	showed	variable	results	with	respect	to	which	delivery	method	was	
most	successful.	Detection	of	Exendin-4	expression	by	histological	analysis	determined	
AAV	infection	yielded	superior	results	to	plasmid	transfection	(Figure	4-7),	however,	all	
other	studies	suggested	that	plasmid	was	the	most	effective	method	for	protein	
secretion	in	both	histological	analysis	and	media	concentration	(Figures	4-8	through	4-
10.	
Published	data	suggests	that	the	timeline	for	AAV	based	secretion	to	become	evident	is	
greater	than	that	for	plasmid	based	secretion.	Based	on	this	evidence,	the	7	day	timeline	
that	was	prohibited	by	the	ability	of	C2C12	cells	to	remain	viable	was	simply	not	long	
enough	for	the	AAV	study	(Grieger	and	Samulski,	2005).		
It	should	also	be	noted	that	both	GLP-1	and	Exendin-4	are	secreted	from	C2C12	
myoblasts	almost	immediately	after	synthesis	due	to	these	particular	cells	lacking	a	
storage	facility.	Any	positive	staining	is	a	good	indicator	of	protein	synthesis	and	
expression,	but	in	hindsight,	may	not	have	been	the	best	method	to	use	for	attempting	
to	evaluate	the	efficacy	of	the	delivery	system.	Other	studies	have	effectively	used	RT-
PCR	to	determine	protein	secretion,	specifically	GLP-1,	in	both	C2C12	and	HEK-293	cells	
(Lee	et	al.,	2006;	Mahmoud,	2010).	
Further	evaluation	of	the	secretory	properties	versus	storage	facilities	may	have	yielded	
further	insight	into	the	systems.	For	example,	cell	lysate	analysis	would	have	allowed	a	
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quantitative	determination	of	the	concentration	of	both	GLP-1	and	Exendin-4	that	had	
not	yet	been	secreted.	This	has	somewhat	been	determined	in	previous	works	
(Mahmoud,	2010)	but	no	direct	comparison	between	plasmid	and	viral	vectors,	using	
the	same	transgene	sequences,	has	yet	been	performed.	
	
The	optimisation	of	transfection/infection	may	be	of	interest	in	further	studies,	although	
it	should	be	borne	in	mind	that	optimisation	during	in	vitro	studies	does	not	necessarily	
translate	into	optimisation	of	in	vivo	results.	However,	the	general	proof	of	concept	has	
been	established	and	it	is	worthwhile	to	move	this	system	into	an	in	vivo	model.	
Nevertheless,	the	possibility	of	including	other	methods,	such	as	electroporation	to	
enhance	delivery	and	RT-PCR	for	further	analysis,	could	also	be	considered,	in	
conjunction	with	altered	vectors	to	gain	an	even	greater	efficiency	of	expression	(Léger	
et	al.,	2011).	As	with	all	alterations	to	a	system,	this	must	be	trialled	in	vitro	before	
moving	into	an	in	vivo	model.	
	
In	conclusion,	the	in	vitro	studies	have	provided	sufficient	confidence	that	the	plasmid	
vectors	could	produce	sustained	expression	of	the	transgenes.	The	results	yielded	from	
the	AAV	in	vitro	studies	showed	some	expression	of	transgenes,	however,	due	to	the	
limitations	of	the	lifespan	of	the	myoblasts/myotubes,	an	in	vivo	study	is	required	to	
provide	a	more	stable,	longer	term	evaluation.	
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5 Chapter	5	–	Assessment	of	constitutive	
expression	of	Exendin4	and	GLP1	via	both	
plasmid	and	AAV	administration	in	vivo	
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5.1 Introduction	
	
Skeletal	muscle	as	a	route	of	delivery	for	gene	therapy	has	many	advantages	and	has	
been	used	repeatedly	as	a	successful	method	in	many	disease	states	(Manno,	2003;	
Mingozzi,	2009;	Qiao	et	al.,	2011).		
Skeletal	muscle	is	a	stable	tissue	with	an	excellent	vascular	supply.	The	muscle	fibres	
provide	a	stable	matrix	for	gene	transcription	and	therefore	confer	long-term	protein	
production,	which	is	secreted	directly	into	the	blood	stream	via	the	large	vascular	supply	
to	the	fibres.	Moreover,	skeletal	muscle	fibres	are	thought	to	persist	for	the	lifetime	of	
the	subject,	under	normal	circumstances,	which	means	the	limitations	of	the	gene	
transcription	are	not	hindered	by	cell	turnover	(Qiao	et	al.,	2011).		
Transfection	into	skeletal	muscle	is	most	effective	when	used	with	various	adjuvant	
techniques,	which	help	the	transgenes	integrate	into	the	fibres	more	effectively.	In	this	
study,	the	use	of	hyaluronidase	and	electroporation	were	employed	to	enhance	the	
transfection	efficiency	of	the	plasmid	DNA	in	to	the	rodent	skeletal	muscle.	No	adjuvant	
techniques	were	used	with	AAV	infection	(Mathiesen,	1999).	
Hyaluronidase	helps	to	increase	tissue	permeability	in	the	skeletal	muscle	matrix	by	
lowering	the	viscosity	of	hyaluronan,	via	hydrolysis,	which	is	found	in	the	connective	
tissue	of	the	matrix.	This	creates	a	temporary	permeability	of	the	connective	tissues	to	
allow	the	plasmid,	carrying	the	transgenes,	easy	access	to	the	muscle	fibres	themselves.	
(Mennuni	et	al.,	2002).	
Electroporation	is	again,	another	external	method	of	increasing	tissue	permeability,	by	
creating	a	localised	electro-magnetic	field	across	the	injection	site	to	create	a	temporary	
pore	in	lipid	bilayer	portion	of	cell	membranes.	This	pore	then	allows	larger,	charged	
molecules	(such	as	DNA)	to	pass	through	the	otherwise	impermeable	membrane	
(Mathiesen,	1999;	Mir	et	al.,	1999;	Wells,	2010).		
Both	of	these	techniques	can	be	used	together	to	provide	a	‘best-chance’	scenario,	with	
hyaluronidase	being	administered	prior	to	DNA	introduction,	and	the	electroporation	
technique	being	employed	post	DNA	introduction.		
Several	studies	have	shown	this	combination	of	enhanced	transfection	has	provided	
increased	transfection	efficiencies	and	therefore	higher	levels	of	transgene	expression.	
96 
 
(Aihara	and	Miyazaki,	1998;	Rana	et	al.,	2004;	De	Vry	et	al.,	2010;	Wells,	2010).	
	
Some	studies	have	already	investigated	the	potential	of	GLP-1	and/or	Exendin-4	
expression	in	vivo.	However,	none	of	these	studies	(as	determined	at	the	onset	of	this	
study)	have	used	the	direct	skeletal	muscle	route,	performed	a	direct	comparison	of	
plasmid	and	AAV	vectors	using	the	same	transgenes	or	assessed	the	longevity	of	the	
expression	over	this	time	frame.	
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5.2 Objectives	
	
The	objective	of	this	study	was	to	assess	the	constitutive	expression	of	GLP-1	and	
Exendin-4	in	non-diseased	and	diseased	models	via	administration	using	plasmid	and	
AAV	technologies,	with	the	use	of	adjuvant	techniques	in	the	case	of	plasmid	
transfection.	
	
• Establish	in	vivo	gene	transfer	protocol	for	longer-term	studies	with	Exendin-4	
and	eGFP	reporter	genes,	confirmed	via	regular	blood	sampling	and	in	situ	
reporter	gene	imaging.	
	
• Comparison	of	GLP-1	and	Exendin-4	plasmids	in	a	longer-term	study	in	an	in	vivo	
model	of	insulin	resistance	and	type	2	diabetes.		
	
• Comparison	of	GLP-1	and	Exendin-4	AAV	vectors	in	a	longer	term	in	vivo	study.	
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5.3 General	notes	
	
All	mice	were	housed	in	flat	bottom	cages,	with	a	maximum	of	6	mice	per	cage.	Mice	
were	approximately	3weeks	at	arrival	and	weight	assessment	at	arrival	indicated	no	
significant	differences;	therefore,	mice	were	assigned	groups	randomly.	They	were	
allowed	free	access	to	food	and	water,	unless	a	specific	part	of	the	protocol	required	
restricted	access	to	food,	at	which	point	the	mice	went	no	longer	than	16	hours	without	
food,	but	generally	were	subject	to	no	longer	than	12-14	hours	with	no	food	access.	At	
no	point	were	the	mice	restricted	access	to	water.	The	housing	area	was	subject	to	
12hour	light/dark	cycles	and	all	mice	had	a	1	week	acclimatisation	period	in	their	
assigned	groups	before	any	protocols	were	activated.	During	the	protocols,	mice	were	
monitored	daily	for	clinical	scoring	and	weight	gain	or	loss.	Any	health	and	welfare	
issues	were	discussed	in	full	with	the	area	technicians	and	escalated	to	the	NVS/NACWO	
where	necessary.		
Prior	to	administration,	all	injectable	material	was	subject	to	endotoxin	level	
assessment.	No	injectable	material	was	prepared	with	solutions	if	the	endotoxin	level	
was	found	to	be	>0.25	EU/ml,	in-line	with	the	USP	guidelines	for	endotoxin	limits	for	
water	for	injection	(U.S.	Pharmacopeia	Sterile	Water	for	Injection).	No	final	injectable	
solution	was	used	if	the	total	EU	level	was	found	to	be	>5.0	EU/kg,	which	is	in	line	with	
the	FDA	guidelines	for	non-intrathecal	administration	(FDA	Technical	Guides	-	Bacterial	
Endotoxins/Pyrogens).	Endotoxin	testing	was	carried	out	using	the	EndosafePTS	and	
associated	cartridges	(Charles	River	Laboratories	International	Inc,	MA,	US).	
There	were	no	health	issues	with	the	CD1	females	and	no	intervention	or	special	
measures	were	implemented	at	any	point.	However,	with	the	db/db	females,	weight	
gain	was	rapid	and	obvious	when	compared	to	the	standard	black	6	mouse,	whose	strain	
is	the	background	for	the	db/db	(figure	5-1)	which	resulted	in	small	skin	tears	in	the	
shoulder	region.			
Figure	5-2	indicates	the	location	and	size	of	the	injury	(inside	red	circle).	These	were	
monitored	closely	for	any	signs	of	infection	and	treated	with	standard	green	clay	(no	
active	pharmacological	ingredients	which	may	impact	the	study	results).	The	wounds	
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healed	quickly	and	cleanly	and	no	further	measures	were	needed.	No	other	issues	were	
observed.	
	
Figure	5-1	–	An	example	of	a	dbdb	mouse	and	black	6	(C57BL/6)	of	the	same	age.	Dbdb	mice	
have	a	black	6	background	and	are	bred	with	a	spontaneous	point	mutation	of	the	leptin	
receptor	gene.	
	
Figure	5-2	–	Image	showing	area	and	average	size	of	tearing	observed	in	db/db	females	at	4-6	
weeks	old.	During	the	early	phase	of	rapid	weight	gain,	the	skin	of	the	mice	was	not	given	
enough	time	to	stretch	to	accommodate	the	increase	in	size.	This	resulted	in	small	tears,	localised	
to	the	shoulder	area.	In	all	cases,	the	wounds	healed	quickly	and	cleanly	and	no	intervention	was	
required.	The	red	circle	indicates	the	localised	area	of	injury.	No	other	injury	locales	were	noted.	
100 
 
5.3.1 Vector	Administration	and	adjuvant	techniques	
	
Plasmid	administration	was	coupled	with	hyaluronidase	and	electroporation	as	a	
method	to	increase	the	efficiency	of	vector	uptake	and	subsequent	gene	expression.		
	
For	plasmid	administration,	the	mouse	was	anaesthetised	lightly	to	prevent	movement	
and	reduce	pain	and	stress	via	inhalant	anaesthetic	isoflurane.	The	analgesic	carprofen	
was	administered	subcutaneously	into	the	scruff	of	the	mouse	(dose	50	mg/kg,	total	
volume	0.1	ml).	Hyaluronidase	was	administered	into	the	muscle	in	the	location	of	the	
subsequent	plasmid	administration,	at	a	concentration	of	0.4	U/µl	in	a	total	volume	of	
25µl	prior	to	plasmid	injection,	which	was	at	a	concentration	of	1	µg/µl	in	a	total	volume	
of	50	µl.	Post	plasmid	injection,	the	leg	was	subjected	to	electroporation	(settings	used:	
200	V/cm,	eight	20	ms	pulses).	The	calliper	electrodes	were	stainless	steel	plates	and	
ECG	gel	was	applied	to	the	plates	prior	to	electroporation	taking	place.	All	injections	
were	made	percutaneously	to	both	tibialis	anterior	and	gastrocnemius	muscles,	
perpendicular	to	the	central	portion	of	the	muscle.	
	
AAV	vectors	were	administered	under	the	same	conditions,	without	the	use	of	the	
hyaluronidase	or	electroporation.	The	AAV	vectors	were	administered	in	a	total	volume	
of	50	µl	in	the	following	titre	of	vector	genome	(vg)	(as	determined	appropriate	from	
published	literature	(Zincarelli	et	al.,	2008):	
	
• Exendin	4	-		 1.776x1011	vg/mouse		
• GLP1	-			 1.784x1011	vg/mouse	
• eGFP	-			 1.745x1011	vg/mouse	 	
	
	
Whole	blood	samples	were	obtained	using	standard	tail	venepuncture,	as	larger	
volumes	(approximately	100	µl,	depending	on	the	weight	of	the	animal)	were	required.	
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The	exact	volume	obtained	was	kept	within	the	NC3R	guidelines	for	blood	sampling	
(which	was	also	reflected	within	the	PPL	-	https://www.nc3rs.org.uk/blood-sample-
volumes)	
	
	
5.3.2 Completion	of	study	
	
On	completion	of	the	study	(see	individual	sections	for	duration),	mice	were	euthanized	
as	per	schedule	1	appropriate	protocol,	cervical	dislocation,	or	where	larger	volumes	of	
blood	samples	were	needed,	cardiac	puncture	was	used	and	therefore	mice	were	
subject	to	non-recovery	anaesthesia.	Cervical	dislocation	post	cardiac	puncture	
confirmed	death.		
Pancreas	and	muscle	samples	(anterior	tibialis	and	gastrocnemius	region)	were	
harvested	immediately	after	death	using	a	consistent	standardised	method	of	
dissection.	Pancreas	samples	were	immediately	placed	in	10%	formalin	for	FFPE	
processing.	Muscle	samples	were	placed	in	a	Buffer	A	mixture	(see	chapter	2,	section	
2.2.12)	or	snap	frozen	in	liquid	nitrogen	or	dry	ice	cooled	isopentane	depending	on	
processing	requirements	(snap	frozen	for	sectioning/ICC,	buffer	for	homogenisation	for	
analysis	via	ELISA/EIA)	
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5.4 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	
Exendin	4	in	CD1	mice	via	plasmid	administration,	with	an	accompanying	
eGFP	control	group		
	
This	assessment	took	place	over	the	course	of	30	days	with	CD1	male	mice	as	the	rodent	
subjects.	
	
	
5.4.1 Weight	Evaluation	
	
Monitoring	the	weight	gain	(and/or	loss)	of	the	animals	was	one	of	the	main	indicators	
of	general	health.	Weight	measurements	were	taken	daily,	during	which	time,	a	general	
assessment	of	the	animals	were	made	including	activity	observation	and	skin/fur	checks,	
paying	particular	attention	to	the	injection	and	electroporation	sites	on	the	hind	legs.		
All	mice	showed	normal	weight	gain	and	normal	activity	levels	during	the	course	of	the	
study	(figure	5-3).	However,	fighting	was	observed	between	some	of	the	subjects,	which	
resulted	in	segregation	for	some	or	all	of	the	remainder	of	the	study.		
No	significant	differences	were	observed	between	the	groups	over	the	course	of	the	
study.	All	mice	gained	weight,	which	is	part	of	the	acceptance	criteria	of	the	clinical	
assessment	score	chart	for	general	animal	health	(see	Appendix	1	(8.1),	page	164).		
	
103 
 
	
Figure	5-3	–	Mean	weights	observed	for	all	mice	over	the	course	of	the	study.	No	significant	
difference	was	observed	between	the	two	data	sets	over	the	30	day	period	(n=5;	p.0.05).	
	
5.4.2 IPGTT	and	mean	fasted	glucose	
	
Fasted	IPGTTs	(intraperitoneal	glucose	tolerance	tests)	and	fasted	glucose	
measurements	were	taken	at	various	time	points	throughout	the	study.	Mice	were	
allowed	free	access	to	water	only	for	approximately	12-14	hours	before	being	subjected	
to	the	tests.	For	glucose	measurements	only,	blood	samples	were	taken	using	an	animal	
specific	glucometer	and	strips	(the	AlphaTRAK2	system	(Zoetis,	NJ,	US)),	which	has	been	
specifically	validated	for	rats	and	mice,	using	<5µl	whole	blood	(the	meter	only	needs	a	
minimum	of	0.3	µl	to	make	a	reading)	via	a	small	capillary	sample	obtained	from	the	tail.	
For	the	purpose	of	the	IPGTT	an	initial	glucose	reading	was	taken	(T0)	prior	to	
administration	of	glucose.	Subsequent	glucose	readings	were	taken	at	specific	time	
points	after	administration	of	2	g/kg	glucose	via	intra-peritoneal	injection	and	before	
allowing	free	access	to	food	(T=	15,	30,	60,	90	minutes	post	glucose	administration).		
Results	are	shown	in	figure	5-3,	5-4	and	table	5-1.	No	significant	differences	were	
observed	for	mean	fasted	glucose	or	IPGTT	data	over	the	course	of	the	study.	
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Figure	5-4	–	Mean	fasted	glucose	observed	for	all	mice	over	the	course	of	the	study.	Fasted	
glucose	levels	were	recorded	as	part	of	the	IPGTT	process.	No	significant	difference	was	observed	
between	the	two	data	sets	over	the	30	day	period	(n=5;	p.0.05).	
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Figure	5-5–	IPGTT	data.	IPGTT	analyses	were	obtained	at	3	points	during	the	study.	The	curves	
indicate	a	normal	response	to	IP	glucose,	as	expected	in	a	normal	model	animal	(n=5).		
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DATE	 GROUPING	 REPEATED	MEASURES	-	
BONFERRONI	
IPGTT	DATA	
OVER	ALL	4	
WEEKS	
Ex4	vs.	GLP1	 1.000	
Ex4	vs.	eGFP	 1.000	
GLP1	vs.	eGFP	 1.000	
	
Table	5-1	-	Statistical	analysis	of	IPGTT	data.	Using	repeated	rANOVA	and	Bonferroni	correction	
shows	no	significant	difference	between	any	of	the	groups	(n=5;	p>0.05).	
	
5.4.3 eGFP	expression	as	evaluated	via	IVIS	
	
The	IVIS	spectrum	is	a	non-invasive	method	of	determining	the	location	and	intensity	of	
fluorescent	(or	luminescent)	biomarkers	without	needing	to	sacrifice	the	animal.		
Each	animal	is	lightly	anaesthetised	purely	to	prevent	any	movement	whilst	the	scans	
are	taking	place.	Any	and	all	auto-fluorescence	is	detracted	from	the	expression	
detected	by	the	transgene	by	the	software	associated	with	the	equipment.	The	specific	
intensity	of	each	individual	region	of	interest	is	then	calculated,	and	the	corresponding	
images	can	be	used	to	assess	locale.		
All	mice	were	subjected	to	IVIS	scans	on	a	weekly	basis.	This	evaluates	the	eGFP	
expression	found	in	a	rodent,	independent	of	any	auto-fluorescence	that	may	be	found	
in	all	mammals.		
The	data	obtained	showed	an	increase	in	eGFP	expression,	from	day	8	up	to	day	30,	with	
a	significant	difference	during	this	time	frame	(p>0.05),	suggesting	the	uptake	of	plasmid	
and	successful	transcription	is	taking	place.	
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Figure	5-6	–	eGFP	expression	as	captured	using	the	IVIS	spectrum.	CD1	male	mice	in	the	study	
exploring	the	effects	of	plasmid	introduction	of	Exendin	4	and	eGFP	over	the	course	of	30	days	
(n=5;	p>0.05).	
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Figure	5-7	–	Images	taken	from	IVIS	scanner	showing	the	regions	of	expression	obtained	from	
pVR1012.eGFP.CMV,	without	auto-fluorescence.	One	of	the	mice	was	subject	to	an	IVIS/CT	co-
registration	trial,	hence	not	present	in	image	B.	The	same	mouse	was	sacrificed	early	due	to	
unknown	illness,	therefore	not	present	in	image	C.	On	post-mortem	investigation,	and	
consultation	with	the	NACWO,	the	mouse	appeared	to	have	contracted	a	urinary	tract	infection;	
most	likely	as	a	result	from	a	bite	wound	when	fighting,	males	were	not	used	for	any	further	
studies.		
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5.4.4 Evaluation	of	peptide	concentration	in	blood	plasma		
	
Blood	samples	were	taken	via	venepuncture	and	collected	in	EDTA	tubes.	The	plasma	
concentration	of	Exendin-4	was	then	evaluated	via	EIA	analysis.		
Samples	were	collected	twice	over	the	course	of	the	study,	on	day	15	and	day	30.		
Whilst	the	data	suggest	the	Exendin-4	concentration	was	much	higher	at	day	15	than	
day	30,	due	to	the	large	standard	deviation	observed	within	the	group	at	day	15,	no	
statistically	significant	difference	was	found	(p>0.05).		
	
	
	
	
Figure	5-8	–	Plasma/	serum	Exendin-4	concentration	in	peripheral	blood	samples	obtained	via	
venepuncture	and	analysed	via	Exendin-4	EIA.	Due	to	the	large	variation	seen	in	the	group	at	
day	15,	no	significant	difference	was	observed	(n=6;	p>0.05).	
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5.5 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	
Exendin-4	and	GLP-1	in	db/db	mice	via	plasmid	administration,	with	an	
accompanying	eGFP	control	group	
	
The	study	consisted	of	a	longer	term	assessment	of	both	GLP-1	and	Exendin-4	transgene	
expression	with	db/db	female	mice	as	the	disease	rodent	model.	
5.5.1 Weight	Evaluation	
	
Monitoring	the	weight	gain	(and/or	loss)	of	the	animals	was	one	of	the	main	indicators	
of	general	health.	Weight	measurements	were	taken	daily,	during	which	time,	a	general	
assessment	of	the	animals	were	made	including	activity	observation	and	skin/fur	checks,	
paying	particular	attention	to	the	injection	and	electroporation	sites	on	the	hind	legs.		
All	mice	showed	expected	significant	rapid	weight	gain	and	low	activity	levels	during	the	
course	of	the	study.		
No	significant	differences	were	observed	between	the	differently	treated	groups	over	
the	course	of	the	study.		
	
Figure	5-9	–	Mean	weights	as	recorded	throughout	the	study.	The	mean	weights	±	SD	for	each	
group	are	shown.	No	significant	difference	was	observed	between	the	groups	over	the	course	of	
the	study	(n=6;	p>0.05).	
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5.5.2 IPGTT	and	mean	fasted	glucose	
	
The	methodology	for	fasted	IPGTTs	and	fasted	glucose	measurements	was	the	same	as	
described	above	(5.4.2).	
Fasted	glucose	levels	showed	statistically	significant	differences	were	observed	between	
the	Exendin-4	and	GLP-1	groups	(p<0.05),	and	the	GLP1	and	eGFP	groups	(p<	0.05).	No	
significant	difference	was	observed	between	the	exendin4	and	eGFP	group	(p>0.05).	
Additionally,	repeated	measures	ANOVA	analysis	performed	on	the	IPGTT	data	also	
proved	a	statistically	significant	difference	in	the	glucose	clearance	capabilities	of	the	
Exendin-4	group	(figure	5-10	and	table	5-2)	(n=6;	p<0.05).	
	
 
	
Figure	 5-10	 –	Mean	 fasted	 glucose	 levels	 as	 recorded	 throughout	 the	 study.	 Fasted	 glucose	
levels	were	recorded	as	part	of	the	IPGTT	process.	The	mean	fasted	glucose	(n=6±SD)	are	shown.	
Significant	 differences	were	 found	 between	 the	 Exendin-4	 and	GLP-1	 groups	 (p<0.05),	 and	 the	
GLP1	and	eGFP	groups	(p<	0.05).	No	significant	difference	was	observed	between	the	exendin4	
and	eGFP	group	(p>0.05).	
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Figure	5-11	–	IPGTT	data;	(A)	day	0	(pre-treatment),	(B)	day	7,	(C)	day	14,	(D)	day	28,	(E)	day	35	
and	 (F)	 day	 42.	 Statistical	 analyses	 shows	 there	 is	 a	 significant	 difference	within	 the	 exendin4	
group.	(See	table	5-2)(n=6). 
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DATE	 GROUPING	 REPEATED	MEASURES	–	
BONFERRONI	P-VALUE	
IPGTT	DATA	
OVER	ALL	6	
WEEKS	
Ex4	vs.	GLP1	 0.044*	
Ex4	vs.	eGFP	 0.049*	
GLP1	vs.	eGFP	 1.000	
Table	5-2	-	Statistical	analyses	of	the	IPGTT	data	of	mice	treated	with	muscle-targeted	gene	
therapy	using	pVR1012-EGFP,	-Exendin-4	or	–GLP-1,	respectively	gained	throughout	the	study.	
Using	repeated	measures	ANOVA,	which	considers	data	over	the	whole	time	course,	there	is	a	
statistical	difference	in	favour	of	the	exendin4	group	(n=6;	p<0.05).	
	
 
 
5.5.3 Evaluation	of	peptide	concentration	in	both	blood	plasma	samples	and	muscle	
homogenate	
	
In	order	to	further	confirm	transgene	biosynthesis,	analyses	were	performed	on	both	
blood	plasma	and	muscle	homogenate.	
Bloods	samples	were	taken	via	venepuncture	at	regular	intervals	during	the	study,	in	line	
with	PPL	statements	and	NC3R	guidelines.	Blood	was	collected	in	EDTA	tubes	and	
plasma	was	separated	and/or	muscle	samples	were	homogenised	and	ELISA/EIA	analysis	
was	performed.	
	
An	increase	in	Exendin-4	concentrations	were	observed	in	peripheral	blood	plasma	
samples	up	to	day	28	(figure	5-12).	A	seemingly	steady	decrease	was	observed	at	day	42	
and	further	again	at	day	49.	Whilst	the	final	sample	(day	49)	was	still	much	higher	than	
that	observed	at	day	14,	due	to	the	large	variation	within	the	group	(and	therefore	large	
standard	deviation),	the	only	statistically	significant	difference	was	observed	up	to	day	
28.		
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In	cardiac	puncture	samples,	which	represent	the	single	time	point	at	the	closure	of	the	
study,	Exendin-4	concentration	was	almost	a	quarter	of	what	was	observed	a	the	peak	
of	expression	as	determined	via	peripheral	blood	samples	and	similar	but	still	lower	than	
that	observed	from	the	last	peripheral	sample,	taken	only	1	day	prior	to	cardiac	
puncture	(figures	5-12	and	5-13	versus	5-14),	however,	the	cardiac	puncture	samples	
were	also	analysed	for	cross-reactivity	in	the	ELISA/EIA	assay’s.	This	confirmed	the	
robustness	and	selectivity	of	the	assay	with	negligible	levels	of	Exendin-4	found	in	the	
GLP-1	and	eGFP	groups	(p<0.001)	(figure	5-14).	
GLP-1	concentration	in	cardiac	samples	showed	no	significant	difference	in	any	of	the	
groups	(p>0.05)	(figure	5-14).	
Concentrations	in	muscle	homogenate	followed	the	same	pattern.	The	Exendin04	
concentration	was	significantly	increased	in	the	Exendin-4	groups,	when	compared	to	
the	GLP-1	and	eGFP	groups	(as	expected)(p<0.001)(figure	5-15),	however,	the	
concentration	found	in	the	muscle	homogenate	was	approximately	5	times	reduced	
when	compared	to	the	cardiac	puncture	samples.	There	was	no	statistical	significant	
difference	in	the	GLP-1	concentration	in	muscle	homogenate	between	any	of	the	groups	
(p>0.05)	(figure	5-15).	
	
Additionally,	plasma	insulin	and	fructosamine	were	evaluated	in	the	terminal	samples	
obtained	through	cardiac	puncture.	The	increased	insulin	concentrations	validated	the	
phenotype	of	the	db/db	mice,	all	showing	hyperinsulinemia;	a	difference	in	insulin	
concentration	or	fructosamine,	reflecting	the	average	plasma	glucose	over	the	course	of	
the	study,	was	not	detected	between	the	groups	(figures	5-16	and	5-17).		
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Figure	5-12	–Exendin-4	levels	in	peripheral	blood	samples.		Exendin-4	concentration	was	
measured	in	peripheral	blood	samples	(venepuncture)	at	various	intervals	throughout	the	study,	
via	Exendin-4	EIA.	All	times	points	showed	a	significant	rise	from	pre-treatment	levels,	however	
the	only	statistically	significant	difference	was	observed	up	to	day	28	due	to	the	large	standard	
deviations	observed	at	days	42	and	49		(n=6;	p<0.05)	
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Figure	5-13	–	GP004	GLP1	levels	in	peripheral	blood	samples.	GLP-1	concentration	was	
measured	in	peripheral	blood	samples	(venepuncture)	at	various	intervals	throughout	the	study.	
There	was	no	significant	difference	in	concentration	at	any	time	point	(p>0.05).	The	intervals	
were	not	as	frequent	as	those	collected	for	Exendin-4	concentration	determination	due	to	the	
volume	of	serum	required	for	analysis	and	the	restrictions	in	blood	volume	collection	in	place	on	
the	PPL/PIL.		
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Figure	5-14-	Peptide	concentration	in	cardiac	puncture	serum	samples.	Exendin-4	concentration	
in	cardiac	puncture	serum	samples	from	each	group	shows	negligible	levels	in	the	GLp-1	and	
eGFP	groups,	as	expected,	and	significantly	higher	levels	in	the	Exendn-4	group	(n=6±SD;	
p<0.001).	Additionally,	this	confirms	the	legitimacy	of	the	Exendin-4	EIA	test.	The	GLP-1	
concentrations	obtained	from	the	same	groups	did	not	show	any	significant	difference	between	
any	of	the	groups	(n=6;	p>0.05) 
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Figure	5-15	–	Peptide	concentration	in	muscle	homogenate.	Exendin-4	concentration	in	muscle	
homogenate		samples	from	each	group	shows	negligible	levels	in	the	GLp-1	and	eGFP	groups,	as	
expected,	and	significantly	higher	levels	in	the	Exendn-4	group	(n=6;	p<0.001).	Again,	this	
confirms	the	legitimacy	of	the	Exendin-4	EIA	test.	The	GLP-1	concentrations	obtained	from	the	
same	groups	did	not	show	any	significant	difference	between	any	of	the	groups	(n=6;	p>0.05) 
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Figure	5-16	–	Cardiac	puncture	insulin	analysis.	Blood	taken	via	cardiac	puncture	was	analysed	
for	insulin	content	in	each	of	the	groups.	There	was	no	significant	difference	between	the	groups	
though	each	group	showed	a	marked	increase	in	concentration	when	compared	to	a	non-diabetic	
standard	mouse	serum	control	(n=6;	p<0.05) 
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Figure	5-17	–	Fructosamine	assay	on	cardiac	puncture	samples.		A	fructosamine	assay	was	
conducted	on	blood	from	cardiac	puncture	from	each	group.	The	only	significant	difference	
observed	was	between	the	eGFP	group	and	the	clean	sera	control	(n=6;	p<0.05). 
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5.5.4    Immunohistochemical	analysis	of	pancreas		
 
The	entire	pancreas	was	harvested	from	each	animal	at	the	time	of	death.	This	was	
immediately	placed	in	a	10%	formalin	solution	prior	to	FFPE	processing.		
Sections	were	obtained	from	each	tissue	block	and	analyses	were	performed	to	
establish	the	general	health	of	the	pancreas	and	an	attempt	to	establish	both	insulin	and	
glucagon	content.	
No	obvious	differences	were	observed	between	each	of	the	3	groups	under	standard	
bright	field	H&E	microscopy	(figure	5-17).		
Sections	were	then	stained	for	insulin	and	glucagon	and	software	
(http://imagej.nih.gov/ij/)	utilised	to	calculate	and	compare	the	area	staining	positive	
for	both	(figure	5-18).	Image	J	analysis	is	further	explained	in	method	section	2.2.16.	
	
Pancreas	
sections
Exendin	4 GLP1 eGFP
	
Figure	 5-18	 –	 Examples	 of	 FFPE	 pancreas	 samples.	 	 FFPE	 pancreas	 samples	 were	 sectioned	
(4µm)	and	double	 stained	 (DAB	and	nickel	 respectively)	 for	 insulin	and	glucagon.	The	 resulting	
images	were	used	to	assess	islet	area	for	the	pancreas.	X400	magnification.	
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Figure	5-19	–	Insulin	content	in	pancreas	samples	as	measured	via	IHC	staining.	IHC	and	the	
resulting	image	analysis	was	used	to	calculate	the	%	area	of	positive	insulin	stain	using	colour	
deconvolution	processing.	A	significant	difference	(p>0.05)	was	observed	between	the	Exendin	4	
group	and	the	eGFP	group,	and	the	GLP1	group	and	the	eGFP	group.	No	significant	difference	
was	observed	between	the	Exendin-4	and	GLP1	group.	
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5.5.5 Assessment	of	eGFP	expression	as	measured	via	IVIS-spectrum	
	
IVIS	scans	were	performed,	as	described	on	5.4.3.	
A	minor	update	to	the	PPL/PIL	allowed	increased	IVIS	scans	to	take	place	for	this	study.	
Three	out	of	the	5	mice	of	the	eGFP	group	died	before	the	completion	of	the	study.	The	
uptake	of	the	vector	had	already	been	confirmed	in	the	previous	study	(see	section	3.4),	
however,	this	group	was	still	included	in	the	study	protocol	as	the	expected	longevity	of	
this	study	was	greater	than	previous.	Using	ANOVA	to	determine	statistical	significance,	
it	was	determined	that	the	expression	gained	in	this	study	was	also	significant	
(p<0.0001)	indicating	the	phenotype	of	the	animal	(db/db)	did	not	hamper	the	
transgene	biosynthesis.	
Figure	5-20	shows	the	localised	area	of	eGFP	expression	during	the	study.	The	resulting	
quantitative	data	obtained	is	shown	in	figure	5-21,	the	group	was	split	between	the	2	
mice	that	survived	the	entire	duration	and	the	3	that	were	deceased	part	way	through.	
Peak	expression	was	observed	early	in	this	study	at	day	10,	which	is	in	contrast	to	the	
expression	trend	observed	in	the	previous	study	which	was	still	increasing	at	day	30	
(figure	4-5).	
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Figure	5-20	-	Images	of	eGFP	intensity	in	individual	mice	over	the	length	of	the	study.	Localised	
areas	of	expression	are	observed	in	all	mice,	although	expression	seen	in	mouse	NN	is	marginal	
compared	with	the	others	in	the	group.	These	images	correlate	with	the	data	shown	in	Figure	5-
21 
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Figure	5-21–	Longitudinal	eGFP	expression	in	mice	transfected	using	pVR1012-eGFP,	was	
analysed	using	IVIS	Spectrum	instrumentation	and	software	(Perkin	Elmer).	Only	2	of	the	mice	
survived	the	full	course	of	the	study.	Graph	A	shows	the	3	mice	who	survived	up	to	day	27	
scanning	whilst	Graph	B	shows	the	2	mice	which	survived	up	to	the	45	day	scanning.	The	mean	
eGFP	intensity	peaks	at	an	early	time	point	(between	days	6-10)	for	both	data	sets.	The	longer	
time	course	indicates	a	slight	second	may	be	occurring	post	day	40,	however	this	cannot	be	
sufficiently	substantiated	by	the	current	data. 
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5.6 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	
Exendin	4	and	GLP1	in	CD1	mice	via	viral	(AAV)	administration,	with	an	
accompanying	eGFP	control	group	
	
Much	of	the	literature	available	suggests	AAV	vectors	have	an	initial	lag	in	expression	
time,	although	AAV	is	not	as	slow	as	other	viral	based	vectors	(for	example	retrovirus),	
the	ssDNA	still	needs	to	be	converted	to	dsDNA,	meaning	any	expression	obtained	from	
the	transgene	will	be	slower	than	that	obtained	with	plasmid	DNA.	Due	to	this,	the	AAV	
studies	were	deliberately	scheduled	over	a	longer	period	of	time	than	the	plasmid	
studies.		
	
	
5.6.1 Weight	Evaluation	
	
All	mice	were	monitored	as	per	above.	All	mice	showed	normal	weight	gain	and	
expected	activity	levels	during	the	course	of	the	study.		
No	significant	differences	were	observed	between	the	groups	over	the	course	of	the	
study.	All	mice	gained	weight.		
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Figure	5-22	–	Mean	weights	of	mice	throughout	the	study.	Mice	were	monitored	daily	and	the	
weights	obtained	showed	no	significant	difference	between	the	3	groups	(n=6;	p>0.05).	
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5.6.2 IPGTT	and	mean	fasted	glucose	
	
Measurements	were	performed	as	per	previous	studies.	
	
No	significant	difference	was	observed	between	any	of	the	three	groups	with	regards	to	
mean	fasted	glucose	(figure	1-23)(n=6;	p>0.05).	
	
	
 
	
Figure	5-23	–	Mean	fasted	glucose-	Fasted	glucose	levels	were	recorded	as	part	of	the	IPGTT	
process.	No	significant	difference	was	observed	between	any	of	the	three	groups	(n=6;	p>0.05)	
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Figure	5-24	–	IPGTT	data.	(A)	day	0	(pre-treatment),	(B)	day	13,	(C)	day	27,	(D)	day	41,	(E)	day	69	
and	(F)	day	131.	Statistical	analyses	(see	table	1-3)	shows	there	is	no	significant	difference	within	
the	exendin4	group	(n=5;p>0.05)	 
	
A	 B	
C	 D	
E	 F	
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DATE	 GROUPING	 REPEATED	MEASURES	-	
BONFERRONI	
IPGTT	DATA	
OVER	ALL	19	
WEEKS	
Ex4	vs.	GLP1	 1.000	
Ex4	vs.	eGFP	 1.000	
GLP1	vs.	eGFP	 1.000	
Table	5-3	–	statistical	analyses	of	IPGTT	data.	No	significant	difference	when	analysed	using	
rANOVA	with	Bonferroni	correction	(n=6;	p>0.05).	
	
5.6.3 Evaluation	of	peptide	concentration	in	blood	plasma	samples		
	
In	order	to	further	confirm	transgene	biosynthesis,	analyses	were	performed	on	both	
blood	plasma	and	muscle	homogenate.	
Bloods	samples	were	taken	via	venepuncture	and	regular	intervals	during	the	study,	in	
line	with	PPL	statements	and	NC3R	guidelines.	Blood	plasma	was	separated	and/or	
muscle	samples	were	homogenised	and	ELISA/EIA	analysis	was	performed.	
	
An	increase	in	Exendin	4	levels	were	observed	in	peripheral	blood	plasma	samples	were	
observed	up	to	day	74,	albeit	a	variable	trend.	A	seemingly	steady	decrease	was	
observed	post	day	74.	Whilst	the	final	sample	(day	102)	was	still	higher	than	that	
observed	at	day	11,	The	statistical	significance	was	great,	despite	the	large	standard	
deviations,	due	to	the	large	increase	in	circulating	concentration	at	day	74	(almost	1500	
fold	increase	compared	with	pre-treatment)	(Figure	5-25)	(n=6;	p<0.0001).	
The	increase	in	circulating	GLP-1	concentration	was	also	found	to	be	statistically	
significant	(figure	5-26,	n=6;	p<0.05)	and	followed	the	same	wave	like	pattern	as	
observed	with	the	Exendin-4	levels,	although	the	GLP-1	trend	is	more	pronounced.	The	
statistical	significance	is	less	due	to	the	large	standard	deviations,	the	higher	GLP-1	
levels	pre-treatment	and	the	smaller	increase	from	pre-treatment	to	peak	concentration	
at	day	74.	
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Figure	5-25	–	Exendin	4	concentration	in	peripheral	blood	samples	as	determined	by	EIA.	An	
increase	in	Exendin	4	levels	were	observed	in	peripheral	blood	plasma	samples	were	observed	up	
to	day	74,	albeit	a	variable	trend.	A	seemingly	steady	decrease	was	observed	post	day	74.	Whilst	
the	final	sample	(day	102)	was	still	higher	than	that	observed	at	day	11,	The	statistical	
significance	was	great,	despite	the	large	standard	deviations,	due	to	the	large	increase	in	
circulating	concentration	at	day	74	(almost	1500	fold	increase	compared	with	pre-treatment)	
(Figure	1-25)	(n=6;	p<0.0001).	
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Figure	5-26	–	GLP1	concentration	in	peripheral	blood	samples	as	determined	by	ELISA.	The	
increase	in	circulating	GLP-1	concentration	was	also	found	to	be	statistically	significant	(figure	1-
26,	n=6;	p<0.05)	and	followed	the	same	wave	like	pattern	as	observed	with	the	Exendin-4	levels,	
although	the	GLP-1	trend	is	more	pronounced.	The	statistical	significance	is	less	due	to	the	large	
standard	deviations,	the	higher	GLP-1	levels	pre-treatment	and	the	smaller	increase	from	pre-
treatment	to	peak	concentration	at	day	74.	
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5.6.4    Immunohistochemical	analysis	of	pancreas		
	
As	with	the	plasmid	studies,	the	entire	pancreas	was	harvested	from	each	animal	at	the	
time	of	death.	This	was	immediately	placed	in	a	10%	formalin	solution	prior	to	FFPE	
processing.		
Sections	were	obtained	from	each	tissue	block	and	analyses	were	performed	to	
establish	the	general	health	of	the	pancreas	and	an	attempt	to	establish	both	insulin	and	
glucagon	content.	
No	obvious	differences	were	observed	between	each	of	the	3	groups	under	standard	
bright	field	H&E	microscopy.		
Sections	were	then	stained	for	insulin	and	glucagon	and	software	utilised	to	calculate	
the	area,	which	stained	positive	for	both,	and	thus	establishing	a	percentage	content	per	
sample.			
	
	
	
Figure	5-27	pancreas	section	staining	Insulin	content	in	pancreas	samples	as	measured	via	IHC.	
Staining	and	image	analysis	was	used	to	calculate	the	%	area	of	positive	insulin	stain	using	colour	
deconvolution	processing.	No	significant	difference	was	observed	between	any	of	the	3	groups	
(n=6;	p>0.05).	
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5.6.4.1 Assessment	of	eGFP	expression	as	measured	via	IVIS-spectrum	
	
IVIS	scans	were	performed,	as	described	on	5.4.3.	
Unfortunately,	the	IVIS	scans	returned	no	evidence	of	transgene	expression	in	any	of	the	
mice	at	any	time	point	over	the	duration	of	the	study,	as	shown	in	figure	5-28.		
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Figure	5-28-	IVIS	image	sequences.	No	expression	was	observed	in	any	animal	over	the	entire	
duration	of	the	study.		
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5.7 Discussion	
	
5.7.1 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	Exendin	4	
in	CD1	mice	via	plasmid	administration,	with	an	accompanying	eGFP	control	
group		
	
Males	continuous	fighting	resulted	in	bite	wounds	to	the	tail	on	several	of	the	mice.	
None	appeared	infected	but	on	recommendations	from	the	NVS	no	procedures	involving	
venepuncture	were	allowed	until	the	fighters	had	been	separated	and	the	wounds	
healed.	This	is	the	reasoning	behind	the	large	gaps	in	data	acquisition.	As	a	result,	the	
following	studies	were	all	conducted	in	female	mice.		
	
One	of	the	mice	from	the	GFP	group	was	involved	in	a	co-registration	trial	between	the	
IVIS	spectrum	and	CT	scan.	The	mouse	was	anaesthetised	using	0.3	ml	
ketamine/medatomidate	(50	mg/kg	and	0.5	mg/kg	respectively)	via	IP	injection	with	0.5	
ml	antisedan	reversal	post	procedure.	Unfortunately	this	particular	mouse	died,	and	
after	minor	post	mortem	investigation,	it	appeared	to	be	caused	by	an	internal	infection	
(enlarged	bladder	containing	both	blood	and	urine).	Again,	after	consultation	with	the	
NVS,	this	could	have	been	caused	by	a	bite	wound	when	the	mice	were	fighting.	
	
The	PPL/PIL	was	altered	slightly	after	this	study	to	allow	for	further	blood	samples	to	be	
taken.	All	was	in	accordance	with	the	recommended	volume	in	the	NCR	3R	guidelines.	
This	allowed	slightly	larger	volumes	to	be	taken	via	venepuncture	for	ELISA/EIA	and	for	
more	IPGTT	tests	to	take	place.		
We	also	altered	the	number	of	times	animals	were	allowed	to	be	anaesthetised	to	allow	
more	IVIS	scans	to	take	place.	This	was	deemed	acceptable	an	appropriate	as	the	
anaesthesia	required	for	IVIS	is	quick	and	light.	The	animals	do	not	undergo	any	painful	
treatments	(IVIS	is	non-invasive,	anaesthesia	is	only	required	to	keep	the	animals	still	
whilst	they	are	being	scanned)	and	recovery	time	is	less	than	1	minute	once	removed	
from	the	chamber.		
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This	protocol	was	successful	in	establishing	a	sustained	delivery	method	resulting	in	
eGFP	expression	for	up	to	30days,	as	observed	throughout	via	IVIS	scan.	Unfortunately	
the	Exendin-4	expression	did	not	reflect	the	sustained	increase	in	eGFP	expression.	
Exendin-4	concentrations	peaked	at	day	15,	and	whilst	there	was	no	statistical	
significance	due	to	the	large	standard	deviations,	the	drop	at	day	30	was	large.	Further	
investigation	into	the	reasoning	behind	this	would	be	of	interest.	
	
5.7.2 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	Exendin	4	
and	GLP1	in	db/db	mice	via	plasmid	administration,	with	an	accompanying	
eGFP	control	group	
	
The	db/db	females	(changed	from	males	to	females	due	to	the	fighting	observed	
previously	and	the	potential	of	not	being	able	to	obtain	data	due	to	animal	welfare).		
Animals	receiving	the	control	plasmid	(eGFP)	were	separated	into	2	groups	of	3	rather	
than	the	standard	group	of	6	due	to	the	expected	large	weight	gain	and	polydipsia	(and	
therefore	polyuria),	and	was	determined	the	mice	would	be	more	comfortable	in	
smaller	groups.	
The	rapid	weight	gain	seen	in	these	mice	resulted	in	small	tears	appearing	in	the	skin,	
close	to	the	shoulder	area.	This	healed	quickly	with	no	incidences	of	infection.	The	
animals	did	not	appear	to	be	in	distress	and	green	clay	was	used	as	a	non-medicinal	
soothing	agent.	Using	the	scorecard	(appendix	8.1)	there	was	no	call	for	any	procedure	
modifications.		
The	db/db	phenotype	is	typically	known	to	be	a	severe	model	for	type	2	diabetes.	
Information	obtained	from	The	Jackson	Laboratory	database	(jaxmice.jax.org)	indicates	
the	following;	Death	will	typically	occur	within	10months	of	age,	during	which	time,	the	
phenotypic	indicators	linked	with	diabetes	start	at	a	very	early	age.	Plasma	insulin	
concentrations	begin	to	rise	at	10-14	days,	they	are	classed	as	obese	at	3-4	weeks	and	
blood	sugar	levels	start	to	rise	uncontrollably	at	4-8	weeks	(exogenous	insulin	will	not	
control	this	rise).	Classic	diabetic	signs	are	seen	(polyphagia,	polydipsia	and	polyuria)	and	
there	is	a	depletion	of	active	beta-cells.	Wound	healing	is	delayed	and	some	forms	of	
myocardial	disease	are	detectable.		
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As	the	onset	of	symptoms	is	early	and	dramatic,	it	was	important	to	start	the	protocols	
at	an	early	age.	The	mice	were	brought	in	to	the	research	facility	at	3	weeks	and	after	
the	1	week	acclimatisation,	the	protocol	began.	
	
Circulating	GLP-1	levels	were	not	collected	as	consistently	as	those	for	Exendin-4	due	to	
the	volume	of	plasma	required	for	GLP-1	ELISA.	The	Millipore	ELISA	used	required	100µl	
serum	for	analysis.	Dilution	was	permitted,	as	indicated	in	the	protocol	provided	by	the	
manufacturer,	however	it	recommended	no	more	than	50%,	which	meant	that	50µl	was	
still	required.	Due	to	the	restrictions	in	place	for	blood	volume	collection	in	the	PPL/PIL,	
this	was	not	able	to	be	gained	on	a	weekly	basis.	
	
The	IVIS	Spectrum	uses,	in	this	case,	epi-illumination	to	visualise	any	fluorescent	source	
in	vivo.	The	accompanying	software	allows	‘spectral	unmixing’	of	the	resulting	image	
which	differentiates	any	auto-fluorescence	from	that	of	any	other	fluorescent	source.	It	
can	be	clearly	seen	that	some	animals	show	greater	expression	than	others.	This	
suggests	the	uptake	and	subsequent	over	expression	of	the	plasmid	and	gene	relies	
quite	heavily	on	a	good	delivery	technique.	It	has	been	speculated	that	the	age,	gender	
and	species	of	an	animal	can	alter	the	DNA	uptake	and	therefore	transgene	expression.	
However,	as	these	animals	were	all	of	similar	age,	same	gender	and	species,	it	may	also	
be	a	function	of	the	diabetes	that	these	animals	are	more	lethargic	than	others	and	the	
muscle	mass	not	increasing	may	have	implications	on	the	transgene	expression	also.	
This	assumption	can	be	somewhat	validated	by	the	size	of	the	muscles	observed	during	
harvesting,	which	were	considerably	smaller	than	those	in	previous	studies.	The	muscles	
were	unfortunately	not	weighed	to	more	objectively	establish	this.	
Clinical	scoring	to	assess	overall	health	was	difficult	due	to	the	size	of	the	dbdb	mice.	
The	rapid	weight	gain	forced	skin	to	stretch,	and	as	a	result	the	coat	was	more	
pronounced	than	a	‘normal	sized’	mouse	(see	figure	1-1).	As	one	of	the	measures	of	
clinical	health	is	observation	of	coat	(known	as	‘starey’),	the	dbdb	mice	seemed	to	have	
this,	but	this	was	due	to	the	afore	mentioned	skin	stretching	and	the	coat	not	lying	
correctly	against	the	skin.	This	was	therefore	not	included	in	the	clinical	scores	for	these	
mice.	
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Again,	this	protocol	was	successful	in	establishing	a	well	tolerated	delivery	method	in	a	
diseased	model.	The	results	from	the	db/db	study	(figure	5-19)	show	significantly	higher	
levels	of	insulin	in	the	Exendin-4	and	GLP-1	groups,	suggesting	the	hormones	are	having	
some	effect	on	the	β-cells	by	increasing	the	volume	of	insulin	secreted	in	an	attempt	to	
lower	blood	glucose	levels.	This	pattern	is	also	demonstrated	in	the	IPGTT	data,	where	
the	Exendin-4	and	GLP-1	groups	are	both	showing	a	greater	capacity	for	glucose	
reduction	over	the	eGFP	group.	
	
Attempts	were	made	to	analyse	the	glucagon	content	alongside	the	insulin	content	in	
the	pancreas	samples	via	β-cell	mass	determination.	However,	the	colour	deconvolution	
function	could	not	distinguish	between	the	glucagon	positive	areas	and	some	areas	of	
background,	rendering	the	analysis	inconclusive,	and	was	therefore	not	included	in	the	
final	analysis.		
When	comparing	the	results	of	the	insulin	content	in	the	dbdb	mice	to	the	CD1	mice,	the	
differing	results	suggest	a	good	correlation	between	the	expected	levels	of	insulin	in	a	
diseased	and	non-diseased	model.	The	dbdb	mice	are	clearly	showing	increased	levels	of	
insulin	(approx.	15%),	obviously	in	attempt	to	achieve	glucose	homeostasis,	whereas	the	
non-diseased	model	is	showing	much	lower	levels	in	comparison	(approx.	0.6%)		
	
5.7.3 In	Vivo	assessment	of	secretory	properties	and	pharmacodynamics	of	Exendin	4	
and	GLP1	in	CD1	mice	via	viral	(AAV)	administration,	with	an	accompanying	
eGFP	control	group	
	
CD1	females	were	used	to	assess	the	efficacy	of	the	AAV	vectors	using	Exendin-4	and	
GLP-1	as	genes	of	interest.				
The	circulating	peptide	levels	for	both	GLP-1	and	Exendin-4	peaked	at	day	72	(Figures	5-
25	and	5-26),	providing	further	confirmation	that	AAV	based	viral	vectors	require	a	
longer	time	to	synthesise	and	subsequently	secrete	the	optimal	concentrations	of	
transgenes,	as	evidence	by	the	peak	at	anywhere	from	day	10	to	30	when	using	plasmid	
vectors	(Figures	5-8	and	5-12).	However,	the	circulating	levels	of	GLP-1	obtained	from	
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viral	administration	was	far	greater	than	that	obtained	via	plasmid	at	almost	1000	fold	
increase	(Figures	5-14	and	5-26).		
	
Peptide	concentration	in	muscle	homogenate	was	un-retrievable	due	to	an	error	in	the	
storage	of	the	harvested	tissue	which	resulted	in	the	degradation	of	the	protein.	This	
would	have	been	interesting	data	considering	the	observations	made	in	the	circulating	
concentrations	of	peptide.		
	
	
5.7.4 General	Conclusion	
	
These	studies	suffered	from	biological	variation	which	led	to	there	not	being	statistical	
differences	where	there	potentially	could	have	been.	This	is	commonly	encountered	in	
muscle	gene	transfer	studies	(Davis	et	al.,	1993).	
	
The	concentration	determination	of	GLP-1	was	not	consistent.	This	could	be	due	to	the	
method	of	collection,	sample	preparation	and	analysis	or	this	could	have	generated	
higher	levels	of	endogenous	DPP4.	One	aspect	that	was	overlooked	during	this	study	
was	any	determination	of	DPP4	concentration	in	the	GLP-1	group.	Constitutive	
overexpression	of	this	peptide	may	not	increase	the	circulating	levels	of	GLP-1	and	may	
only	trigger	the	release	of	increased	DPP4,	therefore	still	rendering	the	half-life	of	GLP-1	
extremely	short	at	2-3	minutes	and	not	providing	any	clinical	benefit.		
	
The	data	obtained	from	the	plasmid	studies	in	the	diseased	(db/db)	model	suggested	
promising	results	with	regards	to	glucose	clearance	with	Exendin-4,	as	shown	in	the	
IPGTT	data	and	statistical	analysis.	Dose	response	studies	and	further	expanded	
longitudinal	studies	may	increase	the	effect	seen	in	this	study.	One	major	aspect	that	I	
believe	needs	attention	is	the	determination	of	blood	glucose	levels	during	the	IPGTT	
test.	The	AlphaTRAK	2	system	used	has	a	ceiling	of	40	mmol/L,	which	was	reached	
several	times	during	IPGTT	data	acquisition.	Had	the	true	concentration	of	blood	glucose	
been	determined,	the	function	of	the	Exendin-4	may	have	been	greater.	
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Additionally,	due	to	the	loss	of	the	muscle	samples	and	the	lack	of	eGFP	expression	
observed	in	the	AAV	studies,	there	is	only	the	circulating	peptide	data	to	reflect	on.	
However,	the	data	from	both	Exendin-4	and	GLP-1	indicates	an	increase	in	circulating	
levels	for	both	peptides	was	obtained.	This	in	itself	is	worth	repeating	the	AAV	studies	in	
a	normal	model.		
	
In	short,	both	formats	of	vector	have	provided	evidence	of	transgene	biosynthesis	and	
subsequent	expression,	with	plasmid	based	Exendin-4	administration	providing	some	
evidence	of	increased	glucose	clearance	in	a	diabetic	model	and	a	viral	based	GLP-1	
administration	providing	far	superior	circulating	concentrations	in	a	healthy	model.		
A	long	term	study	in	a	milder	diseased	model	would	be	a	very	interesting	next	step.	
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6 Chapter	6	–	General	Discussion	
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The	impaired/reduced	GLP-1	secretion	seen	in	T2DM	patients	makes	GLP1	replacement	
an	extremely	attractive	treatment	methodology.	The	ability	to	replace	endogenous	
compounds	immediately	has	the	benefit	of	reducing	the	possibility	of	initiating	any	sort	
of	immune	response	and	generating	unwanted	and	unnecessary	side	effects.	However,	
the	short	half-life	of	GLP-1	still	remains	the	most	restricting	factor.		
There	have	been	many	methods	investigated	to	try	and	overcome	the	short	half-life	of	
GLP-1,	including	amino	acid	substitution	(as	the	DPP4	targets	only	a	specific	loci	in	the	
endogenous	GLP-1	sequence	–	see	figure	1-4),	DPP4	inhibitors	to	prevent	the	
degradation	altogether	or	the	use	of	GLP-1	mimetics,	such	as	Exendin-4.	However,	all	
current	incretin	therapies	or	incretin	related	substitutions	have	still	only	managed	to	
prolong	the	need	for	injectable	material	to	once	per	week,	with	3	GLP-1	RA’s	currently	
available	(exenatide	extended	release,	albiglutide	and	dulaglutide)	(Karagiannis	et	al.,	
2015)	.		
The	need	for	such	regular	injections	may	lead	to	issues	such	as	hypertrophy/lipoatrophy,	
which	not	only	can	affect	the	patient	by	hindering	the	application	of	the	therapy,	but	
may	also	affect	them	psychologically.	The	potential	for	extended	therapeutic	action	
which	may	be	achievable	through	gene	therapy	is	still	an	extremely	attractive	target	for	
many	researchers,	despite	the	advances	seen	in	current	injectable	treatments	and	the	
potential	issues	associated	with	gene	therapy	delivery	routes.		
In	order	to	provide	successful	and	long	term	gene	expression,	a	suitable	delivery	system	
is	key.	The	use	of	skeletal	muscle	to	uptake	the	gene	vectors	is	a	logical	choice,	due	to	
the	ease	of	access	and	the	muscle	fibres	themselves	having	many	attractive	qualities,	
such	as	a	good	vascular	system.	Studies	have	been	conducted	on	evaluating	the	benefits	
of	skeletal	muscle	against	other	quiescent	based	tissue	(such	as	liver),	on	the	whole,	the	
studies	yielded	extremely	similar	results,	and	certainly	not	enough	benefit	to	warrant	
the	much	more	invasive	procedure	of	using	liver	as	the	target	tissue	(Léger	et	al.,	2011).	
The	vectors	themselves	must	be	well	tolerated	and	not	have	any	adverse	side	effects	
which	would	outweigh	the	benefits	to	whatever	amelioration	the	treatment	provides.	
The	most	popular	vector	types	in	current	gene	therapy	trials	are	viral	based,	with	
lentiviral	and	AAV	based	(several	different	serotypes)	topping	the	list,	for	a	wide	range	
of	disease,	including	Haemophilia	B,	type	2	Leber	congenital	amaurosis	and	X-linked	
144 
 
SCID	(Naldini,	2015).	However,	non-viral	vectors	are	still	very	much	in	use,	with	a	recent	
breakthrough	in	cycstic	fibrosis	treatment	involving	an	inhalant	mixture	containing	
plasmid	DNA	and	a	lipid	complex	showing	increased	lung	function	against	the	placebo	
group	(Alton	et	al.,	2015)	
	
Previous	chapters	have	described	the	process	of	evaluating	the	two	versions	of	vector,	
plasmid	and	AAV,	from	analysis	of	reporter	gene	and	promoter,	through	to	in	vitro	proof	
of	concept,	and	onto	both	diseased	and	non-diseased	in	vivo	models.	In	each	case,	
successful	gene	transfer	and	expression	was	obtained,	albeit	of	variable	quality.		
	
6.1 In	Vitro	studies	to	establish	both	reporter	(eGFP)	and	transgene	(GLP-1	
and	Exendin-4)	expression	in	a	mouse	muscle	cell	line	(C2C12)	
	
Proof	of	concept	studies	in	the	C2C12	cell	line	have	shown	transfection	of	the	plasmid	
vector	pVR1012	containing	a	CMV	promoter	region	and	the	transgenes	in	question	
(eGFP,	Exendin-4	and	GLP-1)	into	myoblast-induced	myotubes	yielded	successful	results.	
All	three	genes	were	found	to	express	over	a	period	of	at	least	48	hours,	and	eventually	
up	to	7	days	(after	moving	to	fibronectin	coated	coverslips),	establishing	that	the	length	
of	expression	in	the	cell	line	model	was	somewhat	dependant	on	the	stability	of	the	
fibres	rather	than	the	vectors	themselves.		
The	C2C12	line	was	determined	the	most	appropriate	model.	The	myoblasts	are	derived	
from	satellite	cells,	which	exist	in	the	muscle	fibre	matrix	in	between	the	sarcolemma	
and	basal	membrane	structures.	The	myoblasts	spontaneously	differentiate	into	
myotubes	in	reduced	serum	media	(Burattini	et	al.,	2004).	A	mouse	muscle	cell	line	was	
the	logical	choice	for	in	vitro	assessment,	taking	into	consideration	the	future	plans	for	
in	vivo	muscle	targeted	delivery.	HEK293	cells	were	transfected	alongside	the	C2C12	for	
comparative	purposes	for	evaluation	of	AAV	in	vitro	due	to	the	reduced	volume	of	AAV	
available.	This	cell	line	is	known	as	being	an	‘easy	to	transfect’	line	and	this	reduced	the	
risk	of	losing	any	AAV	titre	to	loss	of	cells.	HEK293	are	derived	from	human	embryonic	
kidney	cells	and	originally	cultured	in	late	1970’s	they	have	been	extensively	used	for	
research	purposes	due	to	this	very	reason	(Graham	et	al.,	1977).	Although	the	HEK293	
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line	did	show	a	greater	percentage	of	transfection	area	under	the	same	conditions,	the	
muscle	model	of	the	C2C12	line	was	used	in	subsequent	studies	as	skeletal	muscle	is	the	
end	target	tissue.	A	variety	of	transfection	conditions	were	trialled,	however	the	
standard	recommendations	of	Lipofectamine2000	yielded	results	of	no	statistical	
advantage	or	disadvantage,	so	these	conditions	were	utilised.	Transfection,	and	
therefore	subsequent	expression	of	each	of	the	transgenes	was	confirmed	
immunohistochemically	via	fluorescence	staining	of	both	myotubes	and	myoblasts,	and	
the	analysis	of	secreted	expression	via	ELISA/EIA	content	in	the	cell	media.		
The	percentage	of	myoblasts	transfected	was	calculated	via	traditional	means	of	
counting	DAPI	stained	nuclei	and	then	counting	the	number	of	cells	transfected	(to	give	
a	positive	‘green’	eGFP),	and	gaining	percentage	transfected.	However,	when	this	
method	was	used	for	calculating	the	percentage	of	myotubes	transfected,	it	became	
clear	that	a	different	method	was	needed	due	to	the	tubes	becoming	multi-nucleated	
fibres	and	therefore	the	lack	of	clarity	between	what	is	classed	as	positive	transfection.	
Therefore	the	percentage	area	of	transfected	fibres	was	calculated	rather	than	a	count	
of	fibre.	This	was	performed	using	the	ImageJ	image	analysis	software	program	(which	is	
freely	available	for	download)	and	the	colour	deconvolution	function.	This	can	be	
further	manipulated	to	a	binary	image	and	the	percentage	of	black	versus	white	(white	
being	non-transfected	area)	calculated.	This	was	deemed	the	most	appropriate	method	
to	take	into	account	the	variation	of	fibres	per	frame	and	the	subjective	nature	of	
determining	expression.	This	method	was	used	for	all	other	expression	calculations	for	
in	vitro	experiments.	
Extracellular	transgene	protein	was	additionally	detected	in	the	cell	media	for	both	
Exendin-4	and	GLP-1,	as	determined	via	ELISA.	ELISA	detection	for	eGFP	was	also	
attempted,	however	this	remained	unsuccessful.	The	levels	of	GLP-1	were	greatly	
reduced	when	compared	to	those	of	Exendin-4.	This	could	be	attributed	to	enzyme	
degradation,	despite	the	addition	of	DPP4	inhibitor.		
After	transgene	expression,	and	more	importantly,	extra	cellular	expression	was	
confirmed,	studies	moved	from	in	vitro	to	in	vivo.		
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6.2 In	Vivo	studies	to	establish	both	reporter	(eGFP)	and	transgene	(GLP-1	
and	Exendin-4)	expression	in	a	mouse	muscle	cell	line	(C2C12)	
	
In	vivo	studies	were	carried	out	in	both	CD1	(normal)	and	db/db	(diseased)	mice.	These	
studies	were	originally	conducted	using	males,	however,	due	to	un-controllable	fighting,	
resulting	in	wounds	which	prevented	protocols	from	taking	place,	we	switched	to	
females.	This	removed	the	issue	of	fighting	and	resulted	in	less	stressed	animals.		
In	all	in	vivo	protocols,	mice	were	housed	randomly	(due	to	the	very	young	age	of	the	
mice,	no	variation	in	weight	was	seen	so	weight	matching	was	not	viable)	and	allowed	1	
week	to	acclimatise	in	the	CBC	facility	prior	to	any	protocols	commencing.	Mice	were	
monitored	closely	throughout	each	protocol	and	showed	no	signs	of	clinical	issues,	
medical	or	behavioural.	
	All	plasmid	studies	were	performed	using	the	hyaluronidase/electroporation	method,	in	
which	50	µl	hyaluronidase	was	administered	prior	to	plasmid	injection	(1	µg/µl),	and	the	
electroporation	technique	was	performed	post	plasmid	injection.		
All	AAV	studies	were	standard	injection	volume	of	50	µl,	and	slightly	varying	viral	titre.	
No	adjuvant	delivery	techniques	were	utilised	for	AAV.	
	
The	use	of	the	CMV	promoter	was	confirmed	in	an	in	vivo	experiment	as	a	more	than	
acceptable	choice,	as	determined	by	comparison	of	a	muscle	specific	promoter	DES	
(donated	by	Prof.	H.	Lochmuller).	The	CMV	promoter,	surprisingly,	provided	statistically	
significantly	more	positive	transfection	area	than	the	vector	containing	the	muscle	
specific	promoter,	MCK,	over	a	30	day	period.	Other	muscle	specific	promoters	are	
available	and	some	studies	have	shown	these	do	confer	higher	transfection	efficiencies	
(Jonuschies	et	al.,	2014),	however,	due	to	the	work	already	carried	out	within	the	group,	
and	publications	continuing	to	favour	CMV	promoters	for	targeting	skeletal	muscle	over	
tissue	specific	promoters	(Buchlis	et	al.,	2012),	along	with	the	preferable	results	yielded	
from	the	comparative	experiments	conducted	within	this	study	(3.4.2),	the	CMV	
promoter	was	used.	
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Further	studies	using	the	GLP-1	and	Exendin-4	vectors	were	also	performed	in	
conjunction	with	eGFP	reporter	vectors,	which	not	only	acted	as	the	control	group	but	
also	the	monitoring	group	for	use	with	the	IVIS	system.	The	IVIS	system	determined	the	
levels	of	eGFP	expression	in	anaesthetised	rodents.	As	the	backbone	of	the	vectors	were	
identical,	with	the	only	variation	being	the	transgene	insert,	it	was	suggested	the	level	of	
eGFP	expression	could	be	extrapolated	to	determine	the	level	of	expression	for	both	of	
the	other	transgenes.	Attempts	were	made	to	utilise	several	eGFP	ELISA	kits	to	confirm	
this	theory,	by	assessing	the	level	of	expression	at	time	of	death,	as	determined	via	IVIS,	
against	the	amount	of	eGFP	present	in	muscle	homogenate	post	mortem.	
Unfortunately,	the	robustness	of	these	eGFP	ELISA	kits	were	not	sufficient	to	provide	
enough	confidence	in	the	precision	of	the	kits,	and	therefore	the	data	was	not	provided.		
The	software	attached	to	the	equipment,	Living	Image,	has	the	capabilities	to	identify	
each	individual	region	of	interest	and	calculate	the	amount	of	eGFP	expression	without	
the	interference	of	any	auto	fluorescence.	This	allowed	the	real	time	monitoring	of	
expression	without	the	need	to	sacrifice	any	animal’s	part	way	through	protocols.	The	
benefits	of	this	were	particularly	noticed	during	the	time	of	fighting	between	the	CD1	
males,	during	which	time	no	blood	samples	were	permitted	due	to	the	bite	wounds	on	
the	tails	of	the	mice.	
High	levels	of	eGFP	expression	were	seen	in	the	CD1	group,	with	some	instances	of	
expression	in	the	gastrocnemius	region	being	observable	by	the	naked	eye	(figure	3-15).	
Extracellular	GLP-1	and	Exendin-4	were	detected	in	the	blood	stream	when	serum	was	
analysed	via	ELISA	(GLP-1)	or	EIA	(Exendin-4),	obtained	from	venepuncture	blood	
samples.	Final	samples	obtained	via	cardiac	puncture	tended	not	to	provide	directly	
comparable	results	to	those	obtained	via	venepuncture,	even	when	the	samples	were	
obtained	less	than	24hours	apart.	This	is	an	interesting	note	and	one	which,	at	time	of	
writing,	there	was	no	published	data	which	could	explain	this	phenomenon.		
As	expected	in	normal	mice,	the	IPGTT	tests	were	also	normal.	However,	the	process	of	
conducting	the	study	in	a	normal	model,	and	obtaining	normal	IPGTT	results,	
determined	that	using	both	plasmid	and	viral	vectors	to	administer	pharmacologically	
active	GLP-1	and/or	Exendin-4,	and	the	reporter	gene	eGFP	did	not	have	any	adverse	
effect	on	normal,	CD1	mice,	up	to	3months.		
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In	the	db/db	(diabetic)	mice,	circulating	levels	of	GLP-1	and	Exendin-4	were	also	found.	
The	initial,	pre	transgene	delivery	IPGTT	confirmed	abnormal	glucose	control.	The	
circulating	levels	of	transgene	peptide	were	comparable	to	those	found	normal	mice,	
however,	the	IPGTT	results	indicated	the	Exendin-4	administration	via	plasmid	vector	
was	exerting	some	activity	over	glucose	control.	Statistical	analysis	(repeated	measures	
ANOVA)	suggested	a	significant	difference	in	the	results	obtained	for	Exendin-4	plasmid	
based	delivery.		
A	drawback	which	should	be	noted	is	the	limitation	of	the	glucose	meter	used	to	
measure	blood	glucose	levels	in	mice.	The	AlphaTrak2	system	is	only	capable	of	
measuring	blood	glucose	concentrations	up	to	40	mmol/L,	the	glucose	levels	often	hit	
this	limit	meaning	the	actual	difference	in	peak	glucose	concentration	may	have	been	
even	higher	than	recorded	and	furthermore,	restricting	the	statistical	significance	the	
results	yielded.	This	was	deemed	a	major	drawback	of	the	protocol.	Attempts	to	find	
alternative	equipment	were	made,	however	none	were	found.	
	
Even	though	variability	in	the	AAV	results	in	the	CD1	mice	was	observed,	the	results	
indicated	that	successful	biosynthesis	and	expression	was	gained.	However,	the	severity	
of	the	db/db	model	coupled	with	the	extra	time	needed	for	AAV	to	produce	and	release	
transgene	peptide	meant	the	study	was	not	progressed	into	a	diseased	model	study.	
This	does	not	indicate	we	do	not	have	confidence	in	the	gene	delivery	system	and	
resulting	expression,	rather	the	db/db	model	is	not	the	appropriate	disease	model	for	
this	study.	However,	many	successful	studies	have	been	reported.	Buchlis	et	al	(2012)	
has	showed	positive	Factor	IX	expression	was	found	in	a	deceased	haemophilia	B	
participant	(un-related	death)	of	a	trial	conducted	10	years	previously	with	AAV	
mediated	gene	therapy	(Buchlis	et	al.,	2012).	The	Fatima	Bosch	group	(Barcelona)	have	
seen	somewhat	more	related	success	in	treating	diabetic	beagle	dogs	with	AAV1	gene	
therapy.	A	combination	of	insulin	and	glucokinase	transgene	expression	has	led	to	
normal	glucose	homeostasis	for	over	4	years	in	the	large	animal	model	(Callejas	et	al.,	
2013).		
	
There	is	some	concern	that	constitutive,	over	expression	of	GLP-1	may	lead	to	adverse	
effects	such	as	pancreatitis	or	even	pancreatic	cancer	(Elashoff	et	al.,	2011;	Deborah,	
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2013).	However,	recent	studies	have	shown	that	GLP-1	may	also	have	cardio-protective	
properties.	Kinalska	et	al	and	Davidson	have	all	shown	that	either	GLP1	or	Exendin-4	
administration	exerts	some	positive	effect	on	various	cardiac	functions	or	conditions	
that	may	lead	to	adverse	cardiac	events	(Davidson,	2011;	Kinalska	et	al.,	2012).	
Unfortunately,	there	are	as	yet	no	definitive	conclusions	over	the	safety	concerns	or	
protective	actions,	and	the	use	of	GLP-1	and/or	synthetic	homologues,	delivered	by	
whatever	means	is	still	the	most	attractive	and	useful	method	for	glucose	homeostasis	
in	individuals	suffering	from	type	2	diabetes.	No	adverse	effects	were	found	in	the	
pancreas	during	any	of	these	studies.	
	
	
6.3 Future	work	
	
The	most	immediate	requirement	would	be	to	repeat	the	AAV	study.	Although	most	of	
the	data	was	obtained,	the	error	in	sample	storage	meant	the	data	surrounding	the	
hormone	levels	in	muscle	sample	homogenate	was	not	obtained.	This	is	an	important	
step	in	determining	the	efficacy	and	longevity	of	hormone	secretion	in	the	targeted	site	
of	injection.		
This	study	did	show	the	variability	of	the	expression	with	this	system,	and	the	early	peak	
in	activity	seen	in	the	plasmid	system	was	not	evident	here.	This	is	a	known	feature	of	
AAV	systems,	extending	the	duration	of	the	AAV	study	may	show	a	clearer	trend	of	
increase/decrease	in	activity.		
	
Analysis	of	other	organs	may	help	in	identifying	any	possible	adverse	effects	of	
prolonged,	over	expression	of	endogenous	and	synthetic	compounds.	For	example,	
some	reports	of	thyroid	c	cell	carcinoma	in	certain	studies	suggest	that	prolonged	
exposure	to	high	levels	of	GLP1/Exendin-4	may	be	harmful,	however	this	has	not	been	
proven	in	human	subjects	(Aroda	and	Ratner,	2011;	Shih	et	al.,	2012;	Butler	et	al.,	2013).	
Whilst	no	signs	of	pancreatitis	were	identified	in	histological	examination	of	the	
pancreas	samples	from	any	of	the	groups	in	this	particular	study,	reports	have	been	
published	that	this	may	also	be	a	side	effect	(Elashoff	et	al.,	2011;	Deborah,	2013)	.	
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A	conversation	held	with	Prof.	Peter	Flatt	(University	of	Ulster)	suggested	that	the	db/db	
model	used	for	the	diseased	animal	model	studies	may	have	been	an	overly	harsh	form	
of	the	disease	for	a	study	of	this	type.	The	db/db	model	is	clinically	overt	at	an	early	age	
(4-8	weeks)	resulting	in	profound	hyperglycaemia	and	β-cell	failure.		This	incredibly	early	
onset	of	the	phenotype	and	the	practical	time	scale	restrictions	with	working	with	this	
model	in	the	UK	(db/db	mice	are	only	available	from	an	Italian	supplier,	after	genotyping	
at	2-3	weeks,	this,	coupled	with	delivery	time	and	1	weeks	acclimatisation	meant	the	
animals	for	this	study	were	ordered	with	the	specific	requirements	of	early	genotyping	
and	expedited	delivery	to	allow	the	1	weeks	acclimatisation	and	still	meet	the	date	
requirements	for	initiating	the	study	before	the	phenotype	became	too	harsh	and	no	
treatment	methodologies	would	have	been	evident)	may	have	meant	the	time	required	
for	a	gene	therapy	protocol	to	provide	circulating	peptide	levels,	and	therefore	exert	any	
effect,	may	have	been	too	long.			
	
There	have	however	been	studies	that	show	both	GLP-1	and	Exendin-4	can	exert	a	blood	
glucose	lowering	effect	in	db/db	mice,	however	the	administration	was	via	direct	
intraperitoneal	injection	and	based	on	dose	response	experiments.	Meaning	the	blood	
samples	were	collected	at	a	maximum	of	4	hours	post	injection	(Young	et	al.,	1999).	This	
is	very	different	from	assessing	the	potential	of	single	dose	gene	therapy.		
Other	rodent	models	of	diabetes	which	could	be	considered	for	future	use	include	the	
ob/ob	mouse	or	the	Kuo	Kondo	mouse.	The	ob/ob	mouse	was	the	first	rodent	model	of	
insulin	resistance	(1970’s),	as	a	result	of	a	mutation	on	the	leptin	receptor	gene.	They	
gain	weight	rapidly	and	show	hyperinsulinemia	at	approximately	3	to	4	weeks	of	age.	
However,	the	classic	symptom	of	T2DM	of	declining	plasma	insulin	levels	does	not	really	
manifest	until	the	mice	are	over	a	year	old	(Wang	et	al.,	2013).	This	is	in	stark	contrast	to	
the	db/db	mouse,	whose	life	expectancy	is	only	approximately	10	months.	This	would	
make	this	model	much	more	suitable	for	a	gene	therapy	based	protocol.	The	Kuo	Kondo	
mouse	is	also	known	to	exhibit	milder	diabetic	symptoms	(which	still	include	obesity,	
insulin	resistance	and	hyperglycaemia),	the	milder	symptoms	may	allow	the	
determination	of	any	effects	the	transgenes	may	exert,	but,	as	with	the	ob/ob	mouse,	
the	longer	life	span	would	allow	more	in	depth	analysis	(Wang	et	al.,	2013).		
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The	use	of	CD1	mice	as	a	control	may	not	have	given	the	most	representative	baseline	
control.	Dbdb	mice	have	a	black	6	background,	using	this	phenotype	may	have	been	
beneficial	especially	with	regards	to	IVIS	analysis.	It	is	widely	accepted	that	skin	colour	
does	have	some	interference	in	the	absorption	of	the	light	spectrum	which	is	required	
for	data	acquisition.	The	white	coat/pale	skin	of	the	CD1	mouse	may	yield	different	
results	to	the	dark	coat/darker	skin	of	the	dbdb	mouse.	A	small	trial	would	be	relatively	
easy	to	perform,	however,	this	did	not	fall	under	the	remit	of	our	PPL	and	was	therefore	
not	conducted.	
	
	
This	study	was	also	conducted	with	aid	of	RVC.	The	link	with	the	RVC	comes	in	the	form	
of	treatments	for	feline	diabetes.	The	success	of	the	trials	in	rodent	model	will	lead	to	
trials	in	a	larger	animal	model,	which	in	this	case,	would	be	cats.		
Feline	diabetes	closely	resembles	the	pathophysiology	of	the	human	form	of	T2DM	in	
many	ways	and	can	be	used	as	a	good	larger	animal	model	for	advanced	therapy	trials.	
Feline	diabetes,	as	with	the	most	common	appearance	in	type	2	diabetes,	occurs	mostly	
in	obese,	middle	age	cats	that	have	relatively	low	circulating	concentrations	of	insulin	at	
fast.	As	with	humans,	cats	are	also	subject	to	various	risk	factors,	which	are	largely	the	
same	as	those	described	previously	in	section	1.2.1,	mainly	due	to	the	fact	that	cats	are	
companion	animals	and	have	been	exposed	to	the	same	environment	and	lifestyle	traits	
as	their	owners	(O'Brien,	2002;	Rand	et	al.,	2004;	Henson	and	O'Brien,	2006).		
One	of	the	causes	of	decreased	β-cell	function	is	islet	amyloidosis.	This	occurs	in	over	
90%	of	FDM	and	T2DM	patients	and	is	one	of	the	causes	of	loss	of	β-cell	function	in	
conjunction	with	approximately	50%	loss	in	β-cell	mass.	Islet	amyloidosis	in	only	seen	in	
a	limited	number	of	species.	Rodents	do	not	succumb	to	this	form	of	β-cell	destruction	
(O'Brien,	2002).	These	close	links	make	cats	an	excellent	model	for	studying	and	
ultimately	providing	not	only	a	treatment	for	human	T2DM,	but	a	treatment	for	feline	
diabetes	also,	which	is	an	ever	increasing	problem	for	cats	and	their	owners.	Other	large	
animal	models	have	also	been	used.	The	Bosch	group	(Barcelona)		have	successfully	
used	beagle	dogs	in	a	long	term	study	which	saw	the	dogs	off	insulin	for	up	to	4	years	
(Callejas	et	al.,	2013).	
152 
 
	
There	is	also	always	the	possibility	of	using	newer	and	novel	vectors,	which	are	
continuously	being	developed	globally,	not	necessarily	specifically	for	muscle	targeted	
gene	therapy	of	for	diabetes,	but	any	improvement	in	the	safety	and	efficacy	of	
transgene	delivery	is	only	going	to	improve	the	prospect	for	any	disease	modality	with	
sub-optimal	current	treatments.		
Treatments	which	target	α-cells	rather	than	β-cells	(glucagon	function	rather	than	
insulin)	have	been	described.	These	could	either	target	α-cells	themselves	(i.e.	destroy	
the	cells)	or	be	based	on	the	well-known	incretin	effect	and	target	glucagon	receptors	
on	the	α-cells	(Gcgr).	Antagonizing	these	receptors	could	be	another	route	to	reducing	
both	postprandial	and	fasting	hyperglycaemia	in	t2dm	patients	(Bagger	et	al.,	2011a;	
Christensen	et	al.,	2011).		
Studies	have	shown	that	merging	standard	vectors	together	to	produce	new,	novel	
structures	have	performed	better	in	certain	circumstances.		The	Samulski	group	has	
demonstrated	that	by	fusing	selected	features	of	two	or	more	different	AAV	serotypes,		
to	form		what	they	term	‘hybrid	serotypes’,	can	generate	higher	efficiency	vectors	that	
can	be	tailored	to	the	target	end	game	(Choi	et	al.,	2005).			
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8 Appendices	
	
8.1 Appendix	1	–	Clinical	assessment	score	chart	
	
	
	
	
	
Scoring:	 	 	 	 	 	 	 	 	 	
≤	6	–	continue	with	protocol/monitoring	 	 	 	 	 	
>8	–	perform	blood	glucose	to	assess	levels	 	 	 	 	 	
>12	–	perform	blood	glucose	levels	and	obtain	advice/assessment	from	NVS	/	
NACWO	
	
	
	
	
	
	
	
	
	
Weight	 Score	 Eyes/Nose	 Score	 Skin	tone	 Score	 Behaviour	 Score	 Coat	 Score	 Faeces	 Score	
Weight	
Gain	
0	 Normal	 0	 Normal	 0	 Normal	 0	 Normal	 0	 Normal	 0	
No	change	 0	 sunken	 1	 Tents;	1-2	
sec	
2	 Apathetic	/	
inactive	
2	 Lack	of	
grooming	
1	 Soft	 1	
<5%	loss	 2	 	 	Tents;	
persist	
4	 Immobile	/	non-
responsive	
4	 Starey	 2	 Diarrhoea	 2	
<10%	loss	 4	 	 	 	 	 	 	 	 	 	 	
>15%	loss	 6	 	 	 	 	 	 	 	 	 	 	
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8.2 Appendix	2	–	Example	animal	study	protocol	
	
Each	animal	study	had	a	corresponding	protocol	which	outlined	each	procedure,	the	
date	of	the	procedure	and,	where	appropriate,	the	volume	of	blood	taken,	to	ensure	
compliance	with	the	PPL/PIL.		
	
PPL:60/4374	Gene	therapy	and	cell	transplantation	in	diabetes	
Prof.	James	Shaw	PIL:	60/6566	Tel	Ext	8129	Mobile	07738727495	
Primary	Responsible:	Gillian	Patterson	PIL	60/13372	Tel	ext	7422	Mob	07736771181	
Supervision:	James	Shaw	(as	above)	
Animal	husbandry:	Chris	Huggins	and	CBC	
	
Muscle	Targeted	Gene	Therapy	Study	–	GP004	
Diabetic	mouse	study	utilizing	exendin	4,	GLP1	and	eGFP	(control)	plasmids	
	
License	Reference:	19b3	
	
Aim:	To	determine	the	effectiveness	of	the	Exendin-4	and	GLP-1	plasmids	in	a	diabetic	
model	
	
Animal	Strain:	db/db	
Sex:	Female	 	
DOB:	19/12/12	-	4	weeks	(at	start	of	study	after	1	week	acclimatisation)	
Number:	18	
Animal	supplier:	Charles	River	
	
Group	1:	n=6	(db/db)	–	pVR1012.CMV.Ex4	
Group	2:	n=6	(db/db)	–	pVR1012.CMV.GLP1	
Group	3:	n=6	(db/db)	–	pVR1012.CMV.eGFP	
	
All	animals	will	be	subject	to	the	following	clinical	scoring	assessment;	
	
Relative	blood	volume	(see	
http://www.nc3rs.org.uk/bloodsamplingmicrosite/page.asp?id=419):	
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60ml/kg	–	under	our	current	license	guidelines;	no	more	than	15%	of	the	circulating	
blood	volume	can	be	taken	in	a	rolling	28day	period.	
	
E.g.	Mouse	is	35g	therefore	~2.1ml	of	circulating	blood;	@15%,	~315µl	can	be	taken	over	
a	28day	period.	
	
IVIS	scanning	can	be	performed	up	to	4	times	in	a	24hour	period	for	a	maximum	of	5	
days	or	twice	per	week	for	any	studies	lasting	longer	than	5	days.	
	
Weights	will	be	taken	during	the	1	week	acclimatisation	to	obtain	a	baseline	which	will	
be	used	to	monitor	health	(as	well	as	other	observations)	during	study.	
	
	
	
	
Day	 Dat
e	
T
ime	
Procedure	
0 W
ed	
16.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	pre-procedure	IVIS	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
1	 T
hurs	
17.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	pre-procedure	peripheral	blood	sample	(for	
ELISA’s)	
• Perform	pre-procedure	IPGTT	(allow	free	access	to	
food/water	post	procedure)	
2	 F
ri	
18.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Administer	carprofen	or	metacam	subcutaneously	(at	
50mg/kg	or	1mg/kg	respectively	-	diluted	to	make	total	
administered	volume	0.1ml).	
• Anaesthetise	animals	with	isoflurane	and	shave	both	
hind	legs.	
• Inject	all	muscle	groups	perpendicularly	percutaneously	
first	with	hyaluronidase	(0.4U/ul	in	25ul	of	normal	
saline)	then	with	50ug	of	plasmid	(1µg/µl	–	total	vol	
50µl)	in	the	central	portion	of	the	muscle	(29	gauge	
needle	0.5ml	insulin	needle	3mm	deep).	Inject	first	in	
the	left	leg	followed	by	the	right.	Injection	duration	is	10	
seconds	for	each.	Hold	needle	in	place	before	
withdrawing	quickly.	Muscles	targeted	are	TA	and	
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gastroc.	
(total	plasmid	requirement	=	200µl	per	mouse)	
• After	injecting	the	second	leg	apply	ECG	gel	to	the	first	
leg	and	electroporate	transcutaneously	(settings:	eight	x	
20ms	pulses	of	200V/cm	with	intervals	of	250ms	applied	
through	2	x	1.5cm2	stainless	steel	plate	electrodes	
placed	on	each	side	of	the	leg).	Electroporation	is	
performed	using	BTX	ECM830	firstly	on	the	left,	
followed	by	the	right	leg.	The	plates	should	be	placed	in	
such	a	manner	that	each	leg	needs	only	one	set	of	
electroporation	for	both	muscle	groups.	The	plates	
should	not	restrict	movement	of	the	leg	but	should	be	
close	enough	to	form	a	circuit	using	the	gel.	
• Place	all	mice	into	relevant	boxes	and	place	in	the	
incubator	for	recovery.	
3	 S
at	
19.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
4	 S
un	
20.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
5	 M
on	
21.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
6	 T
ues	
22.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
7	 W
ed	
23.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
8	 T
hurs	
24.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
9	 F
ri	
25.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
1
0	
S
at	
26.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
1
1	
S
un	
27.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
1
2	
M
on	
28.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
1 T 29.0 0 • Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
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3	 ues	 1.13	 9.00	
1
4	
W
ed	
30.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
1
5	
T
hurs	
31.0
1.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
1
6	
F
ri	
01.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
1
7	
S
at	
02.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
1
8	
S
un	
03.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
1
9	
M
on	
04.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
2
0	
T
ues	
05.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
2
1	
W
ed	
06.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
2
2	
T
hurs	
07.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	
in	the	cage)	overnight	
2
3	
F
ri	
08.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
2
4	
S
at	
09.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
2
5	
S
un	
10.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
2
6	
M
on	
11.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
2
7	
T
ues	
12.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
2 W 13.0 0 • Weigh	mice	and	clinical	score	
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8	 ed	 2.13	 9.00	
2
9	
T
hurs	
14.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
3
0	
F
ri	
15.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
3
1	
S
at	
16.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
3
2	
S
un	
17.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
3
3	
M
on	
18.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
3
4	
T
ues	
19.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
3
5	
W
ed	
20.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
3
6	
T
hurs	
21.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
3
7	
F
ri	
22.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
3
8	
S
at	
23.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
3
9	
S
un	
24.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
4
0	
M
on	
25.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
4
1	
T
ues	
26.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
4
2	
W
ed	
27.0
2.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
4 T 28.0 	 • Weigh	mice	and	clinical	score	
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3	 hurs	 2.13	 • Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
4
4	
F
ri	
01.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
4
5	
S
at	
02.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
4
6	
S
un	
03.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	(CBC	if	possible	please?)	
4
7	
M
on	
04.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
4
8	
T
ues	
05.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Perform	fasting	glucose	measurement	
4
9	
W
ed	
06.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Fast	mice	from	17.00	(leave	½	food	pellet	per	mouse	in	
the	cage)	overnight	
5
0	
T
hurs	
07.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Obtain	peripheral	blood	sample	
• IPGTT	(allow	free	access	to	food/water	post	procedure)	
5
1	
F
ri	
08.0
3.13	
0
9.00	
• Weigh	mice	and	clinical	score	
• Image	mice	using	IVIS	spectrum	
• Terminate	animals	via	cardiac	puncture	
• Harvest	muscles	by	stripping	skin	of	hindlegs	starting	at	
the	hock	moving	proximally,	remove	fascial	layers	and	
mark	the	area	of	injection	on	the	right	side	by	incision	
using	a	scalpel	blade.		Then	harvest	both	TAs	and	
gastroc	groups	by	transecting	muscle	insertion	
proximally	and	distally.	Cut	along	injection	site	into	two	
pieces	and	snap	freeze	by	placing	directly	into	
isopentane	cooled	via	liquid	nitrogen.	Store	in	cryovials	
and	store	at	-800C	until	needed.	AND/OR	Place	each	of	
the	muscle	groups	into	1.5ml	eppendorf	tubes	
containing	1ml	of	Buffer	A.	
• Muscles	to	be	homogenised	are	to	be	placed,	
seperately,	into	Buffer	A	(containing	protease	
inhibitors),	after	being	weighed.	
• Muscles	to	be	stained	are	to	be	snap	frozen	
(iospentane)	onto	cork	discs	with	coverslip	support	and	
placed	in	cryovials.	
• Remove	pancreases,	weigh	and	place	into	10%	formalin.	
	
NOTES:	
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• Buffer	A	contains	10	mM	HEPES	pH	7·9,	10	mM	KCl,	0·1	mM	EDTA	pH	8·0,	0·1	
mM	EGTA	pH	8·0,	1	mM	dithiothreitol	and	protease	inhibitors	(Roche,	UK),	
10µl/ml	(to	be	added	immediately	before	use)	
	
• IVIS	scans	
o Treatment	groups	to	be	scanned	as	groups	of	3	(machine	only	capable	of	
scanning	a	maximum	of	5).		Each	eGFP	group	animal	to	be	scanned	
individually	(dorsal	and	ventral	views)	2D	and	3D.	
o Each	leg	needs	to	be	shaven	before	each	scan	due	to	dark	fur	interfering	
with	the	light	absorptions	patterns.	
o Scan	muscle	once	harvested?	Need	to	think	about	logistics	
	
• IPGTT	–	ask	for	assistance	from	CBC,	with	a	view	to	handing	procedure	over	in	
the	future		
	
• Peripheral	blood	samples	(~100µl)	–	dates	may	need	altering	once	maximum	
allowable	blood	volumes	have	been	calculated.	
	
• Muscle	group	method	for	snap	freezing	muscles	
o Make	a	surface	incision	in	a	25mm	cork	disc	–	not	cutting	through	the	disc	
o Place	coverslip	in	cut,	perpendicular	to	the	disc	
o Lay	muscle	in	correct	orientation	against	the	coverslip	
o Cover	muscle	in	OCT	medium		
o Place	entire	sample	into	dry	ice	cooled	isopentane	to	freeze.	
o Store	at	-800C	until	needed.		
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